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Orthopedic implant surgeries are on the rise in the United States, with well over a million 
surgeries performed annually. Common materials used for these applications include titanium and 
its alloy, titanium aluminum vanadium (Ti-6Al-4V). Ti-6Al-4V is chosen for this application due 
to its mechanical strength and corrosion resistance. However, Ti-6Al-4V does not support 
osseointegration and is susceptible to bacterial colonization. Therefore, these implants suffer from 
aseptic loosening and infection, necessitating removal and replacement. Revision surgery and 
treatment is financially burdensome and taxing on the patient. Current approaches focus on 
modifying the surface of Ti-6Al-4V through a variety of means to allow for improved 
osseointegration and limited bacterial adhesion.  
 In this work, self-assembled monolayers (SAMs) were used as linkers to immobilize 
bioactive molecules to the Ti-6Al-4V surface that would help encourage osteoblast attachment 
while limiting bacterial adhesion. This was accomplished by forming phosphonic acid head group 
SAMs on the surface of Ti-6Al-4V with different tail groups. These tail groups were then used to 
v 
perform chemical reactions at the interface, using orthogonal chemistry, to covalently link the 
bioactive molecules. Bioactive molecules were chosen that would address both osteoblast 
attachment as well as bacterial adhesion. Vancomycin, an antibiotic effective against Gram 
positive bacteria as well as spermine NONOate, a nitric oxide releasing molecule, were chosen to 
address bacterial adhesion and colonization of Ti-6Al-4V. A cell adhesion peptide, KRSR was 
selected to encourage osteoblast anchoring and viability on the Ti-6Al-4V surface.  
The single, dual, and triple immobilization of these molecules was confirmed through 
diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy. The covalent attachment of 
these molecules resulted in hydrophilic surfaces with contact angle values less than 90°. Nitric 
oxide release from functionalized Ti-6Al-4V was assessed through the Griess assay, with single 
and triple functionalized surfaces releasing comparable amounts of nitric oxide, 77.0 ± 1.8 and 
74.7 ± 1.6 nanomoles respectively. Dual functionalized substrates with co-immobilized spermine 
NONOate exhibited higher nitric oxide release of 107.6 ± 1.5 nanomoles for spermine NONOate 
with KRSR(C) and 117.6 ±1.4 nanomoles for spermine NONOate with vancomycin.  
The activity of the antimicrobial molecules immobilized alone and in conjunction with the 
other bioactive molecules was determined via challenges with Staphylococcus epidermidis (S. 
epidermidis), a Gram positive species and Escherichia coli (E. coli), a Gram negative species 
through fluorescence staining and imaging of the bacteria. Vancomycin immobilized alone was 
able to reduce the viability of S. epidermidis by 64 ± 27%. Spermine NONOate was able to reduce 
viability of E. coli by 27 ± 20% but not that of S. epidermidis. The selectivity observed was 
attributed to Gram positive species’ ability to generate their own nitric oxide, leading to tolerance 
of nitric oxide’s effects. Spermine NONOate was able to prevent the adhesion of both species to 
single functionalized surfaces which has previously been observed in the literature.27-29 
vi 
Antimicrobial effectiveness was only maintained for one of the dual functionalizations, 
when KRSR(C) was co-immobilized with vancomycin. This dual functionalized surface showed 
a reduction in S. epidermidis viability of 36 ± 28%. This was approximately half the reduction in 
viability observed for vancomycin immobilized alone. The loss in effectiveness may be due to 
interactions between vancomycin and KRSR(C) or lower surface loading. Surfaces possessing all 
three bioactive molecules were not able to limit viability of either bacterial species. Local 
concentrations were either not sufficient or interactions between molecules negatively impacted 
their effectiveness.   
 Finally, osteoblast adhesion and viability on functionalized Ti-6Al-4V was characterized 
through fluorescence staining and microscopy. Covalent attachment of these bioactive molecules 
should not elicit cytotoxic effects within osteoblast cells. Furthermore, attachment of the KRSR(C) 
cell adhesion peptide to Ti-6Al-4V was expected to encourage osteoblast adhesion to Ti-6Al-4V 
and improve cell viability. While individual immobilization of bioactive molecules did not 
negatively affect adhesion or viability, KRSR(C) functionalized substrates showed no statistically 
significant increase in live osteoblast adhesion or viability. Surface loading and distribution of the 
cell adhesion peptide dictate its effectiveness at recruiting osteoblast adhesion. These factors may 
contribute to the lack of a positive, observed effect.  
Co-immobilization of spermine NONOate with either vancomycin or KRSR(C) negatively 
impacted osteoblast viability. Dual functionalized substrates exhibited higher concentrations of 
nitric oxide release than single or triple functionalized. The larger, local concentrations are thought 
to be the source of observed cytotoxicity. The lack of observed cytotoxicity on triple functionalized 
substrates supports this, as these substrates showed nitric oxide release consistent with single 
functionalized Ti-6Al-4V.  
vii 
In this work, SAMs were utilized as a platform to chemically immobilize bioactive 
molecules to the Ti-6Al-4V surface aimed at addressing osteoblast adhesion and bacterial 
colonization. This flexible platform allows for the immobilization of a variety of molecules 
including antibiotics, peptides, and nitric oxide releasing compounds. Although in this work 
immobilized molecules did not retain their bioactivity, alternative immobilization strategies can 
be employed. The functional groups within these molecules used in the formation of covalent 
bonds are prevalent in other classes of bioactive molecules. This permits control of the interfacial 
properties of Ti-6Al-4V with bioactive molecules specific to the metal’s application. Furthermore, 
as SAMs form on other metal oxide surfaces, this transferable platform can be used to alter their 
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Chapter 1. Orthopedic Implants 
1.1 Introduction 
Orthopedic implants are currently on the rise in the United States, with over 700,000 knee 
and 300,000 hip replacement surgeries performed annually. 1 These numbers are only expected to 
increase in the coming decades, with predicted occurrences for 2030 of 572,000 hip replacements 
and 3.48 million knee replacements.2 This is due in part to degenerative diseases such as arthritis 
which can lead to pain or loss in joint function.2 These ailments contribute to alteration of the 
mechanical properties of the bone due to excessive loading or the absence of normal biological 
self-healing mechanisms. These issues are addressed by surgically replacing the joints with 
artificial biomaterials to help restore function of these compromised structures.   
In the hip replacement process, the patient’s damaged femoral head is removed and then 
replaced with a metal head and stem that is placed into the hollow center of the femur, either with 
or without cement.3 The damaged cartilage surface of the socket is removed and then replaced with 
a metal socket. This socket is held in place by either screws or cement.4 A plastic, ceramic, or 
metal spacer is inserted between the new ball and the socket to allow for gliding motion. When a 
total knee replacement occurs, the femur is resurfaced to remove any damaged bone or cartilage. 
Then the femoral component is secured to the femur with bone cement. The tibia is prepared for 
the placement of the tibial component. After the tibial component is attached, the implant will be 
checked for issues with alignment, sizing, and positioning. Once implanted, hip and knee 
replacements are expected to last for 10-15 years, and unfortunately, many patients are outliving 
their implants.2, 5-6  
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1.2 Orthopedic Implant Materials   
 There are multiple materials that are used in orthopedic applications, including polymers, 
ceramics, and metals.7 Polymers are commonly used in hip replacements as articulating surfaces 
and as an interposition cementing material between the implant surface and bone. Ceramics are 
employed as articulating surfaces as well. Total hip replacements are commonly comprised of a 
titanium, titanium alloy, or cobalt-chromium alloy femoral stem (cemented with 
polymethylacrylate, (PMMA), or press fit into place), and then connected to a “modular” cobalt-
chromium alloy or ceramic head that articulates on an ultra-high molecular 
weight polyethylene or ceramic acetabular cup fitted into a titanium or cobalt-
chromium cup liner, which is then cemented, screwed or press fitted into place. 
(Figure 1.1).7 Stainless steel has also been used in this application.8 Titanium, 
and its alloy, titanium aluminum vanadium (Ti-6Al-4V) are the primary 
implant materials used in these types of joint replacements.9-12     
1.2.1 Desirable Implant Properties 
The mechanical properties of orthopedic implants are critical to their 
function. Mechanical properties of particular importance include hardness, tensile strength, elastic 
modulus, and elongation.8 The material’s response to repeated cyclic loads or strains is based on 
the fatigue strength of the material, which, in part, determines the long-term success of the implant. 
The implant material being used to replace the natural bone is expected to have mechanical 
properties similar to that of natural bone. 2 For example, the materials used to replace bone should 
have elastic moduli characteristic of that of natural bone, which ranges from 4 to 30 gigapascals 
(GPa), depending on the type of bone being characterized as well as the characterization method.13 
Stainless steel and cobalt-chromium alloys both exhibit significantly higher elastic moduli than 
Figure 1.1: Total 
hip replacement.  
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bone; this leads to insufficient stress transfer to the bone, which can cause bone resorption and 
loosening of the implant, contributing to implant failure.2 This is known as the “stress shielding 
effect”.14 Therefore, a material that exhibits a proper combination of high strength and low elastic 
modulus comparable to that of natural bone is desired. Ti-6Al-4V, a titanium alloy, exhibits an 
elastic modulus closer to that of natural bone when compared to the cobalt-chromium alloys 
(Table 1.1).15 Furthermore, the torsional and axial stiffness of titanium alloys are also closer to 
those of natural bone, and therefore theoretically provide less stress shielding than the 
cobalt/chromium alloys and stainless steel.7, 16  In addition, the strength of titanium alloys is on par 
with that of stainless steel, but it weighs about half of that of stainless steel.8, 17 Ti-6Al-4V is used 
preferentially in orthopedic replacements due to these more desirable mechanical properties, with 
its mechanical strength taking precedence.9-10, 18  
 
 
Although titanium alloys exhibit some desirable mechanical properties, other mechanical 
characteristics are not comparable to the cobalt/chromium alloys. For example, titanium and its 
alloys tend to be softer materials, and they also have poor wear, frictional, and fatigue properties 
(Table 1.2).7, 19 The cyclic loading experienced by the implant may lead to alternating plastic 
deformation of stress induced superelevations produced by grooves or microstructural 
inconsistencies. These areas of heterogeneity are where cracks in the implant material initiate, 
propagate, and finally fracture due to the repeated cyclic loading causing mechanical implant 
failure.19 These undesirable mechanical properties also contribute to the generation of wear debris 
at the implant site, which in itself contributes to implant failure. 
Material Elastic Modulus (GPa) 
Cast cobalt chromium (CoCr) 240 
Stainless steel (SS) AISI 316 210 
Titanium Aluminum Vanadium (Ti-6Al-4V) 112 
Bone 30 
Table 1.1: Elastic moduli of orthopedic implant alloys and natural bone.7 
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Implants should exhibit not only specific mechanical properties, but also appropriate 
chemical and biological compatibility characteristics as well.19-20 The biomaterial’s ability to meet 
these needs strongly influences its success as an implant material. The implanted material should 
be robust enough to resist degradation in vivo.5, 7  This material should not corrode, be susceptible 
to chemical attack, or release toxic species into the human body. Furthermore, the implant material 
should allow for bony in-growth to secure the prosthesis, encourage new bone deposition on its 
surface (osteoinduction) to accelerate the stabilization process, and provide limiting distinctions 
between the bone and implant interface.1-2, 21 It is desired that osteoblasts, the bone cells that form 
new bone, will proliferate and then differentiate on the surface, leading to osseointegration.11, 22  
This process is vital for the successful integration of the implant material into the host tissue.23  
Not only should these materials be attractive to osteoblasts and encourage natural bone modeling, 
they should limit bacterial adhesion. Bacterial adhesion and subsequent proliferation of these 
bacteria on the surface lead to implant infection, further destabilizing the implant, causing implant 


















Co Cr ASTM 
F75 
210-253 




















897-1034 965-1103t 620-689 310 8 
Table 1.2: Mechanical properties of dominant orthopedic biomaterials.7 ASTM = American 
Society for Testing and Materials (ASTM International), t = tension, RC = Rockwell 
Hardness scale, MPa = megapascals, HVN = hardness Vickers number.  
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The materials currently used in orthopedic applications do not meet the totality of necessary 
mechanical, biological, and chemical characteristics for long-term orthopedic implant success. 
Certain implant materials meet or exceed specific demands but falter in other areas.  Therefore, 
implants comprised of these materials will often fail prematurely. This failure necessitates revision 
surgery, which is taxing on the patient. Subsequent revision surgeries have even higher rates of 
implant failure. Therefore, there is a need for improved materials that can meet the requirements 
of their orthopedic applications.   
1.3 Implant Failure and Concerns 
Roughly 10% of implants fail prematurely.7 Implant failure necessitates revision surgery, 
which is often very taxing on the patient due to the presence of co-morbidities. Failure of the 
implant presents itself in a variety of ways. The primary manner of failure is aseptic 
osteolysis/loosening (75%), followed by infection (7%), recurrent dislocation (6%), periprosthetic 
fracture (5%), and surgical error (3%).7, 23-28  These sources of implant failure are often intertwined 
with each other, with specific pathways contributing to multiple modes of failure. 
1.3.1 Aseptic Loosening 
Aseptic loosening is traditionally defined as the failure of the bond between an implant and 
bone in the absence of infection.29 This is a major source of implant failure, and can be difficult to 
diagnose clinically, as signs/symptoms may not appear until the end-stage of the implant’s life.30 
There are many contributing factors for aseptic loosening including biomaterial wear and 
corrosion.31 
The generation of wear debris and the body’s response to this debris, is critical to the 
longevity/success of the orthopedic implant.7, 32-33 Consequences due to wear are the primary 
factors in the long-term performance of orthopedic implants. There are multiple mechanisms and 
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consequences due to wear such as the generation of particulate debris and inflammation. Each of 
these contribute to aseptic loosening and implant failure.  
The formation of wear debris is caused by the loss of material in particulate form, a direct 
consequence of the relative motion between two surfaces of the implant.7 In orthopedic implants, 
wear is caused by three different processes: 1) abrasion, by which a harder surface plows grooves 
into the softer material; 2) adhesion, when a softer material is smeared onto a harder surface 
forming a transfer film, and 3) fatigue, alternative episodes of loading and unloading resulting in 
the formation of subsurface cracks which propagate to form particles that are shed from the 
surface.7  
The micromotion that is experienced at the interface of implant and natural bone is 
enhanced due to the presence of gaps between the implant material and the patient’s bone.1 These 
large gaps are a concern because they are slow to be filled by bony in-growth during osteogenesis, 
hence these large spaces will persist for an extended period of time, destabilizing the implant. 
Increasing the contact between the bone and implant material reduces the size and quantity of 
spaces around the implant, which in turn helps stabilize the joint replacement and limits 
micromotion.1 Micromotion is particularly concerning, due to the generation of wear debris in this 
process which contributes to aseptic loosening and implant failure.  
Another contributing factor to aseptic loosening and destabilization of the implant is 
corrosion. Corrosion leads to degradation of the implant, which reduces its structural integrity, 
weakening its mechanical properties. Furthermore, the release of degradation products is 
potentially detrimental to the patient.7 Corrosion of the implant material is dictated by two 
processes, the thermodynamic driving forces for corrosion and the kinetic barrier to corrosion 
(surface oxide layer).5, 7 In the first process, the chemical driving force or the change in Gibb’s 
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free energy and charge separation control if corrosion will occur. Corrosion in the body is 
exacerbated due to the hostile electrolytic environment in vivo.5 The biological molecules present 
upset the equilibrium of the corrosion reactions of the implant by consuming the products due to 
anodic or cathodic reactions.5 Adsorbed proteins on the biomaterial surface can also contribute to 
corrosion, as adsorbed proteins have been shown to reduce the diffusion of oxygen at specific areas 
on the implant surface, facilitating corrosion in these areas (Figure 1.2). 
The main impediment to corrosion is the formation of a native oxide layer on the surface 
of metal orthopedic implants.5 These passive oxide layers prevent further transport of metallic ions 
as well as electrons across the oxide layer.7 For oxide layers to be effective at preventing corrosion, 
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Figure 1.2: Interface of a passivating alloy surface in contact with a biological environment. 
Figure adapted from Ratner et al.  
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they must present with uniform coverage across the metal, possess a structure that limits ion and 
electron transfer, and they must be robust enough to withstand the mechanical stress and abrasion 
experienced by orthopedic devices.  
If the oxide layer becomes corrupted, then corrosion of the implant material is possible.7 
Dissolved oxygen, inorganic ions, proteins, and the presence of cells can all compromise the oxide 
layer, resulting in corrosion and ion release.5 The integrity of the oxide layer can also be corrupted 
through mechanical means. Therefore, the machining and shaping of the alloy plays a role in 
preserving oxide layer integrity, and preventing subsequent corrosion.7 The unique shaping of 
orthopedic implants causes different areas to experience mechanical stress and abrasion in unique 
ways which can damage the oxide layer. This renders these tapered areas vulnerable to corrosion, 
especially crevice corrosion.7, 34 Furthermore, these oxide layers must also be able to withstand the 
mechanical demands post-implantation. For example, both wear and fretting have been shown to 
result in the rupture of the protective oxide layer, initiating cracks and causing the formation of 
reactive metal atoms on the surface, accelerating corrosion.   
Corrosion, wear, micromotion, and other forms of degradation at the implant site lead to 
the generation of particles in vivo.31, 35-36 These particles are unique depending on the material used 
in the implant. In stainless steel implants, the wear debris is usually encapsulated by a fibrous 
membrane, with little or no inflammation.7 The particles themselves are primarily composed of 
iron oxide and hydroxide species. In cobalt-chromium systems, the products are chromium 
phosphate. Finally, in the case of titanium-based alloys, despite their high corrosion resistance due 
to the stable titanium oxide layer, particles with the same elemental composition as the parent alloy 
are observed. The larger insoluble species are a concern given that the body will attempt to clear 
them, which causes inflammation at the implant site, discussed in more detail later. 
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As the presence of wear and corrosion degrades the implant, there is concern over the 
leaching of chemically and biologically active metal ions which can travel to surrounding tissues 
and organs, with potential negative health consequences to the patient. 7 Patients who have 
orthopedic implants have potentially higher blood serum levels of common implant metals, when 
compared to those without an implant.37 The presence of elevated serum levels is of concern due 
to the toxic nature of the elements present in implants. Elevated levels of ions can cause a host of 
ailments including carcinogenicity, anemia, and neuroglial dysfunction. These ailments are 
generally due to soluble forms of these wear debris, and therefore more needs to be known about 
the cytotoxic effects of these elements in the forms released from implants.38 
The generation of wear particles at the implant site due to micromotion elicits particular 
responses from the body.1, 39 Macrophages, a type of immune cell, attempt to ingest these wear 
particles.40 If macrophages ingest these particles, a host of biochemical processes occur. These 
include the activation of T-cells, the release of pro-inflammatory mediators, cytotoxicity, DNA 
damage, and oxidative stress.7 Macrophages contribute to local inflammation by secreting pro-
inflammatory cytokines (Figure 1.3).30 These cytokines lead to the recruitment of osteoclasts, 
bone cells that break down bone, and contribute to the local resorption of bone tissue.1 Other 
factors in bone resorption include the enzymes responsible for catabolism of the organic 
components of bone such as collagen.7 These include metalloproteinases collagenase and 
stromelysin. Prostaglandins are also important messengers in the osteolytic cascade produced by 
implant debris.7 Other mediators involved in stimulation or inhibition of osteoclast differentiation 
and maturation and osteoprotegerin have been suggested as key players in the development and 
progression of bone loss due to implant debris.  
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Normal bone maintenance requires the balance of both bone formation and bone resorption, 
which involves the function of both osteoblasts and osteoclasts.7 Therefore a decrease in 
osteoblastic bone formation or an increase in osteoclastic bone resorption can result in net bone 
loss and osteolysis, the destruction of bone tissue. Bone loss around an implant is a concern for 
implant stability given that it is a major cause of aseptic loosening.41  
1.3.2 Infection 
The presence of inflammation at the implant-bone interface is a concern not only for aseptic 
loosening, but for infection as well. The presence of inflammation at the implant site can 
potentially make the implant more susceptible to microbial colonization.42-43 If the host’s cells can 
reach and occupy the implant surface first, this will limit the potential for aseptic loosening, and 
provide a defensive barrier against microbial attachment and colonization.23 There are multiple 
species of bacteria that will colonize an implant, with Staphylococcus bacteria, particularly 
Staphylococcus aureus and Staphylococcus epidermidis accounting for a majority (70%) of 
implant infections.26, 44-47 Pseudomonas aeruginosa accounts for another 8% of infections.7, 48-50 
Figure 1.3: Pathways that contribute to aseptic loosening of orthopedic implants, a main 
cause of implant failure.  
Wear particles Pro-inflammatory cytokine 
Osteoclast Macrophage 
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These sessile bacteria will adhere to the implant surface as it provides a preferential place for 
attachment.51 
Attachment and subsequent colonization occur via multiple factors. Frist, initial 
interactions between the bacteria and the implant surface occur. These include hydrophobic, 
electrostatic, and Lifshitz-Van der Waals forces, among others.44, 52 It is thought that the degree of 
hydrophobicity of the staphylococcal bacterial cell surface and that of the biomaterial play a critical 
role in initial attachment.52 There are also specific proteins, the autolysins, which help mediate 
attachment. This type of protein has dual roles: enzymatic and adhesive. The second step in 
bacterial colonization is growth-dependent cell accumulation resulting in multiple cell layers in 
microcolonies.7, 44 In S. epidermidis this aggregation is linked with a β-1,6-linked 
glycosaminoglycan polysaccharide complex, known as polysaccharide intercellular adhesion 
(PIA) which is regulated by the Ica gene locus.7 Although this complex is conserved in related 
staphylococci, PIA and Ica are not required for biofilm formation, as bacteria lacking these are 
able to form biofilms. Once adhered after the second step, bacteria will produce a protective, 
polymeric, extracellular matrix known as a biofilm.53 This extracellular matrix contains a variety 
of materials including expolysaccharides, proteins, teichoic acids, and extracellular DNA.44, 54 This 
protective matrix renders the bacteria less susceptible to antibiotics, disinfectants, phagocytosis, 
and other mechanisms of infection response from the host.44, 48 In the last step of the cycle, the 
bacteria previously encased and protected in the biofilm disperse, returning to their initial 
planktonic form, ready to invade a new area (Figure 1.4).26, 44, 54 These biofilms are very difficult 
to treat with traditional antibiotics, not only because of the biofilm matrix, but also because many 
of these bacteria are resistant to clinically used antibiotics. High systemic doses of antibiotics are 
often needed to achieve effective local concentrations. Furthermore, microbial growth on the 
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implant hinders osteoblast adhesion and proliferation on the surface, negatively affecting implant 
integration. If treatment of these infections is unsuccessful, the implant must be removed.  
1.4 Current Directions 
1.4.1 Alternative Implant Alloys  
When using various alloys, there is often a tradeoff with different properties of the material. 
For instance, one may use titanium for its inertness, over stainless steel and cobalt-chromium, but 
then may lose some of the beneficial mechanical properties. In order to impart desirable properties 
into metallic implant materials, various metals will be alloyed with previously existing alloys.7 
These “new” alloys are often variations on the alloys already used clinically in orthopedic 
implants, including the stainless steels, cobalt-chromium alloys, and titanium alloys. Outside of 
these groups zirconium and tantalum alloys are also used. These materials form stable oxide layers, 
which help prevent corrosion. These materials are also hard and have high wear resistance. The 
drawback being that these materials are expensive. In addition, one must still consider the potential 
Figure 1.4: Formation of bacterial biofilms on orthopedic devices.   
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for corruption of the oxide layer, which would render the alloy vulnerable to corrosion, as is 
observed with currently utilized materials.  
Alteration of other implant alloys includes substitution of toxic elements with less toxic 
ones: i.e. vanadium for the less toxic metals niobium and iron in Ti-6Al-4V.7 These alternative 
alloys have similar properties to traditional Ti-6Al-4V, but with supposedly higher fatigue strength 
and a lower elastic modulus. This enhances bone to implant transfer and limits stress shielding. 
Modification of stainless steel alloys is also an area of interest. In these alloys, a high nitrogen 
content is incorporated to maintain its fatigue strength and improve resistance to pitting corrosion 
and crevice corrosion, as compared to nickel-containing alloys.  
1.4.2 Surface Modification 
 Since the interface between the surface and the host tissue is critical to implant success, 
the modification of the implant surface is of extreme interest in current research.11, 15, 17, 55-60 Many 
of the previously described chemical and biological phenomena: corrosion, osteoblast attachment, 
and bacterial adhesion, occur at the implant-tissue interface. The surface of the metallic implant 
can be modified by a variety of methods. These methods address either aseptic loosening or 
infection, with few examples addressing both.  
As the gaps that occur between the implant material and natural bone contribute to aseptic 
loosening and subsequent failure, research has tried to address this issue with gap-bridging 
coatings.1 These coatings are designed to swell to fill the gap between the implant and host tissue, 
ideally reducing micromotion and wear-particle induced osteolysis. The selection of the coating 
materials needs to be thoroughly considered, as the coating should not be susceptible to mechanical 
wear and negatively impact the implant’s utility. It should be composed of a material that does not 
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degrade or lead to the accumulation of toxic byproducts in vivo. Materials used for these coatings 
include hydrogels, foams, or deformable elastic metallic structures. Several of the current coatings 
contain Nitinol, a nickel-titanium alloy.61 There is some concern over the use of Nitinol, given its 
high nickel content. If the oxide layer of the Nitinol becomes damaged, nickel ions can release 
from this material. This is of concern as there are potential toxic and allergenic worries for nickel.62 
The most common type of coatings, porous coatings, are either metallic or ceramic foams 
on the surface that have been utilized for decades to facilitate bony in growth (osteoconduction) to 
help stabilize the implant.1 Many different types of porous structures have been developed, with 
beads commonly sintered together to form either open, interconnected pores or closed, individual 
pores. Other examples include trabecular metals and wire meshes.63  These types of modifications 
have had poor clinical success, with revision rates around 10%, which is on par with unmodified 
implants.64-65 Researchers are currently examining methods to optimize the pore structure to 
facilitate osteointegration, while also combating infection, another major contributor to implant 
failure.  
Hydroxyapatite coatings are also of interest for surface modification to improve 
osteointegration, given hydroxyapatite’s presence in natural bone.66-71 These coatings have been 
functionalized with antimicrobial agents to help prevent infection of the implant material. The 
concern with these functionalized materials is their mechanical stability as well as controlling the 
release of the antimicrobial agents to be most beneficial at preventing infection.1 Therefore, 
different methods of incorporation of the antimicrobial molecule either onto or into the surface 
coating have been examined in an attempt to adjust the timeframe of which these antimicrobials 
are viable, to provide longer-term protection from bacterial infection.72  
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Directly modifying the topography of the implant surface is another area of interest to 
improve the interactions between the implant and host.1 Modifying the surface topography to 
increase the surface area and porosity of the implant can improve osteoblast adhesion and in-
growth which help prevent aseptic loosening.73 Furthermore, the surface can be etched to create 
pits which serve as points of attachment for osteoblasts. Altered surface energy could prevent the 
adhesion of bacteria via passive means. In tailoring these surface properties, the chemical and 
mechanical stability of the implant should not be compromised. 
One of the long-standing clinical approaches to improving the implant-host interaction is 
bioactive glass coatings.1, 74-78 These coatings contain elements and molecules to encourage 
osteogenesis such as calcium and growth factors.79 These coatings deliver a surface apatite layer 
during dissolution, promoting osteogenesis. Unless modified with other substances, these coatings 
have limited antimicrobial properties. Although there are those that combine these bioactive glass 
coatings with antimicrobial agents to prevent infection.42, 80 In these functionalized coatings, 
design is critical. The antimicrobial agents must remain active through the manufacturing process 
and need to prevent infection on an appropriate time-frame. These coatings must also be strongly 
adhered to the implant material, to avoid delamination and cracking. 
1.5 Summary  
 A variety of materials are utilized in orthopedic implants. Unfortunately, no single material 
meets the totality of demands for these applications. Therefore, implants are susceptible to failure 
due to aseptic loosening and bacterial colonization. These issues are currently addressed through 
surface modification. However, these modifications are rarely multifunctional, focusing on only 
one cause of implant failure. Therefore, as the rates of knee and hip implants are expected to arise, 
future endeavors should address both aseptic loosening and infection of the implant.   
15
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Chapter 2: Formation and Characterization of Multi-tailed Self-assembled Monolayers on 
Titanium Aluminum Vanadium 
2.1 Introduction 
 Although no one material meets the totality of desirable characteristics for load-bearing 
orthopedic implants, titanium aluminum vanadium (Ti-6Al-4V), a titanium alloy, is frequently 
used as the femoral stem in hip replacement and as the femoral and tibial components in total knee 
replacements.1-3 The ubiquity of Ti-6Al-4V in these applications is due to its high strength to 
weight ratio, moderate moduli, corrosion resistance, and biocompatiblity.4-7 The material’s  bulk 
mechanical properties are owed to the presence of both aluminum and vanadium in the alloy, with 
Ti-6Al-4V consisting of 90% titanium, 6% aluminum, and 4% vanadium by weight.8-10 Aluminum 
stabilizes the α phase, whereas vanadium stabilizes the β phase and does not form chemical 
compounds with titanium. Therefore, Ti-6Al-4V exhibits higher tensile and yield strengths due to 
the presence of both of these phases at room temperature when compared to titanium alone.2, 11  
The chemical properties of Ti-6Al-4V, are dictated by the material’s surface content. Once 
exposed to water or oxygen, a thin (4-6 nm thick), strongly adhered oxide layer is formed on the 
surface of Ti-6Al-4V.2, 12 This layer consists of titanium dioxide followed by aluminum oxide 
(9%), and vanadium oxide (2%).10, 13 This oxide layer contributes to the inertness and corrosion 
resistance of the alloy and dictates its interfacial properties.2  
Ti-6Al-4V is chosen for orthopedic implant applications due to its high strength to weight 
ratio and corrosion resistance.4 However, Ti-6Al-4V suffers from poor osseointegration. It does 
not allow for the recruitment of immature cells onto the surface to then differentiate into 
preosteoclasts (osteoinduction) or for the growth of mature osteoblasts on the surface 
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(osteoconduction).14-15 Osteoblasts at the implant surface are necessary for the deposition of new 
bone, allowing for osseointegration. The alloy is also susceptible to bacterial colonization and 
biofilm formation, which can lead to implant infection.16-19 Poor osseointegration and/or infection 
contribute to implant failure.18, 20-26   
2.1.1 Surface Modification with Self-Assembled Monolayers 
Modification of the alloy surface is difficult due to the presence of the stable, relatively 
chemically inert oxide layer.27 However, the surface of Ti-6Al-4V can be modified using self-
assembled monolayers (SAMs).28 SAMs are molecular assemblies that form spontaneously on 
metal oxides and other surfaces.29-35 Monolayers are formed when organic molecules in the 
solution phase adsorb onto the substrate surface (Figure 2.1).31 These films are designed to be 
non-toxic and strongly adhered to the metal oxide surface. SAM molecules are comprised of three 
parts, an organic acid head group, an alkyl chain, and tail group (Figure 2.1b). The organic acid 
head group chemically binds to the oxide layer of the metal. SAM head groups include carboxylic, 
sulfonic, hydroxamic, and phosphonic acid.4, 30 The alkyl chain provides stability to the SAM 
through van der Waals interactions, with longer alkyl chains leading to increased stability. 36-37 
These SAMs can be described as either ordered or disordered (Figure 2.2).38 In ordered SAMs, 
the alkyl chains exist in a trans configuration. In disordered or loosely-packed monolayers, the 
alkyl chains possess cis orientations. The tail group aids stability through interactions such as 
hydrogen bonding or electrostatic forces.39 Since SAMs can form defined structures on the surface, 
these tail groups are presented at the interface in a consistent, active manner.  The tail group allows 












 Metal Oxide Metal Oxide 
Figure 2.2: a) SAMs can form in an ordered, crystalline all ordered all trans configuration. b) 
SAMs in a disordered, liquid-like monolayer with gauche interactions. 
Figure 2.1: a) SAM molecule interacting with the metal oxide surface. b) SAM components 












SAMs formed on orthopedic implant materials can be used as a flexible platform for 
altering the interfacial properties, allowing for the formation of a multifunctional surface.33 In this 
work, SAMs comprised of a phosphonic acid head group were chosen. Phosphonic acid was 
chosen as the head group due to its increased stability over SAMs possessing a carboxylic acid 
head group when formed on titanium dioxide, a primary component of the Ti-6Al-4V surface.30  
Commercially, phosphonic acid SAM molecules of various tail groups are available. These 
functional tail groups allow for specific, organic reactions at the surface. A selection of these SAM 
molecules with similar alkyl chain lengths was chosen to modify the surface of Ti-6Al-4V. 
In order to generate a flexible SAM platform, multifunctionality was incorporated via the 
presentation of different tail groups at the interface. Here, a systematic approach was undertaken 
to form SAMs of one or multiple tail groups on Ti-6Al-4V (Figure 2.3). This was performed to 
determine SAM combinations that were easily formed, chemically stable to solvent, possessing 
tail groups with unique reactivities.      
  
 
Figure 2.3: a) Single modification of Ti-6Al-4V with SAMs possessing on type of tail group. 
b) Dual modification of Ti-6Al-4V with SAMs possessing two different tail groups. c) Triple 
modification of Ti-6Al-4V with SAMs possessing three different types of tail groups.  
Metal Oxide Metal Oxide Metal Oxide 
a) b) c) 
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2.2 Materials  
11-phosphonoundecanoic acid (96% purity), 11-hydroxyundecylphosphonic acid (≥95% 
purity), 11-phosphonoundecylacrylate, 12-aminododecylphosphonic acid hydrochloride salt 
(≥95% purity), 12-mercaptododecylphosphonic acid (95% purity), and retinoic acid (≥98% purity) 
were obtained from Sigma Aldrich and used as received. Tetrahydrofuran, Optima grade, obtained 
from Fisher Scientific was distilled over sodium and benzophenone prior to use. Methanol was 
obtained from Duquesne University and dried over 4A molecular sieves. Ethanol and 18 MΩ water 
were also obtained from Duquesne University. Ti-6Al-4V, 0.52 mm thickness was purchased from 
Goodfellow Inc. (Coraopolis, PA US) and prepared as described below.  
2.3 Methods 
2.3.1 Preparation of Titanium Aluminum Vanadium 
Ti-6Al-4V was prepared by sanding with 150, 320, 400, and 600 grit sand paper. Substrates 
were then cut into 1 cm by 1 cm coupons. These coupons were sonicated in acetone for 15 minutes 
and then placed in boiling methanol for 15 minutes to remove any residue from the surface. Then, 
substrates were removed and placed sanded-side-up on a petri dish in a 120°C oven overnight to 
dry. After drying, substrates were stored in a glass vial until use. 
2.3.2 Formation of Self-assembled Monolayers on Titanium Aluminum Vanadium 
2.3.2.1 Single Modification with Self-assembled Monolayers 
SAMs were formed using a thin layer chromatography (TLC) aerosol sprayer with nitrogen 
as the propellant, where the phosphonic acid solutions (Table 2.1), were sprayed onto the Ti-6Al-
4V coupons. Deposition conditions including substrate temperature, solution temperature, number 
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of spray cycles, drying time/temperature were altered to facilitate SAM formation (Table 2.2, 







SAMs were then rinsed in the solvent used to dissolve the acid for 15 minutes to remove 
any loosely bound material and allowed to dry overnight in a 60°C oven. Substrates were sonicated 
in solvent for 15 minutes to test the stability of formed SAMs and then placed in a 60°C oven to 
dry prior to analysis. The formation of ordered and stable SAMs in this part of the project was 
Phosphonic Acid Concentration (mM) Solvent 
11-phosphonoundecanoic acid  1.0 Methanol 
11-hydroxyundecylphosphonic acid  1.0 Tetrahydrofuran 
11-phosphonoundecylacrylate  2.0 Tetrahydrofuran 
12-aminododecylphosphonic acid  0.5 Ethanol 
12-mercaptododecylphosphonic acid 1.0 Tetrahydrofuran 
















Carboxylic 3 4 55 60 18 
Hydroxyl 3 4 55 60 18 
Acrylate 3 4 55 60 18 
Amine 2 4 55 60 18 
















Aerosol  5 4 55 60 18 
Solution  NA 55 55 60 18 
Aerosol  5 55 4 60 18 
Table 2.1: Formation of phosphonic acid solutions. 
Table 2.2: Formation conditions for single modified Ti-6Al-4V. 
Table 2.3: Formation methods attempted to form ordered and stable SAMs of bromine 
terminated phosphonic acid.  
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crucial, since these deposition conditions were used as the initial parameters for the formation of 
dual modified Ti-6Al-4V.  
2.3.2.2 Dual Modification with Self-assembled Monolayers 
 The phosphonic acid molecules were used in combination to generate surfaces with two 
different SAM tails at the interface. Bromine was excluded from the combinations as it did not 
successfully form SAMs. Reaction conditions determined in the above section were used as 
starting points for the formation of dual modified Ti-6Al-4V (Table 2.1, Table 2.2). The different 
phosphonic acid solutions were sprayed separately during each spray cycle. The order of spraying 
as well as other reaction conditions were altered to form stable and ordered SAMs on the Ti-6Al-
4V surface (Table 2.4).      
 
 
After deposition, SAMs were rinsed in the solvents used to dissolve the acids for 15 
minutes and allowed to dry overnight in a 60°C oven. Substrates were sonicated in solvent for 15 




















Carboxylic (1) & acrylate (2) 2 4 55 1,2 60 18 
Carboxylic (1) & thiol (3) 2 4 55 3,1 60 18 
Carboxylic (1) & amine (4) 3 4 55 4,1 60 18 
Carboxylic (1) & hydroxyl (5) 3 4 55 5,1 60 18 
Acrylate (2) & thiol (3) 3 4 55 3,2 60 18 
Acrylate (2) & amine (4) 2 4 55 4,2 60 18 
Acrylate (2) & hydroxyl (5) 3 4 55 5,2 60 18 
Thiol (3) & amine (4) 3 4 55 4,3 60 18 
Thiol (3) & hydroxyl (5) 3 4 55 5,3 60 18 
Amine (4) & hydroxyl (5) 2 4 55 5,4 60 18 
Table 2.4:  Formation conditions for dual modified Ti-6Al-4V. 
30
2.3.2.3 Triple Modification with Self-assembled Monolayers 
Combinations of three different phosphonic acids were used to form SAMs on the Ti-6Al-
4V surface. Reaction conditions including substrate temperature, number of spray cycles, and 
order of SAM deposition were modified from those used to form single and dual SAMs on Ti-6Al-
4V (Table 2.5). Phosphonic acid solvent and concentration remained constant (Table 2.1). After 
deposition, SAMs were rinsed in the solvents used to dissolve the acids for 15 minutes and allowed 
to dry overnight in a 60°C oven. Substrates were sonicated in solvent for 15 minutes to test the 
























Thiol (3), acrylate (2), 
& carboxylic (1) 
2 4 55 1,3,2 60 18 
Thiol (3), acrylate (2), 
& amine (4) 
2 4 55 4,3,2 60 18 
Thiol (3), acrylate (2), 
& hydroxyl (5) 
2 4 55 5,3,2 60 18 
Thiol (3), carboxylic 
(1), & hydroxyl (5) 
2 4 55 3,5,1 60 18 
Thiol (3), amine (4), & 
hydroxyl (5) 
2 4 55 3,5,4 60 18 
Acrylate (2), carboxylic 
(1), & amine (4) 
2 4 55 2,1,4 60 18 
Acrylate (2), carboxylic 
(1), & hydroxyl (5) 
3 4 55 1,2,5 60 18 
Acrylate (2), amine (4), 
& hydroxyl (5) 
2 4 55 2,5,4 60 18 
Carboxylic (1), amine 
(4), & hydroxyl (5) 
2 4 55 5,1,4 60 18 
Table 2.5:  Formation conditions for triple modified Ti-6Al-4V. 
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2.3.3 Characterization of Self-assembled Monolayers 
2.3.3.1 Diffuse Reflectance Infrared Spectroscopy 
SAM formation was confirmed through diffuse reflectance infrared Fourier transform 
(DRIFT) spectroscopy using a Thermo Nicolet-Nexus FT-IR with a diffuse reflectance attachment. 
The spectra were collected under N2 to suppress stretches associated with CO2 and H2O. A total 
of 256 scans were collected per sample with a resolution of 4 cm-1. Unmodified Ti-6Al-4V 
substrates were used as the backgrounds for analysis; they did not possess stretches in the spectral 
regions of interest. 
2.3.3.2 Contact Angle  
The wettability of unmodified and modified Ti-6Al-4V substrates was examined using 
static contact angle analysis. This was performed after the substrates were sonicated in solvent for 
15 minutes and allowed to dry overnight. Millipore water (4 µL) was brought into contact with the 
coupon surface using a 10 µL syringe. A total of three drops were placed on each surface, on a 
total of three different substrates of each modification type were examined (n=9). The droplets 
were then analyzed using Image J software to obtain contact angle values. Contact angle values of 
the modified substrates were then compared to unmodified substrates and standard deviations (SD) 
were calculated. 
2.3.3.3 Matrix-assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) Mass 
Spectrometry 
MALDI-TOF was used to distinguish between the formation of monolayers and 
multilayers on the triple modified Ti-6Al-4V. In addition, this technique was used to confirm the 
presence of each phosphonic acid SAM on a triple modified surface. An Agilent Technologies 
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(G3250AA) LC/MSD-TOF mass spectrometry system with model G1969A AP MALDI source 
was used. The SAM modified coupons were fixed to the MALDI target using double-sided tape. 
Substrates were then spotted with a 10 mg/mL solution of retinoic acid in tetrahydrofuran 
repeatedly, until the substrates were covered. Spectra were collected on three different areas on 
each substrate in negative mode with the capillary voltage at 3500 V, a fragmentor voltage of 350 
V, and a skimmer voltage of 65 V. Nitrogen drying gas at 325 °C, was used to purge the instrument.  
2.4 Results 
2.4.1 Characterization of Self-Assembled Monolayer Ordering and Binding 
The formation of ordered and stable SAMs on Ti-6Al-4V was confirmed through DRIFT 
spectroscopy. Peaks attributed to the CH2 asym and sym stretching of the alkyl chain were used to 
indicate if an ordered SAM with aligned, all trans, alkyl chains was formed. A SAM was 
considered ordered if the CH2 asym was <2918 cm
-1 and the CH2 sym was <2850 cm
-1.30 These 
SAMs are considered crystalline with close packing of their alkyl chains. Conversely, CH2 asym 
stretching of >2918 cm-1 and CH2 sym >2850cm
-1 within the IR spectrum indicates cis 
confirmations of the alkyl chains with gauche interactions. These SAMs are characterized as more 
liquid-like.44  
DRIFT was used to determine the binding mode of the molecules in the SAM to the surface 
of Ti-6Al-4V by examining the absence or presence of peaks indicative of the phosphonic acid 
head group. The position of the stretches in the spectrum of the phosphonic acid solid were 
compared to their position in the deposited SAM. The stretches of the phosphonic acid head group 
included the P=O stretch at 1211 cm-1, P-O asym and sym at 1075 and 1003 cm-1, as well as P-OH 
stretching at 947 and 931 cm-1.  The presence of the P=O, P-O, and P-OH stretch within the 
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spectrum indicates monodentate binding, whereas the presence of P=O and P-O stretching 
represent bidentate finding, and the presence of a single stretch for P-O indicates tridentate binding 
(Figure 2.4).  The ordering of the alkyl chain and binding of the head group were determined after 






2.4.1.1 Single Modification of Titanium Aluminum Vanadium with SAMs 
The formation of SAMs possessing one type of functional tail on the surface of Ti-6Al-4V 
was achieved through alteration of the deposition conditions. These conditions were tailored 
specifically to each SAM molecule. SAMs were ordered and stable after sonication with the CH2 
asym stretch at <2918 cm-1 and the CH2 sym stretch at <2850 cm
-1 (Figure 2.5, Table 2.6). In the 
case of the bromine terminated phosphonic acid, ordered and stable SAMs were not formed despite 
rigorous attempts to optimize reaction conditions.  
Figure 2.4: Potential binding modes of phosphonic acid SAMs to oxide surface: a) 
monodentate, b) bidentate, c) tridentate, d) mixed with covalent bonding in conjunction with 
hydrogen bonding to surface hydroxyls. 
a) b) c) d) 
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These phosphonic acid headgroups of the SAMs exhibited various binding modes to the 
Ti-6Al-4V surface. All but one type of the SAMs formed presented stretches corresponding to 
mixed binding to the surface, in which hydrogen bonding in conjunction with covalent bonding 
was occurring between the surface and the SAM headgroup (Figure 2.6, Table 2.7). 
SAM CH2 asym Stretch Position (cm-1) CH2 sym Stretch Position (cm-1) 
12-mercaptododecylphosphonic acid 2914 2847 
12-aminododecylphosphonic acid 2915 2847 
11-phosphonoundecanoic acid 2912 2848 
11-phosphonoundecylacrylate 2915 2847 
11-hydroxyundecylphosphonic acid 2915 2847 
12-bromododecylphosphonic acid - - 
Table 2.6: Ordering of phosphonic acid SAMs on Ti-6Al-4V. 
Figure 2.5: DRIFT spectrum of the methylene stretching region of the carboxylic terminated 
SAM indicating the presence of ordered alkyl chains with all trans confirmations attributed to 
the position of the CH2 asym at 2912 cm
-1 and the CH2 sym at 2848 cm
-1.  
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Stretches corresponding to the functional tail group of the SAM molecules were observed 
within the IR spectra; their presence indicated the presentation of the functional tail at the interface 
(Figure 2.7, Table 2.8). The spectra of hydroxyl and carboxylic terminated SAMs both contained 
OH stretching at 3110 cm-1 and 3154 cm-1 respectively. Additionally, the IR spectrum of a SAM 
with a carboxylic acid tail group contained a C=O stretch due to the presence of the carbonyl at 




12-mercaptododecylphosphonic acid 1203, 1018, 941 P=O, P-O, P-OH Monodentate 
12-aminododecylphosphonic acid 1123, 915 P-O, P-OH Mixed 
11-phosphonoundecanoic acid 1207, 1003 P=O, P-O Bidentate 
11-phosphonoundecylacrylate 976 P-O/P-OH Mixed 
11-hydroxyundecylphosphonic acid 1188, 996 P-O, P-OH Mixed 
12-bromododecylphosphonic acid - - - 
Table 2.7: Binding of phosphonic acid SAMs to Ti-6Al-4V. 
Figure 2.6: DRIFT spectrum of the binding region, where the peak at 1207 cm-1 corresponds 
to P=O stretching and the peak at 1003 cm-1 represents a combination of P-O and P-OH 
stretching.  
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1719 cm-1. N-H stretching and bending of the amine tail group was observed within the spectrum 
of the amine terminated phosphonic acid SAM at 3171 cm-1 and 2941 cm-1. The IR spectrum of 
the acrylate terminated SAM possessed C=O stretching due to the carbonyl observed at 1722 cm-
1, as well as stretches representative of the C=C of the alkene at 1632 cm-1. The IR spectrum of the 
thiol terminated SAM did not possess stretches representative of the functional tail group. This is 
attributed to the weak nature of the C-S and S-H stretches, which renders them of little diagnostic 










SAM Peak (cm-1) Corresponding Stretch 
12-mercaptododecylphosphonic acid - - 
12-aminododecylphosphonic acid 3171, 2941 N-H, salt 
11-phosphonoundecanoic acid 3154,1719, 1650 OH, C=O, C-O 
11-phosphonoundecylacrylate 1722, 1632, 1426 C=O, C=C, C-H 
11-hydroxyundecylphosphonic acid 3110 OH 
12-bromododecylphosphonic acid - - 
Table 2.8: Stretches of SAM functional tail groups observed within the IR spectra. 
Figure 2.7: DRIFT spectrum of the regions possessing stretches attributable to the functional 
tail group of the carboxylic terminated SAM including OH stretching at 3154 cm-1 and C=O 
stretching at 1719 cm-1.  
























2.4.1.2 Dual Modification of Titanium Aluminum Vanadium with SAMs 
The reaction conditions utilized for the formation of ordered and stable SAMs possessing 
one tail group were used as the foundation for the generation of SAMs with two different tail 
groups. Each phosphonic acid molecule used in the formation of single modified surfaces was used 
to form unique combinations of dual modified surfaces, with the exception of the bromine 
terminated molecule, since this did not form stable SAMs on its own. The presence of more than 
one tail group required alteration of these initial methods. With adjustment, SAMs possessing more 
than one tail group were formed on the Ti-6Al-4V surface. All SAMs were ordered and stable 
through sonication (Figure 2.8, Table 2.9). The binding of these SAMs to the oxide surface was 









Figure 2.8: DRIFT spectrum of the methylene stretching region of the carboxylic and acrylate 
terminated SAMs indicating the presence of ordered alkyl chains with all trans confirmations 
attributed to the position of the CH2 asym at 2914 cm
























      





























SAM Combination CH2 asym Stretch Position (cm-1) CH2 sym Stretch Position (cm-1) 
Carboxylic & Acrylate 2914 2846 
Carboxylic & Thiol 2916 2848 
Carboxylic & Amine 2914 2847 
Carboxylic & Hydroxyl 2912 2845 
Acrylate & Thiol 2914 2847 
Acrylate & Amine 2914 2846 
Acrylate & Hydroxyl 2914 2847 
Thiol & Amine 2914 2847 
Thiol & Hydroxyl 2914 2847 
Amine & Hydroxyl 2914 2846 
Table 2.9: Ordering of dual phosphonic acid SAMs on Ti-6Al-4V. 
Figure 2.9: DRIFT spectrum of the binding region, where the peak at 1111 cm-1 corresponds 








Carboxylic & Acrylate 1111, 871 P-O, P-OH Mixed 
Carboxylic & Thiol 1145 P-O Tridentate 
Carboxylic & Amine 1125, 913 P-O, P-OH Mixed 
Carboxylic & Hydroxyl 1082,913 P-O, P-OH Mixed 
Acrylate & Thiol 1166, 1079, 908 P-O, P-OH Mixed 
Acrylate & Amine 1206, 1145, 980 P=O, P-O, P-OH Monodentate 
Acrylate & Hydroxyl 1069, 969 P-O, P-OH Mixed 
Thiol & Amine 1125, 1051, 916 P-O, P-OH Mixed 
Thiol & Hydroxyl 1064, 914 P-O, P-OH Mixed 
Amine & Hydroxyl 1049, 922 P-O, P-OH Mixed 
 
2.4.1.3 Triple Modification of Titanium Aluminum Vanadium with SAMs 
 Finally, SAMs of three different tail groups were formed on the surface of Ti-6Al-4V. This 
resulted in ten unique combinations of tail groups. The conditions used for the duals were used as 
the foundation for the reaction conditions, and these conditions were then altered to facilitate 
stabled and ordered SAM formation (Table 2.11, Figure 2.10). The binding of these mixed SAMs 
was again representative of that observed for single and dual modified surfaces with a mixed 
binding mode illustrating covalent bonding in conjunction with hydrogen bonding to the surface 
(Figure 2.11, Table 2.12). 
SAM Combination CH2 asym Stretch Position (cm-1) CH2 sym Stretch Position (cm-1) 
Thiol, Acrylate, & Carboxylic 2916 2848 
Thiol, Acrylate, & Amine 2914 2846 
Thiol, Acrylate & Hydroxyl 2914 2847 
Thiol, Carboxylic & Amine 2914 2847 
Thiol, Carboxylic, & Hydroxyl 2918 2849 
Thiol, Amine, & Hydroxyl 2913 2847 
Acrylate, Carboxylic, & Amine 2914 2847 
Acrylate, Carboxylic, & Hydroxyl 2914 2847 
Carboxylic, Amine, & Hydroxyl 2913 2847 
Acrylate, Amine, & Hydroxyl 2914 2846 
Table 2.10: Binding of dual phosphonic acid SAMs to Ti-6Al-4V. 
Table 2.11: Ordering of triple phosphonic acid SAMs to Ti-6Al-4V. 
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Thiol, Acrylate, & Carboxylic 1092, 909 P-O, P-OH Mixed 
Thiol, Acrylate, & Amine 1145, 991 P-O, P-OH Mixed 
Thiol, Acrylate & Hydroxyl 1049, 987 P-O, P-OH Mixed 
Thiol, Carboxylic & Amine 1126,918 P-O, P-OH Mixed 
Thiol, Carboxylic, & Hydroxyl 1088, 902 P-O, P-OH Mixed 
Thiol, Amine, & Hydroxyl 1101, 905 P-O, P-OH Mixed 
Acrylate, Carboxylic, & Amine 1076, 922 P-O, P-OH Mixed 
Acrylate, Carboxylic, & Hydroxyl 1142, 1003 P-O Tridentate 
Carboxylic, Amine, & Hydroxyl 1090, 919 P-O, P-OH Mixed 
Acrylate, Amine, & Hydroxyl 1087,918 P-O, P-OH Mixed 
Table 2.12: Binding of mixed phosphonic acid SAMs to Ti-6Al-4V. 
Figure 2.10: DRIFT spectrum of the methylene stretching region of the carboxylic, thiol, and 
acrylate terminated SAMs indicating the presence of ordered alkyl chains with all trans 
confirmations attributed to the position of the CH2 asym at 2916 cm
-1 and the CH2 sym at 2848 
cm-1. 
41























2.4.2 Wettability of Unmodified and SAM Modified Titanium Aluminum Vanadium 
The hydrophobicity of SAM modified and unmodified Ti-6Al-4V substrates was examined 
using static contact angle analysis to determine what effect SAM tail groups had on this property. 
Surfaces were considered hydrophilic if they exhibited a contact angle value <90˚, in which the 
water droplet preferentially interacted with the surface, and hydrophobic if the value was >90˚.  
2.4.2.1 Wettability of Single Modified Titanium Aluminum Vanadium 
The unmodified Ti-6Al-4V exhibited a hydrophilic contact angle value (<90°) at 77 ± 4° 
(Table 2.13). This was expected given the presence of hydroxyls and oxygens on the Ti-6Al-4V 
surface.27 Modification of the Ti-6Al-4V surface with a single type of phosphonic acid SAM also 
resulted in hydrophilic contact angle values (Table 2.13, Figure 2.12). The hydrophilic nature of 
Figure 2.11: DRIFT spectrum of the binding region, where the peak at 1092 cm-1 corresponds 
to P-O stretching and the peak at 909 cm-1 represents a P-OH stretch with hydrogen bonding to 
the surface. 
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the values observed for the thiol, carboxylic, hydroxyl, and amine terminated SAMs were expected 
given the ability of these tail groups to hydrogen bond.46 The contact angle value observed for the 
acrylate terminated was not expected; the presence of an alkene at the end of the alkyl chain would 
likely result in an unfavorable interaction with water. However, this SAM resulted in a hydrophilic 
surface (52 ± 8°). This is attributed to the presentation of the ester, 
and not the alkene tail of the acrylate at the interface. The standard 
deviations also indicate that there was variability in SAM 





2.4.2.2 Wettability of Dual Modified Titanium Aluminum Vanadium 
When examining SAMs of dual tail groups formed on Ti-6Al-
4V, hydrophilic contact angle values were also observed (Table 2.14, 
Figure 2.13). This was anticipated as several of the phosphonic 
acid SAMs exhibited hydrophilic contact angle values when 
formed individually. The tail groups of these acids are capable 
of hydrogen bonding, which contributes to the hydrophilic values observed when SAMs comprised 
of these acids were formed in combination. The carboxylic and acrylate dual modified Ti-6Al-4V 
and carboxylic and thiol dual modified Ti-6Al-4V presented hydrophilic contact angle values with 
large standard deviations (42 ± 11°, 23 ±11°). These large standard deviations indicate variability 
Phosphonic Acid SAM Value (deg) ±Stdev 
12-mercaptododecylphosphonic acid 33 5 
12-aminododecylphosphonic acid 59 5 
11-phosphonoundecanoic acid 47 7 
11-phosphonoundecylacrylate 52 8 
11-hydroxyundecylphosphonic acid 54 8 
Unmodified Ti-6Al-4V 77 4 
Table 2.13: Contact angle results for single SAMs on Ti-6Al-4V. 
Figure 2.12: Contact angle 
image of amine terminated 
SAMs on Ti-6Al-4V. 
Figure 2.13: Contact angle 
image of carboxylic and 
hydroxyl terminated SAMs 
on Ti-6Al-4V. 
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in the presentation of the tail groups at the interface. The orientation of the molecules at the 






2.4.2.3 Wettability of Triple Modified Titanium Aluminum Vanadium 
Triple modification of Ti-6Al-4V with three different tail 
groups simultaneously resulted in hydrophilic contact angle values as 
well (Table 2.15, Figure 2.14). This was anticipated as several 
of the phosphonic acid SAMs exhibited hydrophilic contact 
angle values when formed individually and in combination. One 
exception to this trend was the mixed SAM comprised of thiol, acrylate, and carboxylic terminated 
phosphonic acids. This combination resulted in surface with a higher contact angle (75 ± 4°) value, 
indicating less hydrophilicity. This was not observed when the acrylate was used to form SAMs 
alone or in combination with the other phosphonic acids. The inclusion of acrylate with the 
carboxylic and thiol terminated phosphonic acids may have resulted in multilayers in which the 
alkyl chain was exposed at the interface. This alkyl chain would increase the hydrophobicity of 
the surface. 
 
SAM Combination Value (deg) ±Stdev 
Carboxylic & Acrylate 42 11 
Carboxylic & Thiol 23 11 
Carboxylic & Amine 49 3 
Carboxylic & Hydroxyl 36 7 
Acrylate & Thiol 33 5 
Acrylate & Amine 59 6 
Acrylate & Hydroxyl 47 3 
Thiol & Amine 59 4 
Thiol & Hydroxyl 61 3 
Amine & Hydroxyl 63 6 
Table 2.14: Contact angle results for dual SAMs on Ti-6Al-4V. 
Figure 2.14: Contact angle 
image of carboxylic, 
acrylate, and thiol 









2.4.3 MALDI Analysis of SAMs Formed on Titanium Aluminum Vanadium 
 Substrates were subjected to MALDI analysis to confirm the formation of monolayers or 
multilayers on the surface. This technique was also used to determine the presence of the three 
individual phosphonic acids on the same modified substrate. Desorption of the bound molecules 
either resulted in observation of the monomer (monolayer) or dimer m/z (multilayer) of the 
phosphonic acid within the mass spectrum. MALDI-TOF analysis of an acrylate, carboxylic, and 
thiol triple modified surface revealed the presence of both monomer and dimer peaks of each 
phosphonic acid (Table 2.16, Figure 2.15).  In the case of the monomers, the values observed for 
each phosphonic acid corresponded to the loss of a hydrogen. This indicated that on this triple 
modified surface, multilayers were formed with monolayer coverage on parts of the substrate. This 
supports the hydrophobic contact angle values observed for this combination of SAMs. The 
stacking of the multilayers contributed to the hydrophobic nature of these substrates as the alkyl 
chains are potentially presented at the interface. 
 
 
SAM Combination Value (deg) ±Stdev 
Thiol, Acrylate, & Carboxylic 75 4 
Thiol, Acrylate, & Amine 52 7 
Thiol, Acrylate & Hydroxyl 51 6 
Thiol, Carboxylic & Amine 56 6 
Thiol, Carboxylic, & Hydroxyl 36 4 
Thiol, Amine, & Hydroxyl 54 3 
Acrylate, Carboxylic, & Amine 52 6 
Acrylate, Carboxylic, & Hydroxyl 61 4 
Carboxylic, Amine, & Hydroxyl 58 6 
Acrylate, Amine, & Hydroxyl 64 4 









 The formation of ordered and stable SAMs on metal oxide surfaces is dependent on 
properties of both the organic acids used and the surface chemistry of the metal.30, 47-50 In this 
study, SAMs were formed on the same alloy, Ti-6Al-4V. Therefore, differences observed in SAM 
formation are characteristic of the organic acids used. SAMs are formed due to the acid-base 
chemistry that occurs between the organic acid head group and the metal oxide substrate.30, 36-37, 51 
In one proposed mechanism, the µ-oxo and hydroxyl groups present on the surface act as Lewis 
bases and thus react with the organic acids.30 This generates a strong, covalent bond. In an 
alternative proposed method, proton transfer from the organic to the surface hydroxyls followed 
by dehydration leads to an ionic interaction between the deprotonated organic and dehydrated 
surface.30 
Molecule Actual Mass Observed (m/z) Error (ppm) 
11-phosphonoundecyl acrylate 305.1523 305.1507 5.2433 
11-phosphonoundecanoic acid 265.1210 265.1193 6.4122 
12-mercaptododecylphosphonic acid 281.1346 281.1334 4.2684 
Figure 2.15: MALDI results for a) carboxylic terminated SAM, b) acrylate terminated SAM, 
and c) thiol terminated SAM on triple modified Ti-6Al-4V. 
a) b) c) 
Table 2.16: MALDI results for acrylate, carboxylic, and thiol SAMs on Ti-6Al-4V. 
46
Traits of the organic acid that can affect SAM formation include the acidity of the head 
group, length of the alkyl chain, and the potential for tail group interactions.30, 52-55 The acidity of 
the head group is considered a potential factor given its role in the binding mechanism. The SAMs 
formed here all contained the same phosphonic acid head group with the same immediate 
neighboring atoms. The head groups of these SAMs bound to the surface in similar manners with 
evidence of covalent bonding as illustrated by the presence of the P-O stretch in conjunction with 
weaker, intermolecular hydrogen bonding between the phosphonic acid head group and a surface 
hydroxyl as evidenced by the shifted P-OH stretch. Although attachment occurred through both 
strong and weak mechanisms, the SAMs formed were stable through sonication, indicating the 
SAMs were tightly bound to the surface. 
Another parameter affecting SAM formation is the length of the alkyl chain.4  The length 
of the alkyl chain affects stability through the potential for van der Waals interactions. A longer 
alkyl chain enhances these interactions, which aids in SAM stability. The phosphonic acid 
molecules used in this study contained uninterrupted alkyl chains of similar length, 11-12 carbons. 
Therefore, alkyl chain length does not explain observed differences in SAM formation. Finally, 
the tail group of the SAM molecule can affect stability through hydrogen bonding and electrostatic 
interactions.54, 56 The variability in SAM formation is most likely due to the different tail groups 
of each molecule and their interactions with each other when used in combination to form SAMs 
on Ti-6Al-4V.  
 After alteration of reaction conditions, ordered SAMs of each phosphonic acid were formed 
on Ti-6Al-4V (Table 2.6). This was with the exception of the bromine terminated phosphonic acid 
molecule. SAMs of this molecule were not successfully formed on the surface, despite rigorous 
optimization of reaction conditions. This is potentially due to the large, atomic radius of bromine, 
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which could interfere with alignment of the alkyl chains, minimizing the van der Waals 
interactions, destabilizing the SAM. Additionally, unlike the majority of the other phosphonic 
acids studied, the bromine terminated molecule is incapable of hydrogen bonding in a traditional 
manner which would help stabilize the SAM.57  
 The other phosphonic acids were able to form SAMs on the surface of Ti-6Al-4V in a facile 
manner. The molecules terminated in thiol, amine, carboxylic acid, or hydroxyl were capable of 
hydrogen bonding with neighboring molecules. These interactions aided in film stability. The 
acrylate terminated phosphonic acid also formed ordered and stable SAMs without the influence 
of hydrogen bonding. For the acrylate terminated SAMs, the van der Waals interactions were 
sufficient to stabilize the film.  
Contact angle analysis of the SAMs formed indicated hydrophilic surfaces (Table 2.13). 
This was expected given these molecules’ ability to hydrogen bond.32, 58 Of note, is the low value 
observed for thiol terminated SAMs. This indicates a favorable interaction between the water 
droplet and modified surface. This value was lower than that observed for the other molecules 
capable of hydrogen bonding. These molecules may form a hydrogen bonding network with 
themselves, which limits their ability to hydrogen bond with the water molecule.59 This would 
increase the hydrophobicity of the surface. Hydrogen bonding of the carboxylic and hydroxyl 
terminated SAMs was evidenced by the position and broad appearance of these peaks in the IR 
spectrum (Table 2.8). 
 The acrylate terminated SAM also resulted in a hydrophilic contact angle value. Alkene 
terminated SAMs typically exhibit hydrophobic contact angle values due the presentation of the 
C=C bond at the surface.60 Therefore, the hydrophilic behavior observed here was unexpected. It 
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is possible that the orientation of the SAM on the substrate prevented the presentation of the alkene 
at the interface. The presence of the ester of the tail group may explain the hydrophilic value. 
When the phosphonic acids molecules were used in combination to form SAMs on Ti-6Al-
4V, these SAMs were also ordered and stable through sonication (Table 2.9). The incorporation 
of more than one tail group did not interfere substantially with the close packing of the alkyl chain. 
Stability of these SAMs was also aided through hydrogen bonding between the different 
phosphonic acid molecules. These SAMs presented hydrophilic contact angle values (Table 2.14). 
Hydrophilic values were anticipated as the phosphonic acids exhibited hydrophilic contact angle 
values when used individually in the formation of SAMs. Variability in surface coverage of the 
SAMs was noted in the carboxylic and acrylate as well as carboxylic and thiol combinations. These 
samples possessed larger standard deviations in contact angle values compared to the other 
combinations. Isolation of hydrophilic molecules by more hydrophobic molecules on the surface 
limits the wettability of the hydrophilic molecules.61 Therefore, it is possible that distribution of 
these molecules on the surface is not presented in an even manner; phase segregation of the 
molecules may be occurring which would account for the larger, observed standard deviation.61-65 
This should be examined further through atomic force microscopy and mass spectrometry to 
understand the distribution of the molecules on the surface. 
 Finally, all three phosphonic acids were utilized in the formation of SAMs to generate triple 
modified Ti-6Al-4V. These SAMs were ordered through stability testing (Table 2.11) In the 
formation of these SAMs, the deposition conditions were altered to reduce the number of spray 
cycles (Table 2.5). This was done to limit the opportunity for multilayering within the SAM. 
Despite this modification, multilayer was observed in one of the samples where thiol, acrylate, and 
carboxylic acid terminated SAMs were formed simultaneously. 
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 Evidence of multilayering within this sample was observed in the contact angle and 
MALDI-TOF analyses. These samples exhibited a higher contact angle value (75 ± 4°) than 
observed for the other mixed SAMs (Table 2.15). The individual phosphonic acid molecules used 
in this mixed SAM all exhibited hydrophilic contact angle values when formed alone and in 
combination with each other (Table 2.13, Table 2.14). If the SAMs were forming multilayers on 
the surface, the alkyl chain of these SAMs may be presented at the interface to some extent, which 
would account for the larger contact angle value. Evidence of multilayering in this mixture was 
also observed through MALDI-TOF analysis via the presence of both monomer and dimer peaks 
of each phosphonic acid molecule in the mass spectrum (Table 2.16). The presence of the dimer 
within the mass spectrum for each phosphonic acid indicates that these molecules were involved 
in multilayer formation.66 The presence of the monomer implies that some portions of the substrate 
possessed only monolayer coverage. Therefore, heterogeneity of the substrate occurred in which 
some portions demonstrated monolayer coverage and others multilayer coverage. This can be 
addressed through decreasing the number of spray cycles.  
2.6 Conclusions  
SAMs with phosphonic acid head groups of various tail groups were formed alone and in 
combination on the surface of Ti-6Al-4V. These SAMs were ordered and stable through sonication 
with covalent and hydrogen bonding to the surface observed. The tail groups at the interface 
resulted in hydrophilic surfaces with evidence of hydrogen bonding where applicable. The 
systematic study of these SAMs allowed for insight into which phosphonic acid molecules are 
suitable for the formation of SAMs alone and in combination with each other. SAMs that are 
ordered present the functional tail in a consistent, predictable manner at the interface. 
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 Understanding which SAMs were ordered and stable allowed for the determination of 
which functional tails were optimal for the second portion of this project. In the second portion, 
these SAMs were used as chemical anchors to immobilize bioactive molecules to the Ti-6Al-4V 
surface. The thiol, acrylate, and carboxylic phosphonic acids were chosen for this part as they were 
ordered and stable through rinse and sonication alone and in combination. Although these SAMs 
did exhibit multilayering, their tail groups’ unique reactivities allowed for orthogonal 
immobilization of the chosen bioactive molecules.  
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Chapter 3: Functionalization of Titanium Aluminum Vanadium with Bioactive Molecules 
3.1 Introduction 
The two main causes of orthopedic implant failure are infection and aseptic loosening.1-7 
Addressing these concerns with surface modification is desired, as these processes occur at the 
interface between the implant and host tissue. Current approaches focus on modifying the surface 
with bioactive molecules to encourage the deposition of new bone, while preventing the 
attachment and proliferation of bacteria.2, 8-9 Therefore, the molecules chosen in this work for the 
functionalization of Ti-6Al-4V via self-assembled monolayers (SAMs) addressed both bacterial 
adhesion and osseointegration.  
 3.1.1 Vancomycin 
Orthopedic implants are susceptible to colonization by several types of bacteria, including 
both Gram positive and Gram negative species.3, 10-12 However, Gram positive species, such as 
Stapylococcus bacteria account for a majority of infections (70%).4 Infection is addressed 
clinically through intravenous administration of antibiotics.13   Often, vancomycin, a glycopeptide 
antibiotic that targets Gram positive bacteria, with very limited efficacy against Gram negative 
species, is used to treat orthopedic implant infection.13-17 Vancomycin forms hydrogen bonds with 
the peptidoglycan terminal residues through four hydrogens and one oxygen from five secondary 
amides within its structure (Figure 3.1).18-21 This interaction causes vancomycin to prevent the 
crosslinking of peptides within the peptidoglycan layer (Figure 3.2).22-24 This compromises the 
integrity of the cell walls, rendering the cells incapable of responding to changes in osmotic 











Immobilization of vancomycin to the implant surface is preferred over systemic 
administration for several reasons. This approach allows for direct delivery of the antibiotic to the 
site of infection, where it is more likely to be effective, compared to a high concentration of 
circulating systemic antibiotic which results in insufficient drug concentrations at the site of 
infection.4 Direct surface delivery reduces potentially harmful side effects as local concentrations 
are sufficient to combat the infection without the side effects and toxicity associated with high 
systemic doses.17, 22, 25-26 In previous studies, immobilized vancomycin on ceramic materials was 
as successful as soluble vancomycin in culture against bacteria.18 When immobilized to SS 316L 
using SAMs as linkers, vancomycin reduced biofilm formation by 99% for 48 hours.27 Therefore, 
chemically linking vancomycin to the surface of Ti-6Al-4V using the previously developed 
Figure 3.1: Interactions between vancomycin and the D-ala-D-ala residues in the bacterial 
peptidoglycan wall which are crucial to its mechanism of action.  
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tunable SAM platform would help prevent the growth of Gram positive bacteria. Immobilization 
of vancomycin to Ti-6Al-4V in conjunction with other bioactive molecules in a multifunctional 
coating using SAMs as the linker system has not been reported in the literature.  
   
 
 
D-alanine bound through van der Waals interactions and hydrogen bonding 
Enzyme unable to recognize 
site; no cross-linking occurs 
Cell wall is compromised 
Pentaglycine chain D-alanine 
D-glutamate L-lysine 
N-acetylglucosamine Cross-linking enzyme 
Vancomycin 
N-acetylmuramic acid 
Figure 3.2: Mechanism of action for vancomycin against bacteria species in which 
vancomycin interacts with D-alanine residues of peptides of the peptidoglycan layer. This 
interaction prevents a crosslinking enzyme from recognizing the residues and therefore 
crosslinking does not occur, which compromises the integrity of the cell wall.  
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3.1.2 Nitric Oxide Donor Spermine NONOate 
 Nitric oxide (NO) is a cell-signaling molecule that plays a role in several biological 
processes including vasodilation, cancer, host infection, and wound repair.28-35 It is produced in 
the body by the nitric oxide synthase (NOS) enzyme.29, 36 The formation of NO through NOS in 
macrophages and monocytes allows these cells to be cytostatic and cytotoxic to various viruses, 
bacteria, fungi, and tumor cells.37 The antibacterial effect of NO is attributed to the nitrosative and 
oxidative stress it causes in a virus or bacterial cell.38 NO reacts with oxygen, water, and 
superoxides within the body to form highly reactive nitrogen and oxygen intermediates (Figure 
3.3). These reactive species overwhelm the cell’s ability to eliminate these species, which leads to 
damage of the bacterial deoxyribonucleic acid, lipids, and proteins.39 The modes of action for these 
occurrences include deamination of the deoxynucleotides in DNA, disruption of the reaction sites 







Figure 3.3: Intracellular and extracellular targets of endogenously and exogenously delivered 
NO (Image adapted from Carpenter et al.)39. 
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Furthermore, evidence suggests that NO can trigger a dispersal event in biofilms (Figure 
3.4).41 The release of planktonic bacterial cells from the biofilm renders them susceptible to 
treatment with traditional antibiotics. The mechanism of dispersal is not entirely understood, but 
it is attributed to nutrient availability, cell lysis within the biofilm, and release of quorum sensing 
molecules.38, 41 Nanomolar concentrations of NO are capable of decreasing biomass and increasing 
planktonic biomass of single and mixed biofilms containing E.coli, S. epidermidis, Vibrio cholera, 
C.albicans, and P. 
aeruginosa.38, 42 It has also 
been observed that coupling 
NO with an antibiotic increases the 
effectiveness of the antibiotic through 
synergistic effects.38, 43-45   
 NO’s antibacterial capability is limited by its delivery method.34, 46 Several donors have 
been synthesized to allow for the controlled release of NO. These include NO-metal complexes, 
nitroamines, N-diazeniumdiolates (NONOates), and S-nitrosothiols (RSNOs).33, 37 NONOates are 
the most widely used donors in NO releasing biomaterials.47 These donors release two moles of 
NO per parent compound under physiological conditions. They are formed via the reaction of a 
secondary amine with high pressure NO gas.48-49 A second basic residue, such as a metal alkoxide 
base, is necessary to deprotonate the secondary amine within the diazeniumdiolate backbone.50 
The diazeniumdiolate can then perform a nucleophilic attack of the NO. The cation from the 
alkoxide base stabilizes the resulting anionic NONOate.48-49 Upon protonation of the NO moiety 
of the NONOate donor, the NO is released. The structure of the amine precursor affects the release 
kinetics of the NO. Diethylenetriamine NONOate (DETA/NONOate) has a half-life of 20 hours, 





whereas diethylamine NONOate (DEA/NONOate) has a half-life of 2-4 minutes.51-52 This 
difference is due to hydrogen bond stabilization due to the presence of additional amines.50  
 These NO releasing molecules are incorporated into polymeric coatings in order to achieve 
local release on metals.53 For example, Nablo and coworkers developed a stainless steel implant 
material coated with a silica sol-gel containing a NONOate donor. Release of NO from these 
materials were in the picomole per cubic centimeter per second range (pmol cm-3 s-1; with sustained 
release for over 24 hours. These modified surfaces also reduced Staphylococcal bacterial adhesion. 
Holt et al. coated the surface of commercially pure titanium fixation pins with a silica xerogel 
possessing a NONOate functionality.54 Here, pmol cm-2 s-1 amounts of NO were released which 
reduced bacterial adhesion at 48 days post implantation in a mouse model. Previous work using 
SAMs to immobilize NO releasing molecules to the surface of Ti-6Al-4V demonstrated a 41.5 ± 
1.5% reduction in E. coli growth and a 25.3 ± 0.6% reduction in S. epidermidis growth when 
compared to controls.43 Also, a synergistic effect between the NO and an antibiotic, tetracycline, 
was observed. Furthermore, NO modified Ti-6Al-4V did not demonstrate any cytotoxic effects 
against mouse fibroblasts for 24 hours.43-44 
 In this work, spermine NONOate, which has a half-life of approximately 39 minutes, was 
chosen as the NO releasing compound for the functionalization of Ti-6Al-4V.55 Preliminary work 
by Autumn Schultz suggested enhanced antimicrobial effectiveness over other NONOates. The 
immobilization of both vancomycin and spermine NONOate to the surface of Ti-6Al-4V via SAMs 
would mitigate bacterial adhesion and proliferation allowing for a synergistic antimicrobial effect. 
3.1.3 Cell Adhesion Peptide Lys-Arg-Ser-Arg (KRSR) 
Ti-6Al-4V orthopedic implants suffer from poor osseointegration, as the alloy is neither 
osteoinductive or osteoconductive.2, 56-57 A common approach to engineering cell and tissue 
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behavior at device surfaces is to modify the material to selectively interact with a specific cell type 
through biomolecular recognition events.58 Often, peptides containing cell-binding domains found 
in the extracellular matrix (ECM) proteins are immobilized on the material to promote cell 
adhesion via ligand-receptor interactions.58-60 These peptides are specifically chosen to target 
osteoblasts, allowing for osteoblast adhesion and proliferation onto the implant surface.61 The use 
of cell adhesion peptides in orthopedic applications is attractive for several reasons. Peptides can 
be produced synthetically allowing for precise control of their chemical composition allowing for 
a broad range of synthetic applications.60, 62  
One such group of peptides are those possessing the Arg-Gly-Asp (RGD) sequence.60, 63 
This sequence is present in fibronectin, an ECM protein, and serves as an attachment cue. Peptides 
containing the RGD sequence serve as ligands for integrins.59, 64 Peptides possessing the RGD 
sequence  not only promote cell attachment, but they also enhance other fundamental cell functions 
such as mineralization in osteoblasts. Another class of cell adhesion peptides includes those that 
bind proteoglycans via electrostatic interactions.58 An example of this type is Lys-Arg-Ser-Arg 
(KRSR).65 Research has suggested improved osteoblast adhesion with KRSR compared to RGD 
modified surfaces.63, 65-67 KRSR peptides have also been shown to promote the selective adhesion 
of osteoblasts while, simultaneously, inhibiting the adhesion of soft-tissue forming cells like 
fibroblasts (scar tissue).68  
There are various methods to adhere these bioactive molecules to the surface. Molecules 
can be adsorbed to the surface by simple dipping methods.62-63 While this is a facile approach, it 
provides little control over the kinetics and delivery. A different strategy for controlled release 
from surfaces is the physical entrapment of biomolecules, where the molecules are retained by a 
barrier but not chemically bound to it. These often involve polymer-based matrices, ceramic 
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coatings, or reservoir systems.69 There are several concerns with this approach. These include 
cracking or degradation of the coating, local inflammation, lack of controlled release, and toxicity 
of degradation products.  
Covalent binding of bioactive molecules to the surface is an alternative method of delivery. 
Functionalization of Ti-6Al-4V using SAMs as chemical linkers allows for coatings that are 
strongly adhered with consistent presentation of bioactive molecules. In this work KRSR modified 
with a sacrificial cysteine was immobilized to the Ti-Al-4V surface using a SAM as a chemical 
linker. KRSR was chosen over a RGD containing peptide due to its specificity for osteoblasts over 
fibroblasts and enhanced cell adhesion properties.65-66, 68, 70-72 
3.1.4 Triple Functionalization through Orthogonal Chemistry  
 Immobilization of bioactive molecules to the surface of Ti-6Al-4V using SAMs as 
chemical linkers must consider both the appropriate SAM, as well as the target functional group 
within the bioactive molecule. In the formation of a triple functionalized surface, a SAM linker 
system, in which three unique tail groups were presented at the interface was desired. The unique 
chemistries of these tails allowed for specific, predictable reactions between the SAM and the 
target moiety of the bioactive molecule. Functional groups within the bioactive molecules that did 
not participate in their mechanism of action were selected. Therefore, these molecules would 
theoretically maintain their bioactivity once immobilized. Finally, orthogonal chemistries were 
used to covalently link the bioactive molecules to the surface. This approach avoids non-specific 





11-phosphonoundecanoic acid (96% purity), 11-phosphonoundecylacrylate, 12-
mercaptododecylphosphonic acid (95% purity), N-hydroxysuccinimide (NHS) (98%), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), vancomycin hydrochloride 
(≥80%), and Dulbecco’s phosphate buffered saline were obtained from Sigma Aldrich and used as 
received. 3-maleimidopropionic acid N-hydroxysuccinimide ester (99%) was supplied by Alfa 
Aesar. Spermine NONOate (≥98%) and the nitrate/nitrite colorimetric assay kit were supplied by 
Cayman Chemical. KRSRC (≥98%) was synthesized by GenScript. Tetrahydrofuran, Optima 
grade, obtained from Fisher Scientific was distilled over sodium and benzophenone prior to use. 
Acetonitrile was also supplied by Fisher Scientific. Methanol was obtained from Duquesne 
University and dried over 4A molecular sieves. Ethanol and 18 MΩ water were also obtained from 
Duquesne University. Titanium aluminum vanadium (Ti-6Al-4V), 0.52 mm thickness was 
purchased from Goodfellow Inc. (Coraopolis, PA US). 
3.3 Methods 
3.3.1 Preparation of Titanium Aluminum Vanadium 
Ti-6Al-4V was prepared by sanding with 150, 320, 400, and 600 grit sand paper. Substrates 
were then cut into 1 cm by 1 cm coupons. These coupons were sonicated in acetone for 15 minutes 
and then placed in boiling methanol for 15 minutes to remove any residue from the surface. Then, 
substrates were removed and placed sanded-side-up on a petri dish in a 120°C oven overnight to 




3.3.2 Formation of Single Functionalized Ti-6Al-4V 
 Ti-6Al-4V substrates modified with one type of SAM were used to immobilize either 
vancomycin, spermine NONOate, or KRSR(C) to the surface (Table 3.1). 
    
 
3.3.2.1 Immobilization of Vancomycin (R1) 
Immobilization of vancomycin to the Ti-6Al-4V surface was accomplished through 
crosslinking with 3-maleimidopropionic acid N-hydroxysuccinimide ester to thiol terminated 
SAMs (Scheme 3.1). A primary amine present within the vancomycin structure, that was not 
responsible for its bioactivity, was used to form an amide bond with the crosslinking agent. Then, 
the thiol tail of a SAM formed on Ti-6Al-4V was used to form a C-S bond to the maleimide portion 
of the crosslinker, chemically linking vancomycin to the surface.   
First, thiol terminated SAMs were formed on Ti-6Al-4V. Ti-6Al-4V substrates were 
chilled at 4°C for 30 minutes, while a solution of 1 mM 12-mercaptodocdecylphosphonic acid in 
tetrahydrofuran was warmed to 55°C. Substrates were then sprayed with the warm phosphonic 
acid solution. This was repeated for three cycles. After the last spray, substrates were dried in a 
60°C oven overnight. After a 15-minute rinse in deposition solvent and overnight drying, 
substrates were ready for vancomycin immobilization.  
A solution of 2 mg/mL vancomycin and 20 mM 3-maleimidopropionic acid N-
hydroxysuccinimide ester was prepared in 50/50 (v/v) acetonitrile and water. The reaction 
proceeded for one hour protected from light at room temperature. Then, substrates modified with 
SAM Tail Group Bioactive Molecule Target Moiety 
Acrylate KRSR(C) SH 
Carboxylic Spermine NONOate NH2 
Thiol Vancomycin NH2 
Table 3.1: SAMs and target moieties for the single functionalization of Ti-6Al-4V. 
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the thiol terminated SAM were placed modified-side-up in the vancomycin/linker solution for one 
hour, protected from light, under N2, at room temperature. After one hour, substrates were removed 
and rinsed in reaction solvent for one minute prior to drying overnight under vacuum.    
3.3.2.2 Immobilization of KRSR(C) (R2) 
 The cell adhesion peptide KRSR was purchased with the addition of a sacrificial cysteine. 
This cysteine possessed a free thiol that was used to form a C-S bond with the alkene of an acrylate 
terminated SAM via a base catalyzed thiol-ene Michael addition (Scheme 3.2).  
Acrylate terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates at 4°C 
for 30 minutes, while a solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran was 
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. This was 
repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After 
Scheme 3.1: Immobilization of vancomycin to thiol terminated SAMs through a) amide bond 
formation between vancomycin and the NHS portion of the crosslinker followed by b) C-S 
bond formation between a thiol terminated SAM and the maleimide linker. 
Reaction of thiol 
with maleimide 
Formation of C-S 
bond 









a 15-minute rinse in deposition solvent and overnight drying, substrates were ready for KRSR(C) 
immobilization. 
Ti-6Al-4V modified with acrylate terminated SAMs was placed sanded-side up in a 
solution containing 1 mg/mL of KRSR(C) and 5 µL of triethylamine. The reaction was performed 
over ice, protected from light, under N2 for four hours. After four hours, substrates were removed, 






3.3.2.3 Immobilization of Spermine NONOate (R3) 
 The nitric oxide releasing molecule spermine NONOate was immobilized to Ti-6Al-4V 
through amide bond formation with a SAM possessing a carboxylic tail group and EDC/NHS 
coupling (Scheme 3.3).  
Carboxylic acid terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates 
at 4°C for 30 minutes, while a solution of 1 mM 11-phosphonoundecanoic acid in methanol was 
warmed at 55°C. Substrates were then sprayed with the warm phosphonic acid solution. Substrates 





Formation of C-S bond 
Scheme 3.2: Immobilization of KRSR(C) to acrylate terminated SAMs via base catalyzed 
thiol-ene Michael addition.   
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spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent 













Substrates modified with a carboxylic acid terminated SAM were placed sanded-side-up 
in a solution that was 20 mM in EDC and 50 mM in NHS in 2-propanol. The solution was allowed 
Scheme 3.3: Immobilization of spermine NONOate to carboxylic terminated SAMs through 
a) EDC/NHS activation, followed by b) amide bond formation between a primary amine of 
spermine NONOate and the carboxylic tail of a phosphonic acid SAM through displacement 
of the NHS group. 














to react for 30 minutes at room temperature, protected from light, under N2. After 30 minutes, 
substrates were removed and allowed to dry under vacuum for one hour. Substrates were then 
placed in a 20 mM spermine NONOate solution prepared in a mixture of ethanol and water (4:1, 
v/v). Then, substrates were rinsed in ethanol and water (4:1) for one minute, and then allowed to 
dry under vacuum overnight.  
3.3.3 Formation of Dual Functionalized Ti-6Al-4V 
SAMs with two different tail groups at the interface were used to co-immobilize 
vancomycin, spermine NONOate, or KRSR(C) (Table 3.2).  
 
3.3.3.1 Immobilization of Vancomycin and KRSR(C) (R1 & R2) 
 Previous work on ceramic materials has shown that immobilization of vancomycin 
followed by the immobilization of KRSR(C) maintained the bioactivity of both molecules.70 Co-
immobilization of both vancomycin and KRSR(C) to Ti-6Al-4V surfaces was first accomplished 
by forming thiol and acrylate terminated SAMs on Ti-6Al-4V. Ti-6Al-4V was pretreated at 4°C 
for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran 
and a separate solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran were warmed at 
55°C. Using a TLC sprayer, SAMs were deposited through aerosol deposition by spraying 
substrates with the warm phosphonic acid solutions; first with the thiol solution and then the 
acrylate. This was repeated for three cycles. After the last spray, substrates were dried in a 60°C 
oven overnight. After a 15-minute rinse in deposition solvent, substrates were dried overnight prior 
SAM Tail Group Bioactive Molecule Target Moiety 
Acrylate & Carboxylic KRSR & Spermine NONOate SH & NH2 
Acrylate & Thiol KRSR & Vancomycin SH & NH2 
Carboxylic & Thiol Spermine NONOate & Vancomycin NH2 & NH2 
Table 3.2: SAMs and target moieties for the dual functionalization of Ti-6Al-4V.  
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to bioactive molecule immobilization. Then, Ti-6Al-4V modified with acrylate and thiol 
terminated SAMs were used to immobilize vancomycin (R1) (Scheme 3.4). Substrates were dried 





Scheme 3.5: Immobilization of KRSR(C) (R2) to thiol and acrylate terminated SAMs through 
C-S bond formation between the alkene of an acrylate terminated SAM and a free thiol of 
KRSR(C) via a thiol-ene Michael addition after vancomycin (R1) immobilization.  
Scheme 3.4: Immobilization of vancomycin (R1) to thiol and acrylate terminated SAMs 
through amide and C-S bond formation with a maleimide/NHS crosslinker.  
 
Scheme 3.4: Immobilization of vancomycin (R1) to thiol and acrylate terminated SAMs 
through amide and C-S bond formation with a maleimide/NHS crosslinker.  
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3.3.3.2 Immobilization of KRSR(C) and Spermine NONOate (R2 & R3) 
Co-immobilization of both KRSR(C) and spermine NONOate was accomplished by 
forming acrylate and carboxylic terminated SAMs on Ti-6Al-4V. Substrates were pretreated at 
4°C for 30 minutes, while a solution of 1 mM 11-phosphonoundecanoic acid in methanol and a 
separate solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran were warmed at 55°C. 
Substrates were then sprayed with the warm phosphonic acid solutions; first with the acrylate 
solution and then the carboxylic solution. Substrates were dried at room temperature for one 
minute. This was repeated for three cycles. After the last spray, substrates were dried in a 60°C 
oven overnight. After a 15-minute rinse in deposition solvent and overnight drying, substrates were 
ready for bioactive molecule immobilization.  
Ti-6Al-4V modified with acrylate and carboxylic terminated SAMs were utilized to 
immobilize KRSR(C) (R2) (Scheme 3.6). Substrates were dried overnight and used to immobilize 
spermine NONOate (R3) (Scheme 3.7). Spermine NONOate was immobilized last to avoid 
premature release of NO during the long peptide immobilization.   
 
Scheme 3.6: Immobilization of KRSR(C) (R2) to carboxylic acid and acrylate terminated 
SAMs through C-S bond formation between the alkene of an acrylate terminated SAM and a 
free thiol of KRSR(C) via a thiol-ene Michael addition. 
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3.3.3.3 Immobilization of Vancomycin and Spermine NONOate (R1 & R3) 
Co-immobilization of both vancomycin and spermine NONOate was accomplished by 
forming thiol and carboxylic terminated SAMs on Ti-6Al-4V. Substrates were pretreated at 4°C 
for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran 
and a separate solution of 1 mM 11-phosphonoundecanoic acid in methanol were warmed at 55°C. 
Substrates were then sprayed with the warm phosphonic acid solutions; first with the thiol solution 
and then the carboxylic solution. Substrates were dried at room temperature for one minute. This 
was repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. 
After a 15-minute rinse in deposition solvent and overnight drying, substrates were ready for 
bioactive molecule immobilization.  
Immobilization of both vancomycin and spermine NONOate to Ti-6Al-4V surfaces was 
accomplished by using Ti-6Al-4V modified with thiol and carboxylic terminated SAMs to first 
immobilize vancomycin (R1) (Scheme 3.8). Substrates were dried overnight and then 
functionalized with spermine NONOate (R3) (Scheme 3.9). Spermine NONOate was linked last 
to prevent premature NO release.   
Scheme 3.7: Immobilization of spermine NONOate (R3) to acrylate and carboxylic acid 
terminated SAMs via EDC/NHS crosslinking and amide bond formation after KRSR(C) (R2) 
immobilization.  
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Scheme 3.9: Immobilization of spermine NONOate (R3) to thiol and carboxylic acid 
terminated SAMs via EDC/NHS crosslinking and amide bond formation after vancomycin 
(R1) immobilization. 
Scheme 3.8: Immobilization of vancomycin (R1) to thiol and carboxylic acid terminated SAMs 
through amide and C-S bond formation with a maleimide/NHS crosslinker. 
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3.3.4 Formation of Triple Functionalized Ti-6Al-4V 
 SAMs with three different tail groups at the interface were used to immobilize vancomycin, 
KRSR(C), and spermine NONOate (Table 3.3). Immobilizing each bioactive molecule to the 
surface required strategic attachment methods to ensure preservation of the molecules’ activity 
once covalently linked. Vancomycin was covalently linked to the surface first, followed by 
KRSR(C). KRSR(C) was attached second to prevent masking of the peptide due to the large 
vancomycin molecule to help maintain its activity70. Finally, spermine NONOate was attached last 
to the Ti-6Al-4V to inhibit premature NO release during the immobilization steps of the other 
bioactive molecules as spermine release is sensitive to temperature, light, and changes in pH.44 
 
3.3.4.1 Immobilization of Vancomycin, KRSR(C), and Spermine NONOate (R1, R2, &R3)   
Thiol, acrylate, and carboxylic terminated SAMs were formed on Ti-6Al-4V to serve as 
linkers to immobilize the desired bioactive molecules. Substrates were pretreated at 4°C for 30 
minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran, a 
solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran, and a solution of 1 mM 11-
phosphonoundecanoic acid in methanol were warmed to 55°C. Substrates were then sprayed with 
the warm phosphonic acid solutions; first with the thiol solution, then the acrylate solution, and 
then with the carboxylic solution. Substrates were dried at room temperature for one minute. After 
spraying, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition 
solvent and overnight drying, substrates were ready for bioactive molecule immobilization.  
SAM Tail Group Bioactive Molecule Target Moiety 
Thiol, Acrylate, and 
Carboxylic 
Vancomycin, KRSR, and Spermine NONOate NH2, SH, & NH2 
Table 3.3: SAMs and target moieties for the triple functionalization of Ti-6Al-4V. 
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Ti-6Al-4V modified with the acrylate, carboxylic, and thiol terminated SAMs was used to 
immobilize vancomycin (R1) (Scheme 3.10).  After overnight drying, KRSR(C) (R2) was 
covalently linked to the surface (Scheme 3.11). Finally, spermine NONOate (R3) was immobilized 




Scheme 3.10: Immobilization of vancomycin (R1) to thiol, acrylate, and carboxylic acid 
terminated SAMs through amide and C-S bond formation with a maleimide/NHS crosslinker.   
Scheme 3.11: Immobilization of KRSR(C) (R2) to carboxylic acid, thiol, and acrylate 
terminated SAMs through C-S bond formation between the alkene of an acrylate terminated 




3.3.5 Immobilization Characterization 
3.3.5.1 Diffuse Reflectance Infrared Spectroscopy  
Successful immobilization of the bioactive molecules was confirmed through analysis 
using a Thermo Nicolet-Nexus FT-IR with a diffuse reflectance attachment. The spectra were 
collected under N2 to suppress stretches associated with CO2 and H2O. A total of 1024 scans were 
collected per sample with a resolution of 4 cm-1. Unmodified Ti-6Al-4V substrates were used as 
the backgrounds for analysis; they did not possess stretches representative of the SAM molecules. 
Differences in the IR spectrum between the SAM linker and the bioactive molecule were used to 
confirm attachment. 
3.3.5.2 Contact Angle Analysis  
The wettability of unmodified and modified Ti-6Al-4V substrates was examined through 
the use of static contact angle analysis with a Ramè-hart standard contact angle goniometer (Model 
200-U1). This was performed after the substrates were sonicated in solvent for 15 minutes and 
Scheme 3.12: Immobilization of spermine NONOate (R3) to thiol, acrylate, and carboxylic 
acid terminated SAMs via EDC/NHS crosslinking and amide bond formation after vancomycin 
(R1) immobilization and KRSR(C) (R2) immobilization. 
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allowed to dry overnight. Millipore water (2 µL) was brought into contact with the coupon surface 
using a 10 µL syringe. A total of three drops were placed on each surface, and a total of three 
different substrates of each modification type were examined (n=9). The droplets were imaged and 
then analyzed using DROPimage standard software to obtain contact angle values. Contact angle 
values of the functionalized surfaces were compared to unfunctionalized Ti-6Al-4V and standard 
deviations (SD) were calculated.  
3.3.5.3 Release of Nitric Oxide (Griess Assay) 
 NO release from spermine NONOate modified Ti-6Al-4V was assessed through a 
nitrate/nitrate colorimetric assay (Griess) supplied by Cayman Chemical (Figure 3.5).73-74 The 
total concentration of NO released from the system is first measured through the conversion of 
NO3
- to NO2
- by nitrate reductase.75 This was then followed by the addition of the Griess reagents, 
which convert NO2
- into a colored azo compound (λmax =540 nm). The concentration of this 
compound directly determines the concentration of NO2
- as it was converted from NO. NO release 
from spermine NONOate modified substrates was assessed over two hours. Functionalized 
substrates were placed into individual vials and covered with 0.9 mL of phosphate buffered saline 
(PBS). The vials were placed on an incubator/shaker at 37°C, protected from light. Every 15 
minutes, all of the PBS was removed from the vial and frozen at -20°C until assay. The 0.9 mL 
was then replaced with fresh PBS. 
The PBS samples were thawed and added to a 96-well plate as per kit instructions. A 
nitrate/nitrite calibration curve was generated using reagents supplied by the kit. Briefly 80 µL of 
smaple was incubated with 10 µL of enzyme cofactor mixture and 10 µL of nitrate reductase 
mixture. After a one hour incubation, 50 µL of Griess Reagent 1 and 50 µL of Griess Reagent 2 
were added to each well. The contents of the well plate were incubated at room temperature for 10 
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minutes prior to UV-Vis analysis. The absorbance of the wells was read using an Infinite M1000 
microplate reader (Tecan, USA) at an absorbance of 540 nm. The external calibration curve as 
well as dilution factors were used to determine the concentration of NO released from the 
substrates (n=9).  
  
3.4 Results 
3.4.1 Single Functionalized Ti-6Al-4V 
3.4.1.1 Immobilization of Vancomycin (R1) 
 Covalent attachment of vancomycin to thiol terminated SAMs on Ti-6Al-4V was 
accomplished through maleimide/NHS crosslinking (Scheme 3.1). An amide bond was formed 
between the crosslinking agent and a primary amine of the vancomycin. Then, the maleimide with 
the vancomycin linked was used to form a C-S bond between the thiol tail of the SAM and the 
maleimide portion of the crosslinking agent. After immobilization, the thiol terminated SAM was 
ordered with the CH2 asym at 2917 cm
-1 and the CH2 sym at 2848 cm
-1 (Figure 3.6) This indicated 
that the reaction did not affect the packing of the alkyl chains as SAMs retained their all trans 
Figure 3.5: Nitrite/nitrate colorimetric assay for the determination of NO released from 
spermine NONOate functionalized substrates.  
N-(1-
Naphthyl)ethylenediamine 
(Griess Reagent 2) 
Nitrate Nitrite 
Sulfanilamide (Griess Reagent 1) 
Nitrate 
reductase 
Azo product (λmax =540 nm) 
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confirmation. The SAM remained bound to Ti-6Al-4V in a bidentate manner, with a P=O stretch 














Figure 3.6: DRIFT spectra of the methylene stretching region after immobilization of 
vancomycin demonstrating that the alkyl chains of the SAMs were oriented in an all trans 
confirmation as shown by the CH2 asym at 2917 cm




































































Figure 3.7: DRIFT spectra of the immobilization of vancomycin as evidenced by the presence 
of the C=C stretching of the phenol ring at 1488 cm-1 and the C-O stretch at 1227 cm-1. The 
broad peak at 1620 cm-1 is attributable to both the C-OO- stretch and amide I C=O stretching 
within vancomycin. Amide II stretching was observed at 1428 cm-1.  
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Attachment of the vancomycin molecule was evidenced by the presence of the C=C 
stretching of the phenol ring at 1488 cm-1 and the C-O stretch at 1227 cm-1 (Figure 3.7). The broad 
peak at 1620 cm-1 is attributable to both the C-OO- stretch and amide I C=O stretching within 
vancomycin. Amide II stretching was observed at 1428 cm-1. A peak attributable to the lactam 
portion of the maleimide crosslinker was also observed at 1736 cm-1 (Figure 3.7). While stretches 
representative of the vancomycin molecule and linker were observed, the C-S stretch of the bond 
formed between the vancomycin and maleimide/NHS crosslinker was not observed; this stretch is 
not diagnostic in the IR.76 
Covalently attaching vancomycin to thiol terminated SAMs resulted in surfaces that 
exhibited a hydrophilic contact angle value (Table 3.4). The presence of several hydrophilic 
functional groups such as NH and OH within the molecule’s structure would account for the 
hydrophilic contact angle value. This value agrees well with values observed when vancomycin 
was immobilized on stainless steel (24 ± 12°).27 The large standard deviation indicates variability 
in the presentation of the vancomycin at the surface. This could be due to different orientations of 
the molecule or to the presence of the linker at the interface. 
  
 
3.4.1.2 Immobilization of KRSR(C) (R2) 
 The cell adhesion peptide KRSR(C) was covalently linked to the Ti-6Al-4V surface via 
base catalyzed C-S bond formation with the alkene of an acrylate terminated SAM (Scheme 3.2). 
After immobilization, the alkyl chains of the SAM linker remained ordered in an all trans 
Molecule Average ± SD (°) 
Thiol terminated SAM 61.5 ± 7.4 
Immobilized vancomycin 47.4 ± 13.6 
Table 3.4: Contact angle analysis before and after immobilization of vancomycin to thiol 
terminated SAMs.  
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confirmation, as shown by the CH2 asym at 2915 cm
-1 and the CH2 sym at 2847 cm
-1 (Figure 3.8). 
The phosphonic acid head group of the SAM remained bound to the Ti-6Al-4V surface as P=O 
stretching at 1265 cm-1 and P-O stretching at 1144 cm-1 were observed, indicating bidentate 
binding to Ti-6Al-4V (Figure 3.9). Carbonyl stretching of the acrylate functional tail of the SAM 
was also observed at 1726 cm-1 demonstrating the presence of the linker (Figure 3.9). 
 
 Stretches that were attributed to the peptide sequence were observed after immobilization 
(Figure 3.9). Stretches present in the IR spectrum included the C=O amide I stretching at 1671 
cm-1, as well as N-H stretching for amide II at 1567 cm-1 of the peptide backbone. These stretches 
were unique to the peptide and were not observed in the acrylate SAM linker. As with the 
immobilization of vancomycin, stretching due to the C-S bond formed to covalently link the 
KRSR(C) to the acrylate SAM was not observed. 
Figure 3.8: DRIFT spectra of the methylene stretching region after immobilization of 
KRSR(C) demonstrating that the alkyl chains of the SAMs were oriented in an all trans 
confirmation as evidenced by the position of the CH2 asym stretch at 2915 cm
-1 and the CH2 




























After attachment of KRSR(C) to Ti-6Al-4V, the surface wettability decreased (Table 3.5). 
This was unexpected given the presence of several hydrophilic functional groups within the 
peptide, such as NH, OH, and COOH. This may be explained by peptide interactions in which the 
hydrophilic groups are shielded from the water droplet, and the carbon containing backbone is 
exposed. The large standard deviation also indicates variability in the presentation of the peptide 





Molecule Average ± SD (°) 
Acrylate terminated SAM 55.4 ± 8.8 
Immobilized KRSR(C) 89.7 ± 14.7 
Figure 3.9: DRIFT spectra of the immobilization of the KRSR(C) peptide where stretches at 






























Table 3.5: Contact angle analysis before and after immobilization of KRSR(C) to acrylate 
terminated SAMs.  
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3.4.1.3 Immobilization of Spermine NONOate 
 Spermine NONOate was attached to the Ti-6Al-4V surface using EDC/NHS coupling via 
amide bond formation with a carboxylic terminated SAM (Scheme 3.3). After immobilization, the 
alkyl chain became disordered, with cis orientations present within the alkyl chain. The CH2 asym 
stretch was observed at 2928 cm-1 and the CH2 sym stretch was observed at 2854 cm
-1 (Figure 
3.10). Stretches corresponding to the phosphonic acid head group of P-O at 1157 cm-1 and P-OH 
at 918 indicated that the SAM was in a mixed binding mode, with hydrogen bonding to the surface 








After immobilization, stretches representative of the spermine NONOate molecule were 
observed within the IR spectrum. These include the stretch at 1656 cm-1 corresponding to the amide 
I stretch, as well as the amide II stretch at 1563 cm-1 (Figure 3.11). Importantly, a small stretch 
was observed at 1500 cm-1 due to the NO group, which indicates the presence of the nitric oxide 
Figure 3.10: DRIFT spectra of the methylene stretching region after spermine NONOate 
immobilization indicating the presence of a disordered alkyl chain with cis orientations as 
evidenced by the CH2 asym at 2928 cm





























donating moiety within the linked molecule. The attachment of the spermine NONOate to 
carboxylic acid terminated SAMs resulted in surfaces that exhibited a low contact angle value, 
indicating a hydrophilic surface (Table 3.6). The nitric oxide donating group and primary amines 










Release of NO from spermine NONOate modified Ti-6Al-4V was quantified using a 
nitrate/nitrite colorimetric assay.  The degradation of spermine NONOate into NO is a first order 
process.77 An initial burst release of 31.6 ± 0.5 nanomoles of NO was observed at 15 minutes, 
which was 41 ± 0.22% of total NO release, followed by sustained, linear release for two hours 
Molecule Average ± SD (°) 
Carboxylic terminated SAM 37.5 ± 11.8 
Immobilized Spermine NONOate 18.5 ± 9 
Figure 3.11: DRIFT spectra of the immobilization of spermine NONOate molecule where 
stretches were observed at 1656 cm-1 and 1563 cm-1 corresponding to the amide I and amide II 
stretches of the spermine NONOate molecule. 
Table 3.6: Contact angle analysis before and after immobilization of spermine NONOate to 
































(Figure 3.12). This followed a biphasic release pattern, rather than a solely first or second order 








3.4.2 Dual Functionalized Ti-6Al-4V 
3.4.2.1 Immobilization of Vancomycin and KRSR(C) (R1 &R2) 
 Co-immobilization of vancomycin and KRSR(C) to thiol and acrylate terminated SAMs 
was accomplished through specifically designed reactions between the SAM tail group and a target 
functional group within the bioactive molecule. Covalent attachment of vancomycin to thiol 
terminated SAMs on Ti-6Al-4V was accomplished through maleimide/NHS crosslinking (Scheme 
3.4). Then, KRSR(C) was covalently linked via a base catalyzed thiol-ene Michael addition 
(Scheme 3.5). After co-immobilization, the thiol and acrylate terminated SAMs were ordered with 
the CH2 asym at 2914 cm
-1 and the CH2 sym at 2847 cm
-1 (Figure 3.13). This indicated that the 
Figure 3.12: Spermine NONOate functionalized Ti-6Al-4V substrates had a burst release of 
31.6 ± 0.5 nanomoles of nitric oxide at 15 minutes with a total release after two hours of 77.0 
± 1.8 nanomoles of nitric oxide.  

































reaction did not affect the packing of the alkyl chains. The SAMs remained bound to Ti-6Al-4V 
in a tridentate manner, based on the P-O stretch at 1076 cm-1 observed in the IR spectrum (Figure 
3.14).  
 Stretches attributed to either KRSR(C) or vancomycin were observed after immobilization 
(Figure 3.14). This included a broad carbonyl stretch centered around 1737 cm-1. This broad 
stretch has two shoulders, which were also observed after the immobilization of vancomycin, but 
not within the KRSR(C) solid. In addition, amide I and amide II stretches were observed at 1666 
cm-1 and 1568 cm-1, respectively. Stretches of the C-S bonds formed to link the two bioactive 
molecules to the Ti-6Al-4V surface were not observed as C-S stretching is weak in the IR.76 
Covalently attaching vancomycin and KRSR(C) to thiol and acrylate terminated SAMs 
resulted in surfaces that exhibited a hydrophilic contact angle value (Table 3.7).  The presence of 




























Figure 3.13: DRIFT spectra of the methylene stretching region after vancomycin and 
KRSR(C) co-immobilization indicating the presence of an ordered alkyl chain with all trans 
confirmations as evidenced by the CH2 asym stretch at 2914 cm
-1 and the CH2 sym stretch at 
2847 cm-1. 
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contribute to the surface wettability. The presence of similar groups including amines, carboxylic 











3.4.2.2 Immobilization of KRSR(C) and Spermine NONOate (R2 & R3) 
Co-immobilization of KRSR(C) and spermine NONOate to acrylate and carboxylic acid 
terminated SAMs was accomplished through covalent bond formation between the alkene of the 
acrylate and a free thiol of the peptide by a thiol-ene Michael addition (Scheme 3.6), followed by 
Molecule(s) Average ± SD (°) 
Thiol and acrylate terminated SAM 58.7 ± 7.7 
Co-immobilized vancomycin & KRSR(C) 43.8 ± 8.3 
Acrylate terminated SAM 55.4 ± 8.8 
Immobilized KRSR(C) 89.7 ± 14.7 
Thiol terminated SAM 61.5 ± 7.4 
Immobilized vancomycin 47.4 ± 13.6 
Figure 3.14: DRIFT spectra after co-immobilization of vancomycin and KRSR(C) with 
stretches attributable to either KRSR(C) or vancomycin such as a broad carbonyl stretch 
centered around 1737 cm-1 and amide I and amide II stretches at 1666 cm-1 and 1568 cm-1, 





























Table 3.7: Contact angle analysis before and after co-immobilization of vancomycin and 
KRSR(C) to thiol and acrylate terminated SAMs. 
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amide bond formation between the carboxylic SAM and a primary amine within spermine 
NONOate via EDC/NHS crosslinking (Scheme 3.7). After co-immobilization, the acrylate and 
carboxylic terminated SAMs became partially disordered. The CH2 asym stretch at 2921 cm
-1 and 
the CH2 sym stretch at 2849 cm
-1 indicate the presence of both trans and cis orientations within 
the alkyl chain (Figure 3.15). The SAMs remained bound to Ti-6Al-4V in a tridentate manner, 
with a P-O stretch at 1076 cm-1 observed in the IR spectrum (Figure 3.16).  
 Stretches attributable to either KRSR(C) or spermine NONOate were observed after 
immobilization (Figure 3.16). This included a carbonyl stretch centered around 1730 cm-1. This 
stretch can be attributable to the SAM linkers as well as both bioactive molecules. What is unique 
is the presence of the amide I and amide II stretches at 1647 cm-1 and 1554 cm-1, respectively. 




























Figure 3.15: DRIFT spectra of the methylene stretching region after KRSR(C) and spermine 
NONOate co-immobilization indicating the presence of an alkyl chain with both cis and trans 
confirmations as evidenced by the presence of the stretches of CH2 asym at 2921 cm
-1 and the 
CH2 sym at 2849 cm
-1.  
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Furthermore, a small stretch around 1500 cm-1 was observed within the IR spectrum, indicating 
the presence of the nitric oxide donating moiety of spermine NONOate.  
Covalently attaching KRSR(C) and spermine NONOate to acrylate and carboxylic acid 
terminated SAMs resulted in surfaces that exhibited a hydrophilic contact angle value (Table 3.8). 
A hydrophilic value was expected, given the hydrophilicity of surfaces only functionalized with 
spermine NONOate. The value was higher than that observed for surfaces only modified with 
spermine. This increase in contact angle value is likely due to the presence of KRSR(C) at the 
interface which possessed a higher contact angle value than spermine NONOate. This is supported 
by the large standard deviation that was observed, indicating variability in surface chemistry.  
Figure 3.16: DRIFT spectrum after co-immobilization of KRSR(C) and spermine NONOate 
where stretches attributed to either molecule such as a carbonyl stretch centered around 1730 
































The amount of NO released from dual functionalized KRSR(C) and spermine NONOate 
substrates was examined using a Griess assay (Figure 3.17). A burst release of 65.1 ± 0.3 
nanomoles of NO was observed after 15 minutes. This burst release was higher than what was 
observed for single modified substrates. Release from the dual functionalized Ti-6Al-4V was 
observed over a two hour time period. The total release was 107.6 ± 1.5 nanomoles. This may 
indicate physisorption of the spermine NONOate to the surface via electrostatic or other 








Molecule(s) Average ± SD (°) 
Acrylate & carboxylic acid terminated SAM 53.6 ± 10.0 
Co-immobilized KRSR(C) & spermine NONOate 36.4 ± 12.4  
Acrylate terminated SAM 55.4 ± 8.8 
Immobilized KRSR(C) 89.7 ± 14.7 
Carboxylic acid terminated SAM 37.5 ± 11.8 
Immobilized spermine NONOate 18.5 ± 9.0 
Table 3.8: Contact angle analysis before and after co-immobilization of KRSR(C) and 
spermine NONOate to acrylate and carboxylic acid terminated SAMs. 






























Figure 3.17: KRSR(C) and spermine NONOate functionalized Ti-6Al-4V substrates had a 
burst release of 65.1 ± 0.3 nanomoles of nitric oxide at 15 minutes with a total release after two 
hours of 107.6 ± 1.5 nanomoles of nitric oxide.  
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3.4.2.3 Immobilization of Vancomycin and Spermine NONOate (R1 & R3) 
Co-immobilization of vancomycin and spermine NONOate to thiol and carboxylic acid 
terminated SAMs was accomplished through covalent bond formation between the thiol SAM and 
a primary amine of the vancomycin using a maleimide/NHS crosslinker (Scheme 3.8). Then, an 
amide bond was formed between the carboxylic SAM and a primary amine within spermine 
NONOate via EDC/NHS crosslinking (Scheme 3.9). After co-immobilization, the thiol and 
carboxylic terminated SAMs became disordered; the CH2 asym stretch at 2927 cm
-1 and the CH2 
sym stretch at 2854 cm-1 indicated the presence of cis orientations within the alkyl chain (Figure 
3.18). The SAMs remained bound to Ti-6Al-4V in a tridentate manner, with a P-O stretch at 1149 





































Figure 3.18: DRIFT spectra of the methylene stretching region after KRSR(C) and spermine 
NONOate co-immobilization indicating the presence of an alkyl chain with cis confirmations 
as evidenced by the presence of the CH2 asym stretch at 2927 cm
-1 and the CH2 sym stretch at 
2854 cm-1.  
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Stretches attributed to vancomycin and spermine NONOate were observed after 
immobilization (Figure 3.19). This included a carbonyl stretch centered at 1725 cm-1. This stretch 
can be attributed to the SAM linkers as well vancomycin. As with the vancomycin functionalized 
Ti-6Al-4V this C=O stretch contains a shoulder that can be due to the maleimide portion of the 
crosslinker.  Amide I and amide II stretches at 1643 cm-1 and 1549 cm-1 which are present within 
both bioactive molecules were also observed. These stretches are only found within the bioactive 
molecules and not within the SAM linkers. Furthermore, a small stretch around 1500 cm-1 was 
observed within the IR spectrum, indicating the presence of the nitric oxide donating moiety of 
spermine NONOate.  
Covalently attaching vancomycin and spermine NONOate to thiol and carboxylic acid 
terminated SAMs resulted in surfaces that exhibited a hydrophilic contact angle value (Table 3.9). 
A hydrophilic value was expected, given the hydrophilicity of surfaces only functionalized with 






























Figure 3.19: DRIFT spectra of stretches attributable to vancomycin or spermine NONOate 
were observed after immobilization; stretches included the C=O stretch centered around 1725 
cm-1 as well as the amide I and amide II stretches at 1643 cm-1 and 1549 cm-1, respectively. 
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The amount of NO released from dual functionalized vancomycin and spermine NONOate 
substrates was examined using a Griess assay (Figure 3.20). A burst release of 84.9 ± 0.4 
nanomoles of NO was observed after 15 minutes. This burst release was higher than what was 
observed for single modified substrates. Release from the dual functionalized Ti-6Al-4V was 
observed over a two hour time period. The total release was 117.6 ± 1.4 nanomoles. This may 
indicate physisorption of the spermine NONOate to the surface via electrostatic or other 
interactions with the cell adhesion peptide. This is supported by the low contact angle value.  
 
 
Molecule(s) Average ± SD (°) 
Thiol & carboxylic acid terminated SAM 44.4 ± 6.6 
Co-immobilized vancomycin & spermine NONOate 6.3 ± 5.8  
Thiol terminated SAM 61.5 ± 7.4 
Immobilized vancomycin 47.4 ± 13.6 
Carboxylic acid terminated SAM 37.5 ± 11.8 
Immobilized spermine NONOate 18.5 ± 9.0 
Table 3.9: Contact angle analysis before and after co-immobilization of vancomycin and 









3.4.3 Triple Functionalized Ti-6Al-4V (R1, R2, & R3) 
Triple immobilization of vancomycin, KRSR(C), and spermine NONOate to thiol, acrylate 
and carboxylic acid terminated SAMs on Ti-6Al-4V was accomplished through the use of 
orthogonal chemistry, with unique, specific reactions responsible for covalently linking each 
bioactive molecule. The thiol terminated SAM and a primary amine of the vancomycin were used 
in conjunction with a maleimide/NHS crosslinker to form a C-S and amide bond (Scheme 3.10). 
Next, a C-S bond between the acrylate terminated SAM and a thiol within KRSR(C) was formed 
under mildly basic conditions (Scheme 3.11). Then, an amide bond was formed between the 
carboxylic SAM and a primary amine within spermine NONOate via EDC/NHS crosslinking 
(Scheme 3.12). 
Figure 3.20: Vancomycin and spermine NONOate functionalized Ti-6Al-4V substrates had a 
burst release of 84.9 ± 0.4 nanomoles of nitric oxide at 15 minutes with a total release after two 
hours of 117.6 ± 1.4 nanomoles of nitric oxide.  





























After the immobilization of vancomycin, the SAMs were ordered with the CH2 asym 
stretch observed at 2918 cm-1 and the CH2 sym stretch observed at 2849 cm
-1 (Figure 3.21). The 
SAMs were bound to the surface in a monodentate manner as a P=O stretch at 1209 cm-1, a P-O 
cm-1, and a P-OH stretch at 930 cm-1 were observed within the IR spectrum (Figure 3.22). 
Additional stretches observed include a C=O stretch at 1736 cm-1, which is attributable to both 
vancomycin, the SAMs, as well as the lactam rings of the maleimide linker. Amide II stretching 
was present within the IR spectrum at 1586 cm-1 accompanied with a C=C stretch at 1467 cm-1 of 
the phenol rings after vancomycin immobilization (Figure 3.22). These stretches were also 









































Figure 3.21: DRIFT spectra of the methylene stretching region after vancomycin 
immobilization on triple functionalized Ti-6Al-4V. The alkyl chain was ordered with trans 
confirmations as evidenced by the CH2 asym stretch at 2918 cm
-1 and the CH2 sym stretch at 









Next, KRSR(C) was immobilized to the Ti-6Al-4V surface. SAMs were a mixture of 
ordered and disordered with the presence of both cis and trans confirmations within the alkyl 
chain. This was evidenced by the CH2 asym stretch observed at 2919 cm
-1 and the CH2 sym stretch 
observed at 2849 cm-1 (Figure 3.23). Ordered SAMs are preferred as they present their tail groups 
in a consistent manner at the interface. SAMs were bound to the surface in a tridentate manner as 
P=O stretching at 1027 cm-1 was observed in the IR spectrum (Figure 3.24). A carbonyl stretch 
was observed at 1739 cm-1 (Figure 3.24), shifted slightly from what was observed for the 
immobilization of vancomycin at 1736 cm-1.  The broadness of this stretch indicates multiple 
vibrational modes occurring simultaneously. This is expected given the different molecules on the 
surface that exhibit carbonyl stretching. In the IR spectrum, amide I and amide II stretching at 
1670 cm-1 and 1546 cm-1 were also observed. Amide stretching is found within both vancomycin 


































Figure 3.22: DRIFT spectra after the immobilization of vancomycin on triple functionalized 
Ti-6Al-4V. Stretches attributed to vancomycin were observed such as a C=O stretch centered 
around 1736 cm-1, a C=C stretch of the phenol ring at 1467 cm-1, as well as the amide II stretch 
at 1586 cm-1.  
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Figure 3.24: DRIFT spectrum with stretches attributed to vancomycin and KRSR(C) on triple 
functionalized Ti-6Al-4V were observed after immobilization such as a C=O stretch centered 
around 1739 cm-1 as well as the amide I and amide II stretching at 1670 cm-1 and 1586 cm-1, 
respectively.  
Figure 3.23: DRIFT spectra of the methylene stretching region after KRSR(C) immobilization 
on triple functionalized Ti-6Al-4V. The alkyl chain contained both cis and trans confirmations 
as evidenced by the CH2 asym stretch at 2919 cm
-1 and the CH2 sym stretch at 2849 cm
-1.  
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Finally, spermine NONOate was covalently linked to the Ti-6Al-4V surface. SAMs 
remained disordered; the CH2 asym at 2926 cm
-1 and the CH2 sym at 2851 cm
-1 were observed in 
the IR spectrum (Figure 3.25). The shift in the IR stretching could be attributed to destabilization 
of the SAM due to repeated solvent exposure. SAMs remained bound to the surface in a mixed 
manner, as P-O stretches at 1164 cm-1 and 1089 cm-1 as well as a P-OH stretch at 909 cm-1 
indicative of hydrogen bonding to the surface were present within the IR spectrum (Figure 3.26). 
Stretches attributed to spermine NONOate, vancomycin, and KRSR(C) on triple functionalized 
Ti-6Al-4V were observed including a C=O stretch centered around 1736 cm-1 as well as the amide 
I and amide II stretching at 1655 cm-1 and 1564 cm-1, respectively. A small stretch at approximately 
1500 cm-1 indicated the presence of the nitric oxide donating moiety.  
 
 






























Figure 3.25: DRIFT spectra after spermine NONOate immobilization on triple functionalized 
Ti-6Al-4V, SAMs were disordered with CH2 asym stretching and CH2 sym stretching observed 
at 2926 cm-1 and 2851 cm-1, respectively. This indicates cis confirmations within the alkyl 
chain. 
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Covalently attaching vancomycin, KRSR(C), and spermine NONOate to thiol, acrylate, 
and carboxylic acid terminated SAMs resulted in surfaces that exhibited a hydrophilic contact 
angle value (Table 3.10). A hydrophilic value was expected, given the hydrophilicity of the dual 
functionalized surfaces. The amount of NO released from triple functionalized substrates was 
examined using a Griess assay (Figure 3.27). A burst release of 51.0 ± 0.4 nanomoles of NO was 
observed after 15 minutes. This burst release was similar to what was observed for single 
functionalized substrates and lower than dual functionalized substrates. Release from the triple 
functionalized Ti-6Al-4V was observed over a two-hour time period. The total release was 74.7 ± 
1.6 nanomoles. As this is similar to what was observed for Ti-6Al-4V only functionalized with 






























Figure 3.26: DRIFT spectra after spermine NONOate attachment with stretches attributable to 
spermine NONOate, vancomycin, and KRSR(C) observed including a C=O stretch centered 
around 1736 cm-1 as well as the amide I and amide II stretching at 1655 cm-1 and 1564 cm-1, 
respectively.  
 
Figure 3.26: DRIFT spectra after spermine NONOate attachment with stretches attributable to 
spermine NONOate, vancomycin, and KRSR(C) observed includ ng a C=O stretch centered













3.5 Discussion  
 Attachment conditions optimized to form single functionalized substrates were used to 
synthesize dual and triple functionalized substrates through chemical reactions with the SAM tail 
and a target functional group within the bioactive molecule. Successful covalent attachment was 
Molecule(s) Average ± SD (°) 
Thiol, acrylate, & carboxylic acid terminated SAM 23.9 ± 16.6 
Vancomycin, KRSR(C), and spermine NONOate immobilized 13.6 ± 11.2 
Thiol terminated SAM 61.5 ± 7.4 
Immobilized Vancomycin 47.4 ± 13.6 
Carboxylic acid terminated SAM 37.5 ± 11.8 
Immobilized spermine NONOate 18.5 ± 9.0 
Acrylate terminated SAM 55.4 ± 8.8 
Immobilized KRSR(C) 89.7 ± 14.7 
Table 3.10: Contact angle analysis before and after co-immobilization of vancomycin, 
KRSR(C), and spermine NONOate to acrylate, thiol, and carboxylic acid terminated SAMs. 
 
Molecule(s) Average ± SD(°) 
Thiol, acrylate, & carboxylic acid terminated SAM 23.9 ± 16.6 
Vancomycin, KRSR(C), and spermine NONOate immobilized 13.6 ± 11.2 
Thiol terminated SAM 61.5 ± 7.4 
Immobilized Vancomycin 47.4 ± 13.6 
Carboxylic acid terminated SAM 37.5 ± 11.8 
Immobilized spermine NONOate 18.5 ± 9.0 
Acrylate terminated SAM 55.4 ± 8.8 
Immobilized KRSR(C) 89.7 ± 14.7 
 Table 3.10: Contact angle analysis before and after co-immobilization of vancomycin and 
spermine NONOate to acrylate and carboxylic acid terminated SAMs. 





























Figure 3.27: Triple functionalized Ti-6Al-4V substrates had a burst release of 51.0 ± 0.4 
nanomoles of nitric oxide at 15 minutes with a total release after two hours of 74.7 ± 1.6 
nanomoles of nitric oxide.  
 
Figure 3.27: Triple functionalized Ti-6Al-4V substrates had a burst release of 51.0 ± 0.4 
nanomoles of nitric oxide at 15 minutes with a total release after two hours of 74.7 ± 1.6 
nanomoles of nitric oxide.  
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confirmed using IR spectroscopy by comparing stretches present within the bioactive molecule 
and the immobilized molecule.  
Unfortunately, the bioactive molecules and SAM linkers share several functional groups 
including amides, amines, and carboxylic acids. Therefore, stretches that were unique to the 
individual bioactive molecules indicated successful covalent attachment. In vancomycin, these 
stretches corresponded to the phenol ring as well as the lactam rings of the maleimide/NHS 
crosslinking agent (Figure 3.7). Stretches of this linker were expected in the IR as this structure 
remains after immobilization of vancomycin.  
Covalent attachment of the cell adhesion peptide KRSR(C) on dual and triple 
functionalized substrates was difficult to assess given shared functional groups with vancomycin 
and spermine NONOate. Here, attachment was confirmed via the subtle differences in peak 
position. When co-immobilized with vancomycin, the positions of the amide I and amide II 
stretches were used to verify attachment (Figure 3.14). This was similar with spermine NONOate, 
since it shares stretches with KRSR(C) and vancomycin. In the case of spermine NONOate, the 
stretch corresponding to the nitric oxide donating group was diagnostic, therefore attachment was 
confirmed with the presence of this stretch (Figure 3.16).   
The presence of hydrophilic groups within the bioactive molecules at the interface 
contributed to the low contact angle values observed for several of the functionalized surfaces. 
However, KRSR(C) functionalized substrates exhibited a more hydrophobic contact angle value. 
This was not anticipated, as this molecule possesses several hydrophilic portions. Large, 
physiosorbed amounts of KRSR(C) to the surface may explain this. The peptide may have oriented 
itself in a manner in which the hydrophilic portions were shielded. When multiple molecules were 
linked to Ti-6Al-4V, these surfaces illustrated contact angle values that were representative of each 
103
bioactive molecule. Variability in the surface wettability, as evidenced by the standard deviation, 
was observed in several of the combinations. Therefore, it is likely that these molecules were 
unevenly distributed across the surface. This would need to be confirmed with other techniques 
such as mapping mass spectrometry or atomic force microscopy (AFM) which would help 
characterize SAM uniformity as well as the distribution of these molecules on the surface. 
 Uneven distribution or physisorption of spermine NONOate may also explain results for 
substrates functionalized with this bioactive molecule. These substrates exhibited very hydrophilic 
contact angle values, which were difficult to measure, given the droplet’s preference to interact 
with the surface. When nitric oxide release was assessed from the different functionalizations, dual 
functionalized substrates released more nitric oxide than single functionalized substrates. 
Theoretically, single functionalized spermine NONOate would release more nitric oxide than dual 
functionalized substrates, since there would be more sites available for spermine NONOate 
attachment on substrates only possessing carboxylic acid SAMs. The large release from dual 
functionalized indicates physisorption of the spermine NONOate to surfaces possessing 
vancomycin or KRSR(C). It is possible for hydrogen bonding and electrostatic interactions to 
occur between these bioactive molecules. When immobilized with both KRSR(C) and 
vancomycin, nitric oxide release was more comparable to that observed for spermine NONOate 
single functionalized substrates. The presence of both of these other molecules may interfere with 
the spermine’s ability to adsorb to the surface. The quantity of nitric oxide released from single 
and triple functionalized substrates was within values observed for a nitric oxide molecule 





 Using orthogonal chemical reactions, substrates functionalized with vancomycin, 
KRSR(C), and spermine NONOate were formed. Covalent attachment of these bioactive 
molecules was confirmed with IR spectroscopy through distinct differences in the IR spectra 
before and after functionalization. Contact angle analysis and nitric oxide release indicated 
potential physisorption of KRSR(C) and spermine NONOate to Ti-6Al-4V.  
 The covalent attachment of these molecules to Ti-6Al-4V should not affect their bioactivity 
as this would diminish their effectiveness at preventing bacterial adhesion and encouraging 
osteoblast adhesion. Therefore, these substrates were next subjected to bacterial challenges to 
examine their antimicrobial properties. Then, human bone cells were grown on functionalized Ti-
6Al-4V to characterize cytotoxicity of bioactive molecule immobilization. 
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Chapter 4: Bacterial Adhesion and Viability on Functionalized Titanium Aluminum 
Vanadium 
4.1 Introduction  
 Bacteria adhesion to the Ti-6Al-4V surface leads to biofilm formation and subsequent 
infection which contribute to implant failure.1-7 There are several species of bacteria that colonize 
Ti-6Al-4V which include Gram positive Staphylococcus bacteria, such as Staphylococcus aureus 
and Staphylococcus epidermidis and Gram negative species including Pseudomonas aeruginosa.2, 
8 These bacteria can form a biofilm on the implant surface, rendering them difficult to treat with 
traditional antibiotics as antibiotics have difficulty diffusing through the polymer matrix of the 
biofilm.8-9 Compounding this issue, is the development of antibiotic resistant bacteria within this 







In this work, Ti-6Al-4V was functionalized with vancomycin and spermine NONOate. 
Vancomycin is an antibiotic that is effective against Gram positive bacteria and is frequently used 
to treat orthopedic implant infections.10-23 Spermine NONOate is a nitric oxide releasing molecule. 
Nitric oxide exhibits antimicrobial effects whose efficacy is specific to the bacterial species.24-25 
Figure 4.1: Development of antibiotic resistant bacteria within a biofilm.  
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Nitric oxide has also been indicated to cause a dispersal event in biofilms, allowing the bacteria to 
be targeted by traditional antibiotics.26-34 The co-immobilization of both antimicrobial agents to 
the surface would allow for a synergistic effect.26, 35-37  
 Here, functionality of the biomolecules was characterized through bacterial challenges with 
either Staphylococcus epidermidis (S. epidermidis), or Escherichia coli (E. coli). S. epidermidis 
was chosen given its prevalence in orthopedic implant infections. E. coli was used as a 
representative Gram negative species.38 The adhesion of these bacteria to and viability on bioactive 
molecule functionalized Ti-6Al-4V was assessed using fluorescence microscopy. 
4.2 Materials 
Lennox Luria-Bertani (LB) media was obtained from MP Biomedicals, Inc, and two 
capsules were dissolved per 50 mL of double deionized water (ddH2O) and autoclaved prior to 
use. E. coli (ATCC® 25922) and S. epidermidis (ATCC 14990) were obtained from American 
Type Culture Collection (ATCC). The LIVE/DEAD TM BacLightTM Bacterial Viability Kit was 
obtained from Thermo Fisher Scientific. 11-phosphonoundecanoic acid (96% purity), 11-
phosphonoundecylacrylate, 12-mercaptododecylphosphonic acid (95% purity), N-
hydroxysuccinimide (NHS) (98%), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC), vancomycin hydrochloride (≥80%), and Dulbecco’s phosphate buffered 
saline (PBS) were obtained from Sigma Aldrich and used as received. 3-maleimidopropionic acid 
N-hydroxysuccinimide ester (99%) was supplied by Alfa Aesar. Spermine NONOate (≥98%) was 
supplied by Cayman Chemical. KRSRC (≥98%) was synthesized by GenScript. Tetrahydrofuran, 
Optima grade, obtained from Fisher Scientific was distilled over sodium and benzophenone prior 
to use. Acetonitrile was also supplied by Fisher Scientific. Methanol was obtained from Duquesne 
University and dried over 4A molecular sieves. Ethanol and 18 MΩ water were also obtained from 
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Duquesne University. Titanium aluminum vanadium (Ti-6Al-4V), 0.52 mm thickness was 
purchased from Goodfellow Inc. (Coraopolis, PA US). 
4.3 Methods 
4.3.1 Preparation of Titanium Aluminum Vanadium 
Ti-6Al-4V was prepared by sanding with 150, 320, 400, and 600 grit sand paper. Substrates 
were then cut into 1 cm by 1 cm coupons. These coupons were sonicated in acetone for 15 minutes 
and then placed in boiling methanol for 15 minutes to remove any residue from the surface. Then, 
substrates were removed and placed sanded-side-up on a petri dish in a 120°C oven overnight to 
dry. After drying, substrates were stored in a glass vial until use. 
4.3.2 Formation of Single Functionalized Ti-6Al-4V 
4.3.2.1 Immobilization of Vancomycin (R1) 
Ti-6Al-4V substrates were chilled at 4°C for 30 minutes, while a solution of 1 mM 12-
mercaptodocdecylphosphonic acid in tetrahydrofuran was warmed to 55°C. Substrates were then 
sprayed with the warm phosphonic acid solution. This was repeated for three cycles. After the last 
spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent 
and overnight drying, substrates were ready for vancomycin immobilization.  
A solution of 2 mg/mL vancomycin and 20 mM 3-maleimidopropionic acid N-
hydroxysuccinimide ester was prepared in 50/50 (v/v) acetonitrile and water. The reaction 
proceeded for one hour protected from light at room temperature. Then, substrates modified with 
the thiol terminated SAM were placed modified-side-up in the vancomycin/linker solution for one 
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hour, protected from light, under N2, at room temperature. After one hour, substrates were removed 
and rinsed in reaction solvent for one minute prior to drying overnight under vacuum.    
4.3.2.2 Immobilization of KRSR(C) (R2) 
Acrylate terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates at 4°C 
for 30 minutes, while a solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran was 
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. This was 
repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After 
a 15-minute rinse in deposition solvent and overnight drying, substrates were ready for KRSR(C) 
immobilization. 
Ti-6Al-4V modified with acrylate terminated SAMs was placed sanded-side up in a 
solution containing 1 mg/mL of KRSR(C) and 5 µL of triethylamine. The reaction was performed 
over ice, protected from light, under N2 for four hours. After four hours, substrates were removed, 
placed in water for one minute, and then dried overnight under vacuum.  
4.3.2.3 Immobilization of Spermine NONOate (R3) 
Carboxylic acid terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates 
at 4°C for 30 minutes, while a solution of 1 mM 11-phosphonoundecanoic acid in methanol was 
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. Substrates 
were dried at room temperature for one minute. This was repeated for three cycles. After the last 
spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent 
and overnight drying, substrates were ready for spermine NONOate immobilization. 
Substrates modified with a carboxylic terminated SAM were placed sanded-side-up in a 
solution that was 20 mM in EDC and 50 mM in NHS in 2-propanol. The solution was allowed to 
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react for 30 minutes at room temperature, protected from light, under N2. After 30 minutes, 
substrates were removed and allowed to dry under vacuum for one hour. Substrates were then 
placed in a 20 mM spermine NONOate solution prepared in a mixture of ethanol and water (4:1, 
v/v). Then, substrates were rinsed in ethanol and water (4:1) for one minute, and then allowed to 
dry under vacuum overnight.  
4.3.3 Formation of Dual Functionalized Ti-6Al-4V 
4.3.3.1 Immobilization of Vancomycin and KRSR(C) (R1 & R2) 
Co-immobilization of both vancomycin and KRSR(C) to Ti-6Al-4V surfaces was first 
accomplished by forming thiol and acrylate terminated SAMs on Ti-6Al-4V. Ti-6Al-4V was 
pretreated at 4°C for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid 
in tetrahydrofuran and a separate solution of 2 mM 11-phosphonoundecylacrylate in 
tetrahydrofuran were warmed to 55°C. Substrates were then sprayed via aerosol deposition with 
the warm phosphonic acid solutions; first with the thiol solution and then the acrylate. This was 
repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After 
a 15-minute rinse in deposition solvent, substrates were dried overnight prior to bioactive molecule 
immobilization. Then, Ti-6Al-4V modified with acrylate and thiol terminated SAMs was used to 
immobilize vancomycin (R1). Substrates were dried overnight and then KRSR(C) was 
immobilized (R2). 
4.3.3.2 Immobilization of KRSR(C) and Spermine NONOate (R2 & R3) 
Ti-6Al-4V substrates were pretreated at 4°C for 30 minutes, while a solution of 1 mM 11-
phosphonoundecanoic acid in methanol and a separate solution of 2 mM 11-
phosphonoundecylacrylate in tetrahydrofuran were warmed to 55°C. Substrates were then sprayed 
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with the warm phosphonic acid solutions; first with the acrylate solution and then the carboxylic 
acid solution. Substrates were dried at room temperature for one minute. This was repeated for 
three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After a 15-minute 
rinse in deposition solvent and overnight drying, substrates were ready for bioactive molecule 
immobilization.  
Ti-6Al-4V modified with acrylate and carboxylic acid terminated SAMs were utilized to 
immobilize KRSR(C) (R2). Substrates were dried overnight and spermine NONOate was 
immobilized (R3). Spermine NONOate was immobilized last to avoid premature release of NO 
during the long peptide immobilization.    
4.3.3.3 Immobilization of Vancomycin and Spermine NONOate (R1 & R3) 
Co-immobilization of both vancomycin and spermine NONOate was accomplished by 
forming thiol and carboxylic terminated SAMs on Ti-6Al-4V. Substrates were pretreated at 4°C 
for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran 
and a separate solution of 1 mM 11-phosphonoundecanoic acid in methanol were warmed to 55°C. 
Substrates were then sprayed with the warm phosphonic acid solutions; first with the thiol solution 
and then the carboxylic acid solution. Substrates were dried at room temperature for one minute. 
This was repeated for three cycles. After the last spray, substrates were dried in a 60°C oven 
overnight. After a 15-minute rinse in deposition solvent and overnight drying, substrates were 
ready for bioactive molecule immobilization.  
Immobilization of both vancomycin and spermine NONOate to Ti-6Al-4V surfaces was 
accomplished by using Ti-6Al-4V modified with thiol and carboxylic acid terminated SAMs to 
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immobilize vancomycin (R1). Substrates were dried overnight and then spermine NONOate was 
immobilized (R3). Spermine NONOate was linked last to prevent premature NO release.   
4.3.4 Formation of Triple Functionalized Ti-6Al-4V 
4.3.4.1 Immobilization of Vancomycin, KRSR(C), and Spermine NONOate (R1, R2, & R3) 
Thiol, acrylate, and carboxylic acid terminated SAMs were formed on Ti-6Al-4V to serve 
as linkers to immobilize the desired bioactive molecules. Substrates were pretreated at 4°C for 30 
minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran, a 
solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran, and a solution of 1 mM 11-
phosphonoundecanoic acid in methanol were warmed to 55°C. Substrates were then sprayed with 
the warm phosphonic acid solutions; first with the thiol solution, then the acrylate solution, and 
then with the carboxylic acid solution. Substrates were dried at room temperature for one minute. 
After the spraying, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in 
deposition solvent and overnight drying, substrates were ready for bioactive molecule 
immobilization.  
Ti-6Al-4V modified with the acrylate, carboxylic acid, and thiol terminated SAMs was 
used to immobilize vancomycin (R1). After overnight drying, substrates were used to chemically 
link KRSR(C) to the surface (R2). Finally, spermine NONOate was attached to the surface (R3).  
4.3.5 Escherichia coli and Staphylococcus epidermidis Culture 
4.3.5.1 Escherichia coli Culture 
 E. coli (ATCC® 25922) was frozen in vials of glycerol and stored at -80°C until use. A 
culture was started by the addition of one inoculation loop of E. coli to 10 mL of LB media in a T-
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25 cm2 culture flask. The E. coli flask was incubated overnight under shaking conditions at 37°C 
and diluted to an optical density at 600 nm (OD600) of 0.0125 through a twofold dilution before 
beginning bacterial assays.  
4.3.5.2 Staphylococcus epidermidis Culture 
 S. epidermidis (ATCC® 14990) was frozen in vials of glycerol and stored at -80°C until 
use. A culture was started by the addition of one inoculation loop of S. epidermidis to 10 mL of 
LB media in a T-25 cm2 culture flask. The S. epidermidis flask was incubated overnight under 
shaking conditions at 37°C and diluted to an optical density at 600 nm (OD600) of 0.0125 through 
a twofold dilution before beginning bacterial assays. 
4.3.6 Bacterial Viability Determination using Fluorescence Microscopy  
4.3.6.1 Bacterial Viability Assay 
 The viability of bacteria grown on functionalization Ti-6Al-4V surfaces was assessed by 
diluting the resulting overnight bacterial culture of either E. coli or S. epidermidis to an OD600 of 
0.0125 in 50/50 LB Media and PBS. PBS was incorporated to encourage release of the NO from 
spermine NONOate functionalized substrates as it contains molecules capable of donating a proton 
to spermine NONOate, triggering release.36 In each well of a 24-well plate, 800 µL of the 
planktonic 0.0125 OD600 bacteria were added. Three wells each contained (i) bacteria + 
unmodified Ti-6Al-4V, (ii) bacteria + SAM modified Ti-6Al-4V, or (iii) bacteria + bioactive 
molecule functionalized Ti-6Al-4V. The well plate was placed on an incubator/shaker at 37°C for 
1.5 hours while protected from light.  
 After this time, the well plate was removed and then bacteria were stained using the 
LIVE/DEAD TM BacLightTM Bacterial Viability Kit. First, growth media was aspirated off, and 
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then the substrates were washed twice with 0.5 mL of PBS to remove any traces of growth media. 
The dye components were thawed and vortexed briefly. Then, 7.5 µL of component 1 and 7.5 µL 
of component 2 of the stain kit were added to a centrifuge tube, followed by 5 mL of PBS. Then, 
300 µL of the prepared stain were added to each well. The well plate was incubated, protected 
from light, at 37°C for 15 minutes. The wells were then rinsed with 0.5 mL of PBS. Bacteria were 
fixed by adding 0.5 mL of 50/50 glycerin/PBS (v/v). The kit utilizes mixtures of the SYTO®9 
green-fluorescent nucleic acid stain and the red-fluorescent nucleic acid stain, propidium iodide.39 
When used alone, the SYTO®9 stain generally labels all bacteria in a population, those with an 
intact membrane and those with damaged membranes. In contrast, propidium iodide penetrates 
only bacteria with damaged membranes, causing a reduction in the SYTO®9 stain fluorescence 
when both dyes are present. With an appropriate mixture of the SYTO®9 and propidium iodide 
stains, bacteria with an intact cell membrane stain fluorescent green, whereas bacteria with 







Figure 4.2: Staining of bacterial cells with the LIVE/DEAD TM BacLightTM Bacterial 
Viability Kit where SYTO®9 generally labels all bacterial cells and propidium iodide 
selectively stains dead cells, causing a reduction in fluorescence of SYTO®9. 
SYTO®9 
Propidium Iodide 
Viable Cell Dead Cell 
SYTO®9 
SYTO®9 
SYTO®9 Nucleus Nucleus 
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4.3.6.2 Bacteria Counting using Fluorescence Microscopy  
 A Zeiss Axioskop2 MAT materials microscope for imaging was used to image and count 
fluorescently stained bacteria. Bacteria were imaged using 50x magnification and fluorescence 
filters. Three areas on each substrate were imaged. The number of live and dead cells were counted 
on nine images for each sample and control. The number of live adhered bacteria as well as the 
percent viability were calculated. Both values were normalized to bacteria grown on unmodified 
Ti-6Al-4V.  
4.3.6.3 Statistics 
 Statistical analysis was performed using Origin 2019 software. Normality of obtained data 
was determined using the Shapiro-Wilk test. Nonparametric methods including the Kruskal-Wallis 
one-way analysis of variance were used to determine the averages and statistical significance of 
collected data at the p<0.05 level of significance where applicable as data was not normally 
distributed. Statistically analyzed data is presented as mean ± standard error (SE) or as standard 
deviation (SD) where noted. 
4.4 Results 
4.4.1 S. epidermidis Adhesion and Viability 
4.4.1.1 Single Functionalized Ti-6Al-4V 
4.4.1.1.1 Vancomycin Functionalized Ti-6Al-4V 
 Adhesion and viability of S. epidermidis on vancomycin functionalized substrates was 
assessed through fluorescence imaging of the bacteria (Figure 4.3). Vancomycin functionalized 
substrates had statistically less live bacteria cells adhered when compared to the thiol terminated 
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SAM which was used as the linker, but the number of cells was not statistically different than 
unmodified Ti-6Al-4V (Figure 4.4, Table 4.1). While the vancomycin and thiol linker did not 
affect the bacterial adhesion, immobilized vancomycin was able to reduce bacterial viability by 64 
± 27% (SD) (Figure 4.5, Table 4.2). While dead cells were observed on substrates modified with 




         






























Figure 4.3: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) thiol terminated 
SAM modified Ti-6Al-4V c) vancomycin functionalized Ti-6Al-4V.  
c) b) a) 
Figure 4.4: S. epidermidis adhesion to vancomycin functionalized substrates and controls; 






      


































Substrate Normalized Number of Live Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 16 
Thiol terminated SAM on Ti-6Al-4V 181 ± 43 
Vancomycin functionalized Ti-6Al-4V 67 ±10 
Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 8 
Thiol terminated SAM on Ti-6Al-4V 71 ± 7 
Vancomycin functionalized Ti-6Al-4V 36 ± 4 
       * 
Table 4.1: S. epidermidis adhesion to vancomycin functionalized substrates and controls.  
Figure 4.5: S. epidermidis viability on vancomycin functionalized substrates and controls; 
vancomycin exhibited a 64 ± 27% (SD) reduction in viability. # = statistically different, * = 
statistically different than control. 
Table 4.2: S. epidermidis viability on vancomycin functionalized substrates and controls.  
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4.4.1.1.2 Spermine NONOate Functionalized 
Bacteria adhesion and viability were also examined on spermine NONOate functionalized 
substrates (Figure 4.6). Spermine NONOate functionalized substrates exhibited statistically lower 
adhesion compared to unmodified Ti-6Al-4V (Figure 4.7, Table 4.3). While lower adhesion was 





































c) b) a) 
Figure 4.6: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) carboxylic acid 
terminated SAM modified Ti-6Al-4V c) spermine NONOate functionalized Ti-6Al-4V.  
Figure 4.7: S. epidermidis adhesion to spermine NONOate functionalized substrates and 
controls; spermine NONOate decreased bacteria adhesion. # = statistically different, * = 
statistically different than control. 






































Substrate Normalized Number of Live Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 24 
Carboxylic acid terminated SAM on Ti-6Al-4V 36 ± 7 
Spermine NONOate functionalized Ti-6Al-4V 23 ± 4 
Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 1 
Carboxylic acid terminated SAM on Ti-6Al-4V 96 ± 1 
Spermine NONOate functionalized Ti-6Al-4V 94 ± 2 
Table 4.3: S. epidermidis adhesion to spermine NONOate functionalized substrates and 
controls.  
Figure 4.8: S. epidermidis viability on spermine NONOate functionalized substrates and 
controls; spermine NONOate exhibited no reduction in viability. # = statistically different, * = 
statistically different than control. 
Table 4.4: S. epidermidis viability on spermine NONOate functionalized substrates and 
controls.  
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4.4.1.2 Dual Functionalized Ti-6Al-4V 
4.4.1.2.1 Vancomycin and KRSR(C) Dual Functionalized 
 S. epidermidis adhesion to and viability on dual functionalized substrates was also 
examined by imaging the bacteria (Figure 4.9). When vancomycin was co-immobilized with the 
cell adhesion peptide KRSR(C), there was no statistical difference between the number of live 
bacteria cells adhered when compared to the thiol and acrylate SAMs or the control (Figure 4.10, 
Table 4.5) as assayed by fluorescence microscopy. Vancomycin and KRSR(C) substrates were 
able to decrease S. epidermidis viability by 36 ± 28% (SD) compared to viability on unmodified 
Ti-6Al-4V (Figure 4.11, Table 4.6). The reduction in viability was less than that observed for 
vancomycin immobilized alone (64 ±27% (SD)). Substrates functionalized with the bioactive 
molecules also exhibited statistically lower bacterial viability than that observed on thiol and 









Substrate Normalized Number of Live Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 19 
Thiol & acrylate terminated SAMs on Ti-6Al-4V 103 ± 14 
Vancomycin & KRSR(C) functionalized Ti-6Al-4V 74 ± 29 
b) 
Figure 4.9: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) thiol terminated 
and acrylate terminated SAM modified Ti-6Al-4V c) vancomycin and KRSR(C) functionalized 
Ti-6Al-4V.  
c) a) 
Table 4.5: S. epidermidis adhesion to vancomycin and KRSR(C) dual functionalized substrates 
and controls.  
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Figure 4.11: S. epidermidis viability on vancomycin and KRSR(C) dual functionalized 
substrates and controls; vancomycin and KRSR(C) co-immobilized decreased bacteria viability 
by 36 ± 28% (SD). # = statistically different, * = statistically different than controls. 
# 
  * 
Figure 4.10: S. epidermidis adhesion to vancomycin and KRSR(C) dual functionalized 
substrates and controls; vancomycin co-immobilized with KRSR(C) did not affect bacteria 






4.4.1.2.2 Vancomycin and Spermine NONOate Dual Functionalized 
 S. epidermidis was imaged on vancomycin and spermine functionalized substrates using 
fluorescence microscopy (Figure 4.12). Substrates with co-immobilized vancomycin and 
spermine NONOate did not have a statistically different number of live bacterial cells adhered 
compared to unmodified Ti-6Al-4V (Figure 4.13, Table 4.7). The viability of S. epidermidis 
grown on vancomycin and spermine NONOate substrates was not statistically different than the 
control, but it was statistically different than viability for cells grown on thiol and carboxylic acid 




Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 1 
Thiol & acrylate terminated SAMs on Ti-6Al-4V 93 ± 6 
Vancomycin & KRSR(C) functionalized Ti-6Al-4V 64 ± 9 
Substrate Normalized Number of Live Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 18 
Thiol & carboxylic acid terminated SAMs on Ti-6Al-4V 143 ± 22 
Vancomycin & spermine NONOate functionalized Ti-6Al-4V 105 ± 35 
Table 4.6: S. epidermidis viability on vancomycin and KRSR(C) dual functionalized substrates 
and controls.  
c) b) a) 
Figure 4.12: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) thiol terminated 
and carboxylic acid terminated SAM modified Ti-6Al-4V c) vancomycin and spermine 
NONOate functionalized Ti-6Al-4V.  
Table 4.7: S. epidermidis adhesion to vancomycin and spermine NONOate dual functionalized 
substrates and controls.  
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Figure 4.14: S. epidermidis viability on vancomycin and spermine NONOate dual 
functionalized substrates and controls; vancomycin co-immobilized with spermine NONOate 
did not affect bacteria viability. # = statistically different, * = statistically different than control. 
# 
Figure 4.13: S. epidermidis adhesion to vancomycin and spermine NONOate dual 
functionalized substrates and controls; vancomycin co-immobilized with spermine NONOate 





4.4.1.3 Triple Functionalized Ti-6Al-4V 
S. epidermidis adhesion to and viability on triple functionalized surfaces was examined 
through fluorescence microscopy (Figure 4.15). Here, the thiol, carboxylic, and acrylate 
terminated SAMs on the surface were able to prevent bacteria adhesion, when compared to 
unmodified and functionalized Ti-6Al-4V (Table 4.9, Figure 4.16). These SAMs in combination 
were able to prevent the adhesion of S. epidermidis. Bacteria that were adhered on these surfaces 
exhibited statistically comparable viability to unmodified Ti-6Al-4V and Ti-6Al-4V 
functionalized with all three bioactive molecules (Figure 4.17, Table 4.10). 
 
 
Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 9 
Thiol & carboxylic acid terminated SAMs on Ti-6Al-4V 112 ± 5 
Vancomycin & spermine NONOate functionalized Ti-6Al-4V 77 ± 8 
Substrate 
Normalized Number of Live Cells ± 
SE 
Unmodified Ti-6Al-4V 100 ± 9 
Thiol, acrylate, & carboxylic acid terminated SAMs on Ti-6Al-4V 60 ± 13 
Vancomycin, KRSR(C), & spermine NONOate functionalized Ti-6Al-4V 72 ± 11 
Table 4.8: S. epidermidis viability on vancomycin and spermine NONOate dual functionalized 
substrates and controls.  
a) b) c) 
Figure 4.15: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) thiol terminated, 
acrylate terminated, and carboxylic acid terminated SAM modified Ti-6Al-4V c) vancomycin, 
KRSR(C), and spermine NONOate triple functionalized Ti-6Al-4V.  
Table 4.9: S. epidermidis adhesion to vancomycin, KRSR(C), and spermine NONOate triple 
functionalized substrates and controls.  
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Figure 4.16: S. epidermidis adhesion to vancomycin, KRSR(C), and spermine NONOate triple 
functionalized substrates and controls; functionalization did not affect bacteria adhesion. # = 
statistically different, * = statistically different than control. 
Figure 4.17: S. epidermidis viability on vancomycin, KRSR(C), and spermine NONOate triple 
functionalized substrates and controls; functionalization did not affect bacteria viability. # = 





4.4.2 E. coli Adhesion and Viability 
4.4.2.1 Single Functionalized Ti-6Al-4V 
4.4.2.1.1 Vancomycin Functionalized 
Adhesion and viability of E. coli on single functionalized substrates was assessed through 
fluorescence imaging of the bacteria after 1.5 hours (Figure 4.18). Vancomycin functionalized 
substrates had statistically less live bacteria cells adhered when compared to the thiol terminated 
SAM as well as unmodified Ti-6Al-4V (Table 4.11, Figure 4.19). Immobilized vancomycin also 








Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 2 
Thiol, acrylate, & carboxylic acid terminated SAMs on Ti-6Al-4V 96 ± 3 
Vancomycin, KRSR(C), & spermine NONOate functionalized Ti-6Al-4V 93 ± 4 
Substrate Normalized Number of Live Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 23 
Thiol terminated SAM on Ti-6Al-4V 54 ± 7 
Vancomycin functionalized Ti-6Al-4V 41 ±9 
Table 4.10: S. epidermidis viability on vancomycin, KRSR(C), and spermine NONOate triple 
functionalized substrates and controls.  
a) b) c) 
Figure 4.18: Fluorescent images of E. coli on a) Ti-6Al-4V control b) thiol terminated SAM 
modified Ti-6Al-4V c) vancomycin functionalized Ti-6Al-4V.  
Table 4.11: E. coli adhesion to vancomycin functionalized substrates and controls.  
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Figure 4.19: E. coli adhesion to vancomycin functionalized substrates and controls; 
vancomycin reduced bacteria adhesion. # = statistically different, * = statistically different than 
control. 
Figure 4.20: E. coli viability on vancomycin functionalized substrates and controls; 
vancomycin exhibited no reduction in bacteria viability. # = statistically different, * = 





4.4.2.1.2 Spermine NONOate Functionalized 
E. coli bacteria were imaged on spermine NONOate functionalized substrates (Figure 
4.21). Spermine NONOate functionalized substrates had statistically lower E. coli adhesion when 
compared to unmodified Ti-6Al-4V and carboxylic acid SAM modified Ti-6Al-4V (Table 4.13, 
Figure 4.22). Immobilized spermine NONOate decreased E. coli viability by 27 ± 20% (SD) when 
compared to unmodified Ti-6Al-4V control (Figure 4.23, Table 4.14). Also, there was statistically 










Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 0 
Thiol terminated SAM on Ti-6Al-4V 100 ± 0 
Vancomycin functionalized Ti-6Al-4V 100 ± 0 
Substrate Normalized Number of Live Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 9 
Carboxylic acid terminated SAM on Ti-6Al-4V 118 ± 39 
Spermine NONOate functionalized Ti-6Al-4V 29 ± 21 
a) b) c) 
Table 4.12: E. coli viability on vancomycin functionalized substrates and controls.  
Figure 4.21: Fluorescent images of E. coli on a) Ti-6Al-4V control b) carboxylic acid 
terminated SAM modified Ti-6Al-4V c) spermine NONOate functionalized Ti-6Al-4V.  
Table 4.13: E. coli adhesion to spermine NONOate functionalized substrates and controls.  
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  * 
Figure 4.22: E. coli adhesion to spermine NONOate functionalized substrates and controls; 
spermine NONOate decreased bacteria adhesion. # = statistically different, * = statistically 
different than control. 
Figure 4.23: E. coli viability on spermine NONOate functionalized substrates and controls; 
spermine NONOate exhibited a 27 ± 20% (SD) reduction in viability. # = statistically different, 





4.4.2.2 Dual Functionalized Ti-6Al-4V 
4.4.2.2.1 Vancomycin and Spermine NONOate Dual Functionalized 
 E. coli were imaged on the functionalized Ti-6Al-4V surface after a 1.5 hour incubation 
(Figure 4.24). Co-immobilization of vancomycin and spermine NONOate on Ti-6-Al-4V 
generated surfaces that were able to resist E. coli attachment (Table 4.15, Figure 4.25). These 
surfaces also showed statistically less bacterial adhesion than the thiol and carboxylic acid 
terminated SAMs used as linkers. While preventing bacterial adhesion, these surfaces showed no 








Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 0 
Carboxylic acid terminated SAM on Ti-6Al-4V 100 ± 0 
Spermine NONOate functionalized Ti-6Al-4V 73 ± 7 
Substrate Normalized Number of Live Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 14 
Thiol & carboxylic acid terminated SAMs on Ti-6Al-4V 114 ± 12 
Vancomycin & spermine NONOate functionalized Ti-6Al-4V 39 ± 5 
a) b) c) 
Table 4.14: E. coli viability on spermine NONOate functionalized substrates and controls.  
Figure 4.24: Fluorescent images of E. coli on a) Ti-6Al-4V control b) thiol terminated and 
carboxylic acid terminated SAM modified Ti-6Al-4V c) vancomycin and spermine NONOate 
functionalized Ti-6Al-4V.  
Table 4.15: E. coli adhesion to vancomycin and spermine NONOate dual functionalized 
substrates and controls.  
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Figure 4.26: E. coli viability on vancomycin and spermine NONOate dual functionalized 
substrates and controls; vancomycin co-immobilized with spermine NONOate did not affect 
bacteria viability. # = statistically different, * = statistically different than control. 
Figure 4.25: E. coli adhesion to vancomycin and spermine NONOate dual functionalized 
substrates and controls; vancomycin co-immobilized with spermine NONOate reduced bacteria 





4.4.2.2.2 Spermine NONOate and KRSR(C) Dual Functionalized  
The viability and adhesion of E. coli on spermine NONOate and KRSR(C) dual 
functionalized substrates was determined by imaging the bacteria (Figure 4.27). Substrates that 
were functionalized with KRSR(C) and spermine NONOate were unable to affect bacterial 
adhesion (Table 4.17, Figure 4.28). The carboxylic acid and acrylate terminated SAM linkers 
were able to retard adhesion of E. coli. Neither the SAM linkers or the KRSR(C) and spermine 
NONOate dual functionalized substrates affected E. coli viability (Figure 4.29, Table 4.18).  
 
 
Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 0 
Thiol & carboxylic acid terminated SAMs on Ti-6Al-4V 97 ± 1 
Vancomycin & spermine NONOate functionalized Ti-6Al-4V 99 ± 1 
Substrate Normalized Number of Live Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 6 
Acrylate & carboxylic acid terminated SAMs on Ti-6Al-4V 70 ± 6 
KRSR(C) & spermine NONOate functionalized Ti-6Al-4V 87 ± 11 
a) b) c) 
Table 4.16: E. coli viability on vancomycin and spermine NONOate dual functionalized 
substrates and controls.  
Figure 4.27: Fluorescent images of E. coli on a) Ti-6Al-4V control b) acrylate terminated and 
carboxylic acid terminated SAM modified Ti-6Al-4V c) KRSR(C) and spermine NONOate 
functionalized Ti-6Al-4V.  
Table 4.17: E. coli adhesion to KRSR(C) and spermine NONOate dual functionalized 
substrates and controls.  
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Figure 4.29: E. coli viability on KRSR(C) and spermine NONOate dual functionalized 
substrates and controls; spermine NONOate co-immobilized with KRSR(C) did not affect 
bacteria viability. # = statistically different, * = statistically different than control. 
Figure 4.28: E. coli adhesion to KRSR(C) and spermine NONOate dual functionalized 
substrates and controls; spermine NONOate co-immobilized with KRSR(c) did not reduced 





4.4.2.3 Triple Functionalized Ti-6Al-4V 
 The adhesion and viability of E. coli to and on substrates functionalized with vancomycin, 
KRSR(C), and spermine NONOate were examined (Figure 4.30). The SAM linkers used for the 
attachments of the bioactive molecules showed less bacterial adhesion when compared to controls 
(Table 4.19, Figure 4.31). The presentation of the different SAMs at the interface is interfering 
with the bacteria’s ability to adhere. The anti-adhesive properties of spermine NONOate 
previously observed in the single functionalization are absent here as functionalized Ti-6Al-4V 







Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 0 
Acrylate & carboxylic acid terminated SAMs on Ti-6Al-4V 100 ± 0 
KRSR(C) & spermine NONOate functionalized Ti-6Al-4V 100 ± 0 
Substrate 
Normalized Number of Live Cells ± 
SE 
Unmodified Ti-6Al-4V 100 ± 4 
Thiol, acrylate, & carboxylic acid terminated SAMs on Ti-6Al-4V 61 ± 5 
Vancomycin, KRSR(C), & spermine NONOate functionalized Ti-6Al-4V 80 ± 6 
a) b) c) 
Table 4.18: E. coli viability on KRSR(C) and spermine NONOate dual functionalized 
substrates and controls.  
Table 4.19: E. coli adhesion to vancomycin, KRSR(C), and spermine NONOate triple 
functionalized substrates and controls.  
Figure 4.30: Fluorescent images of E. coli on a) Ti-6Al-4V control b) thiol terminated, acrylate 
terminated, and carboxylic acid terminated SAM modified Ti-6Al-4V c) vancomycin, 
KRSR(C), and spermine NONOate triple functionalized Ti-6Al-4V.  
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The SAM linker was able to prevent bacterial adhesion, but its presence on the surface did 
not negatively affect the bacteria viability, since viability was statistically comparable to bacteria 
grown on unmodified Ti-6Al-4V (Table 4.20, Figure 4.32). While vancomycin previously did not 
show activity against E. coli, spermine NONOate demonstrated limited antimicrobial effects. 
When immobilized with vancomycin and KRSR(C), spermine NONOate did not affect bacteria 
viability.   
 
 
Substrate Normalized Viability of Cells ± SE 
Unmodified Ti-6Al-4V 100 ± 6 
Thiol, acrylate, & carboxylic acid terminated SAMs on Ti-6Al-4V 113 ± 1 
Vancomycin, KRSR(C), & spermine NONOate functionalized Ti-6Al-4V 109 ± 1 
  * 
Figure 4.31: E. coli adhesion to vancomycin, KRSR(C), and spermine NONOate triple 
functionalized substrates and controls; functionalization did not affect bacteria adhesion. # = 
statistically different, * = statistically different than control. 
Table 4.20: E. coli viability on vancomycin, KRSR(C), and spermine NONOate triple 
functionalized substrates and controls.  
142




























   The antimicrobial properties of single, dual, and triple functionalized surfaces were 
examined. These surfaces were challenged with either E. coli or S. epidermidis. Initially, the 
adhesion and viability of bacteria on single functionalized substrates was examined. This was 
undertaken to characterize what effect the attached molecules vancomycin or spermine NONOate, 
as well as the SAMs used to covalently link them, had on these properties.  
 Vancomycin is an antibiotic with primary activity against Gram positive species.11, 14, 17 It 
was therefore expected that substrates functionalized with this antibiotic would show efficacy 
against S. epidermidis.14-15, 17-19, 40 Vancomycin functionalization of Ti-6Al-4V decreased the 
viability of S. epidermidis by 64 ± 27% (SD) (Figure 4.5). This illustrates that covalently 
immobilizing vancomycin did not render it ineffective against the bacteria. This result is consistent 
Figure 4.32: E. coli viability on vancomycin, KRSR(C), and spermine NONOate triple 
functionalized substrates and controls; functionalization did not affect bacteria viability. # = 
statistically different, * = statistically different than control. 
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with a previous study where stainless steel was functionalized with vancomycin.10 In this work, 
vancomycin was able to reduce the biomass of Gram positive bacteria biofilms for extended 
periods of time.10  
 Substrates functionalized with vancomycin had no appreciable effect on the viability of E. 
coli (Figure 4.20). Vancomycin has very selective effectiveness against Gram negative species, 
of which E. coli is not included.13, 15, 19, 22, 41 Immobilized vancomycin did inhibit bacterial adhesion 
to the functionalized surface. Nonspecific adhesion occurs through molecular chemistry processes 
such as van der Waals, Lewis acid/base, electrostatic, and hydrophobic forces.42-43  Very generally, 
hydrophilic surfaces can inhibit bacterial adhesion, although this is specific to bacterial species 
and surface.44-46 The hydrophilic nature of the vancomycin functionalized Ti-6Al-4V is one 
explanation for the reduction in E. coli adhesion. One specific method of adhesion for E. coli 
involves their pili.47 Coatings targeting this mechanism utilize sugar-based inhibitors to prevent 
bacterial attachment. Vancomycin is a glycopeptide, with a sugar moiety. Therefore, this, in 
conjunction with the hydrophilic nature of the surface, may be the cause of the observed reduction 
in bacterial adhesion.  
The other molecule of interest was the spermine NONOate, a nitric oxide releasing 
molecule. Nitric oxide has been indicated as an antimicrobial capable of dispersing bacterial 
biofilms.29, 48-53 Substrates functionalized with spermine NONOate did not affect S. epidermidis 
viability (Figure 4.8). However, immobilized spermine NONOate was able to decrease the 
viability of E. coli on functionalized Ti-6Al-4V by 27 ± 20% (SD) (Figure 4.23). The preferential 
susceptibility of Gram negative species over Gram positive species to nitric oxide has been 
observed in other studies.29, 36 Species of Gram positive bacteria are capable of producing their 
own nanomolar (nM) amounts of nitric oxide through bacterial nitric oxide synthase as a defense 
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mechanism to oxidative stress, antimicrobial treatments, and other bacterial species. 54-55 The 
concentrations of nitric oxide released from spermine NONOate functionalized substrates are in 
the nanomolar range. This concentration is comparable to that released by the bacteria naturally. 
Therefore, these organisms are capable of tolerating the amount of nitric oxide released without 
any ill effects to viability.  
While selectivity was observed in spermine NONOate’s ability to affect bacterial viability, 
the nitric oxide releasing molecule prevented the adhesion of both S. epidermidis and E. coli to 
functionalized Ti-6Al-4V (Figure 4.7, Figure 4.22). Bacterial adhesion reduction on nitric oxide 
functionalized surfaces has been reported in the literature for several species, including 
Pseudomonas aeruginosa and Staphylococcus aureus. 48, 52 While each bacterial species has 
unique methods of adhesion, it is thought that NO prevents bacterial adhesion through reactive 
intermediates such as N2O3 and N2O4, which are able to destroy bacterial adhesin proteins which 
mediate surface adhesion.51  
 Next, substrates in which two bioactive molecules were co-immobilized were subjected to 
challenges with either S. epidermidis or E. coli. Substrates were challenged with the bacterial 
species that the immobilized molecules had showed efficacy against when immobilized solely. 
This was undertaken to determine if co-immobilization altered previously observed adhesive and 
viability properties.  
 When vancomycin was co-immobilized with an osteoblast cell adhesion peptide, 
KRSR(C), the viability of S. epidermidis was reduced by 36 ± 28% (SD) (Figure 4.11). This 
reduction was lower than that observed for substrates solely functionalized with vancomycin, 
which showed a 64 ± 27% (SD) reduction in viability. This decrease in effectiveness may be due 
to lower loading of vancomycin on the surface due to the presence of KRSR(C). Interactions 
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between vancomycin and KRSR(C) also can affect vancomycin’s functionality.23 Hydrogen 
bonding interactions between KRSR(C) and vancomycin would negatively affect vancomycin’s 
functionality, as hydrogen bonding is necessary for its mechanism of action against Gram positive 
bacteria.11, 21, 56-57  
A reduction in efficacy was also observed for spermine NONOate when it was co-
immobilized with KRSR(C). These substrates were not able to resist E. coli attachment or impact 
bacterial viability (Figure 4.28, Figure 4.29). Nitric oxide studies on these substrates illustrated 
that the amount of nitric oxide released from this dual functionalized surface was higher than that 
for surfaces only functionalized with spermine NONOate. Therefore, the presence of the KRSR(C) 
is affecting bacterial adhesion. Bacteria often recognize peptide sequences expressed by 
mammalian cells, it is possible that the bacteria is attracted to the KRSR(C) sequence.58 In this 
work, bacteria adhesion to KRSR(C) immobilized alone was not examined, but this should be 
explored further to determine if bacteria preferentially adhere to these surfaces.  
The combination of vancomycin and spermine NONOate on dual functionalized substrates 
was able to resist E. coli adhesion (Figure 4.25) but not S. epidermidis adhesion (Figure 4.13). 
Surfaces single functionalized with either vancomycin or spermine NONOate were also able to 
resist E. coli attachment. Their co-immobilization does not affect the method of action for either 
in preventing the Gram negative’s species adhesion. Vancomycin was unable to significantly affect 
the adhesion of S. epidermidis on single functionalized substrates. Adhesion of S. epidermidis onto 
the dual functionalized substrates possessed a large standard error. The discrepancy in Gram 
positive bacterial adhesion between the single and dual functionalized substrates with spermine 
NONOate may be attributable to variabilities with surface coverage of the bioactive molecules. 
Vancomycin and spermine NONOate dual functionalized substrates did not significantly affect 
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bacterial viability for either species. While vancomycin co-immobilized with KRSR(C) was able 
to affect S. epidermidis viability, in combination with spermine, no such effect was observed. 
Gram positive species of bacteria can produce their own nitric oxide and will do so to combat 
stress to antibiotics. The nanomolar concentrations at the interface are comparable to those 
naturally produced by the bacteria.54-55 Therefore, the presence of the nitric oxide may be inducing 
a change within the bacteria which renders them less susceptible to the vancomycin. This 
hypothesis would need to be examined further however. It is also possible that the vancomycin 
concentration on the surface is not sufficient to decrease viability. Additionally, interactions 
between the spermine NONOate molecule and vancomycin, such as hydrogen bonding, would 
impact vancomycin’s ability to interact with the D-alanine residues within the peptidoglycan wall.  
Interactions with these residues are critical for vancomycin’s mode of action.11  
Finally, the adhesion and viability of bacteria species was examined on triple 
functionalized surfaces that contained vancomycin, KRSR(C), and spermine NONOate. The 
presence of these three molecules at the interface did not affect bacterial adhesion or viability. 
Surface coverage of the antimicrobial agents may not have been sufficient to prevent attachment 
or reduce viability. Interactions discussed previously between the bioactive molecules may also 
contributed to these observations.  
The SAM linkers that were used to covalently attach the three molecules did exhibit an 
effect on the bacteria adhesion but not viability (Figure 4.16, Figure 4.31). Coatings designed 
specifically to resist bacterial adhesion by altering the physicochemical properties of the substrate 
so that conditioning films do not form and/or bacteria-substrate interactions are not favored are an 
area of interest to prevent bacteria colonization.45, 59 These “passive” coatings include 
poly(ethylene glycol), poly(ethylene oxide) brushes, hydrophilic polyurethanes, and others.10, 45-46, 
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60-61 The effectiveness of passive coatings for reducing bacteria adhesion is limited and varies 
drastically depending on bacterial species.9  Within these coatings, surface charging is an important 
factor for controlling bacterial adhesion.43 Alteration of surface charging, with an overall neutral 
charge has been shown to be effective. 43 The presentation of the charged groups of carboxylic 
acid and thiol of the SAM linkers at the interface may be responsible for the reduction in adhesion. 
The distribution of these molecules at the surface was not assessed, therefore this cannot be 
concluded conclusively.   
4.6 Conclusions 
 The ability of functionalized Ti-6Al-4V to prevent bacterial adhesion and reduce bacterial 
viability was examined. Immobilized vancomycin and co-immobilized vancomycin with 
KRSR(C) were able to reduce S. epidermidis viability, with a decrease in effectiveness noted in 
when vancomycin was co-immobilized with KRSR(C). Spermine NONOate was able to reduce 
bacterial adhesion for both species while also inhibiting E. coli viability on single functionalized 
substrates. When vancomycin was co-immobilized with spermine NONOate, no antimicrobial 
properties were observed. Ti-6Al-4V functionalized with vancomycin, KRSR(C), and spermine 
NONOate were also unable to inhibit bacteria viability. The SAM linkers utilized to immobilize 
vancomycin, KRSR(C), and spermine NONOate in combination decreased adhesion of both 
species examined.   
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Chapter 5: Osteoblast Adhesion and Viability on Functionalized Titanium Aluminum 
Vanadium 
5.1 Introduction 
 Successful osseointegration is critical for orthopedic implant stability and longevity.1-7 
Osseointegration is achieved through boney in-growth via the deposition of new bone by 
osteoblasts.8-9 Unfortunately, Ti-6Al-4V is not osteoinductive or osteoconductive.10 This leads to 
loosening of these implants, which contributes to implant failure. In order to combat this, the Ti-
6Al-4V surface can be functionalized with bioactive molecules to encourage osteoblast adhesion.1, 
11-14  
 In this work, Ti-6Al-4V was functionalized with a cell adhesion peptide, KRSR to facilitate 
osteoblast adhesion to the surface. KRSR was synthesized with a sacrificial cysteine whose free 
thiol was used to form a C-S bond between an acrylate terminated SAM and the peptide. This 
peptide was immobilized in conjunction with antimicrobial agents, spermine NONOate and 
vancomycin using SAMs as chemical linkers. Covalent attachment of these molecules should not 
negatively affect osteoblast adhesion or viability on the Ti-6Al-4V surface. Here, osteoblast 
adhesion and viability on bioactive molecule functionalized and SAM modified substrates were 
assessed using fluorescence microscopy.  
5.2 Materials 
Normal human osteoblasts (NHOsts) and osteoblast subculturing reagents (HEPES 
buffered saline, Trypsin/EDTA, and Trypsin neutralizing solution) were purchased from LONZA. 
Osteoblast basal medium and growth supplements were purchased from Cell Applications. The 
LIVE/DEADTM Viability/Cytoxicity Kit for mammalian cells was purchase from Thermo Fisher 
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Scientific. 11-phosphonoundecanoic acid (96% purity), 11-phosphonoundecylacrylate, 12-
mercaptododecylphosphonic acid (95% purity), N-hydroxysuccinimide (NHS) (98%), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), vancomycin hydrochloride 
(≥80%), trypan blue 0.4%, and Dulbecco’s phosphate buffered saline (PBS) were obtained from 
Sigma Aldrich and used as received. 3-maleimidopropionic acid N-hydroxysuccinimide ester 
(99%) was supplied by Alfa Aesar. Spermine NONOate (≥98%) was supplied by Cayman 
Chemical. KRSRC (≥98%) was synthesized by GenScript. Tetrahydrofuran, Optima grade, 
obtained from Fisher Scientific was distilled over sodium and benzophenone prior to use. 
Acetonitrile was also supplied by Fisher Scientific. Methanol was obtained from Duquesne 
University and dried over 4A molecular sieves. Ethanol and 18 MΩ water were also obtained from 
Duquesne University. Titanium aluminum vanadium (Ti-6Al-4V), 0.52 mm thickness was 
purchased from Goodfellow Inc. (Coraopolis, PA US). 
5.3 Methods 
5.3.1 Preparation of Titanium Aluminum Vanadium 
Ti-6Al-4V was prepared by sanding with 150, 320, 400, and 600 grit sand paper. Substrates 
were then cut into 1 cm by 1 cm coupons. These coupons were sonicated in acetone for 15 minutes 
and then placed in boiling methanol for 15 minutes to remove any residue from the surface. Then, 
substrates were removed and placed sanded-side-up on a petri dish in a 120°C oven overnight to 
dry. After drying, substrates were stored in a glass vial until use. 
5.3.2 Formation of Single Functionalized Ti-6Al-4V 
5.3.2.1 Immobilization of Vancomycin (R1) 
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Ti-6Al-4V substrates were chilled at 4°C for 30 minutes, while a solution of 1 mM 12-
mercaptodocdecylphosphonic acid in tetrahydrofuran was warmed to 55°C. Substrates were then 
sprayed with the warm phosphonic acid solution. This was repeated for three cycles. After the last 
spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent 
and overnight drying, substrates were ready for vancomycin immobilization.  
A solution of 2 mg/mL vancomycin and 20 mM 3-maleimidopropionic acid N-
hydroxysuccinimide ester was prepared in 50/50 (v/v) acetonitrile and water. The reaction 
proceeded for one hour protected from light at room temperature. Then, substrates modified with 
the thiol terminated SAM were placed modified-side-up in the vancomycin/linker solution for one 
hour, protected from light, under N2, at room temperature. After one hour, substrates were removed 
and rinsed in reaction solvent for one minute prior to drying overnight under vacuum.    
5.3.2.2 Immobilization of KRSR(C) (R2) 
Acrylate terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates at 4°C 
for 30 minutes, while a solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran was 
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. This was 
repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After 
a 15-minute rinse in deposition solvent and overnight drying, substrates were ready for KRSR(C) 
immobilization. 
Ti-6Al-4V modified with acrylate terminated SAMs was placed sanded-side up in a 
solution containing 1 mg/mL of KRSR(C) and 5 µL of triethylamine. The reaction was performed 
over ice, protected from light, under N2 for four hours. After four hours, substrates were removed, 
placed in water for one minute, and then dried overnight under vacuum.  
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5.3.2.3 Immobilization of Spermine NONOate (R3) 
Carboxylic acid terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates 
at 4°C for 30 minutes, while a solution of 1 mM 11-phosphonoundecanoic acid in methanol was 
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. Substrates 
were dried at room temperature for one minute. This was repeated for three cycles. After the last 
spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent 
and overnight drying, substrates were ready for spermine NONOate immobilization. 
Substrates modified with a carboxylic terminated SAM were placed sanded-side-up in a 
solution that was 20 mM in EDC and 50 mM in NHS in 2-propanol. The solution was allowed to 
react for 30 minutes at room temperature, protected from light, under N2. After 30 minutes, 
substrates were removed and allowed to dry under vacuum for one hour. Substrates were then 
placed in a 20 mM spermine NONOate solution prepared in a mixture of ethanol and water (4:1, 
v/v). Then, substrates were rinsed in ethanol and water (4:1) for one minute, and then allowed to 
dry under vacuum overnight.  
5.3.3 Formation of Dual Functionalized Ti-6Al-4V 
5.3.3.1 Immobilization of Vancomycin and KRSR(C) (R1 & R2) 
Co-immobilization of both vancomycin and KRSR(C) to Ti-6Al-4V surfaces was first 
accomplished by forming thiol and acrylate terminated SAMs on Ti-6Al-4V. Ti-6Al-4V was 
pretreated at 4°C for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid 
in tetrahydrofuran and a separate solution of 2 mM 11-phosphonoundecylacrylate in 
tetrahydrofuran were warmed to 55°C. Substrates were then sprayed via aerosol deposition with 
the warm phosphonic acid solutions; first with the thiol solution and then the acrylate. This was 
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repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After 
a 15-minute rinse in deposition solvent, substrates were dried overnight prior to bioactive molecule 
immobilization. Then, Ti-6Al-4V modified with acrylate and thiol terminated SAMs was used to 
immobilize vancomycin (R1). Substrates were dried overnight and then KRSR(C) was 
immobilized (R2). 
5.3.3.2 Immobilization of KRSR(C) and Spermine NONOate (R2 & R3) 
Ti-6Al-4V substrates were pretreated at 4°C for 30 minutes, while a solution of 1 mM 11-
phosphonoundecanoic acid in methanol and a separate solution of 2 mM 11-
phosphonoundecylacrylate in tetrahydrofuran were warmed to 55°C. Substrates were then sprayed 
with the warm phosphonic acid solutions; first with the acrylate solution and then the carboxylic 
acid solution. Substrates were dried at room temperature for one minute. This was repeated for 
three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After a 15-minute 
rinse in deposition solvent and overnight drying, substrates were ready for bioactive molecule 
immobilization.  
Ti-6Al-4V modified with acrylate and carboxylic acid terminated SAMs were utilized to 
immobilize KRSR(C) (R2). Substrates were dried overnight and spermine NONOate was 
immobilized (R3). Spermine NONOate was immobilized last to avoid premature release of NO 
during the long peptide immobilization.    
5.3.3.3 Immobilization of Vancomycin and Spermine NONOate (R1 & R3) 
Co-immobilization of both vancomycin and spermine NONOate was accomplished by 
forming thiol and carboxylic terminated SAMs on Ti-6Al-4V. Substrates were pretreated at 4°C 
for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran 
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and a separate solution of 1 mM 11-phosphonoundecanoic acid in methanol were warmed to 55°C. 
Substrates were then sprayed with the warm phosphonic acid solutions; first with the thiol solution 
and then the carboxylic acid solution. Substrates were dried at room temperature for one minute. 
This was repeated for three cycles. After the last spray, substrates were dried in a 60°C oven 
overnight. After a 15-minute rinse in deposition solvent and overnight drying, substrates were 
ready for bioactive molecule immobilization.  
Immobilization of both vancomycin and spermine NONOate to Ti-6Al-4V surfaces was 
accomplished by using Ti-6Al-4V modified with thiol and carboxylic acid terminated SAMs to 
immobilize vancomycin (R1). Substrates were dried overnight and then spermine NONOate was 
immobilized (R3). Spermine NONOate was linked last to prevent premature NO release.   
5.3.4 Formation of Triple Functionalized Ti-6Al-4V 
5.3.4.1 Immobilization of Vancomycin, KRSR(C), and Spermine NONOate (R1, R2, & R3) 
Thiol, acrylate, and carboxylic acid terminated SAMs were formed on Ti-6Al-4V to serve 
as linkers to immobilize the desired bioactive molecules. Substrates were pretreated at 4°C for 30 
minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran, a 
solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran, and a solution of 1 mM 11-
phosphonoundecanoic acid in methanol were warmed to 55°C. Substrates were then sprayed with 
the warm phosphonic acid solutions; first with the thiol solution, then the acrylate solution, and 
then with the carboxylic acid solution. Substrates were dried at room temperature for one minute. 
After the spraying, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in 
deposition solvent and overnight drying, substrates were ready for bioactive molecule 
immobilization.  
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Ti-6Al-4V modified with the acrylate, carboxylic acid, and thiol terminated SAMs was 
used to immobilize vancomycin (R1). After overnight drying, substrates were used to chemically 
link KRSR(C) to the surface (R2). Finally, spermine NONOate was attached to the surface (R3).  
5.3.5 Osteoblast Cell Culture 
 Normal human osteoblasts (NHOsts) isolated from a 5-year-old female (LONZA) were 
thawed from a -200˚C liquid N2 dewar and plated into T-75 cm
2 tissue culture flasks at a seeding 
density of 5,000 cells per 5 cm2 of flask surface area. Then, 15 mL of osteoblast basal medium 
(OBM) were added. Tissue culture flasks were then placed into an incubator at 37˚ and 5% CO2 
for 24 hours, to allow live osteoblasts to adhere to the flask interior. After 24 hours, the OBM 
media was replaced to remove any residual cryoprotectant. Then, cell attachment and division 
were monitored daily until attached cells achieved approximately 80% confluence. OBM was 
changed every other day after initial seeding during the days until desired confluence was reached. 
Once cells reached 80% confluence they were subcultured.  
Osteoblasts were subcultured according to the protocol provided by LONZA. Briefly, 15 
mL of HEPES was used to rinse the T-75 cm2 flask. This rinse was discarded. Then, 6 mL of 
trypsin EDTA was introduced into the flask to detach cells. After several minutes and confirmation 
that cells were detached, 12 mL of trypsin neutralizing solution were added. The cell suspension 
was then centrifuged at 21,000 RPM for 5 minutes. The supernatant was aspirated off and cells 
were resuspended in 2 mL of fresh media. In three microcentrifuge vials, 100 µL of trypan blue 
was added with 100 µL of cell suspension. A hemocytometer was then used to count the number 
of cells. Counting was performed in triplicate. Cells were then seeded into new T-75 cm2 flasks at 
a density of 5,000 cells per 5 cm2 of surface area or used for the cell trial.   
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5.3.5.1 Osteoblast Cell Trial 
 NHOsts isolated from a 5-year-old female were cultured to 80% confluence. Cells were 
then detached from the flasks, as described above, and then diluted to 10,000 cells per mL of OBM. 
Then, 1 mL of cell/media suspension was added to each well containing either (i) unmodified Ti-
6Al-4V, (ii) SAM modified Ti-6Al-4V, or (iii) functionalized Ti-6Al-4V. Samples and controls 
were performed in triplicate. Substrates were rinsed in ethanol and allowed to dry in a sterile hood 
prior to placement in the well plate. The well plate was then incubated at 37˚C with 5% CO2. 
Media in the wells was replaced each day. Adhesion and viability on substrates were examined on 
Days 1, 4, and 7.  
5.3.5.2 Osteoblast Imaging 
 After 1, 4, and 7 days the number of attached live and dead cells were determined using 
the LIVE/DEADTM Viability/Cytotoxicity assay kit (Figure 5.1). With this kit, live cells are 
distinguished by the presence of intracellular esterase activity, determined by the enzymatic 
conversion of calcein AM into the fluorescent calcein, which is retained in living cells.15 Ethidium 
homodimer enters cells with damaged membranes and undergoes an enhancement of fluorescence 
upon binding to nucleic acids. Ethidium homodimer is not able to pass through the membrane of 
intact cells.  Briefly, the well plate was removed from the incubator and media was aspirated off. 
Substrates were rinsed with PBS prior to staining with the two dye components of the kit. 
Cells were then imaged with a Zeiss Axioskop2 microscope with AxioVision software and 
fluorescence filters. Three spots on each sample with an area of 0.6 mm were imaged under 10x 
magnification. The number of live cell and dead cells were then counted for each substrate and 
control. The number of live cells was divided by the total number of cells to determine the percent 
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viability. The number of live adhered osteoblasts as well as osteoblast viability was normalized to 







5.3.6 Statistical Analysis 
Statistical analysis was performed using Origin 2019 software. Normality of obtained data 
was determined using the Shapiro-Wilk test. Nonparametric methods including the Kruskal-Wallis 
one-way analysis of variance were used to determine the averages and statistical significance of 
collected data at the p<0.05 level of significance where applicable as data was not normally 
distributed. Statistically analyzed data is presented as mean ± standard error (SE). 
5.4 Results 
5.4.1 Single Functionalized Ti-6Al-4V 
 Covalently linked bioactive molecules and the SAMs used to chemically immobilize them 




Calcein DNA Binding 
Ethidium Homodimer  
Viable Cell Dead Cell 
Figure 5.1: Fluorescent staining of osteoblasts for microscopic imaging where live cells 
fluoresce green due to the conversion of calcein AM to calcein and dead cells fluoresce red 
upon the binding of ethidium homodimer to DNA. 
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functionalized with the cell adhesion peptide KRSR would show an increased number of live 
adhered cells with improved viability over controls as KRSR(C) encourages osteoblast attachment. 
Osteoblast adhesion and viability to substrates functionalized with one bioactive molecule was 
examined by culturing NHOsts and seeding them onto functionalized substrates. Adhesion and 
viability were then assessed on Days 1,4, and 7 through a LIVE/DEADTM Viability/Cytotoxicity 








Functionalization of the Ti-6Al-4V surfaces did not affect the initial attachment of 
osteoblast cells on Day 1 (Table 5.1, Figure 5.3). On Days 4 and 7, functionalized surfaces did 
not affect the number of live cells present on the surfaces when compared to the controls for those 
time points. The number of live cells on each day sampled was statistically comparable to the 
number of live cells adhered to the unmodified Ti-6Al-4V control. 
Figure 5.2: Representative Live/DeadTM fluorescent images of osteoblasts attached to control 
unmodified and bioactive molecule functionalized Ti-6Al-4V on Days 1, 4, and 7. A= 
unmodified Ti-6Al-4V, B= acrylate terminated SAM, C=carboxylic terminated SAM, D= thiol 































The viability of osteoblasts present on functionalized Ti-6Al-4V was characterized (Table 
5.2, Figure 5.4). After 24 hours, osteoblast viability on functionalized substrates was statistically 
similar to unmodified Ti-6Al-4V. This was also observed on Days 4 and 7. The immobilized 
bioactive molecules did not negatively or positively affect osteoblast viability on any of the days 
Substrate 
Normalized Number of Live Osteoblasts ± SE 
Day 1 Day 4 Day 7 
Unmodified Ti-6Al-4V 100 ± 19 100 ± 18 100 ± 18 
KRSR(C) functionalized 111 ± 40 104 ± 26 174 ± 20 
Spermine NONOate functionalized 74 ± 17 68 ± 16 67 ± 13 
Vancomycin functionalized 92 ± 32 92 ± 27 161 ± 43 
Acrylate terminated SAM 80 ± 24 71 ± 25 67 ± 24 
Carboxylic terminated SAM 72 ± 18 101 ± 33 111 ± 33 
Thiol terminated SAM 57 ± 12 91 ± 30 156 ± 40 





































Figure 5.3: Osteoblast adhesion to unmodified and single functionalized Ti-6Al-4V on Days 
1, 4, and 7. Surface modification with SAMs and functionalization with bioactive molecules 
did not affect osteoblast adhesion. 
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Normalized Osteoblast Viability + SE 
Day 1 Day 4 Day 7 
Unmodified Ti-6Al-4V 100 ± 12 100 ± 8 100 ± 8 
KRSR(C) functionalized 111 ± 13 102 ±11 118 ± 5 
Spermine NONOate functionalized 114 ± 10 74 ± 10 90 ± 9 
Vancomycin functionalized 94 ± 11 80 ± 8 110 ± 5 
Acrylate terminated SAM 111 ± 8 94 ± 9 107 ± 12 
Carboxylic terminated SAM 88 ± 9 81 ± 6 96 ± 9 

































Figure 5.4: Osteoblast viability on unmodified and functionalized Ti-6Al-4V on Days 1, 4, 
and 7. Surface modification with SAMs and functionalization with bioactive molecules did 
not affect osteoblast viability. 
Table 5.2: Osteoblast viability on unmodified and functionalized Ti-6Al-4V on Days 1, 4, 
and 7.   
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5.4.2 Dual Functionalized Ti-6Al-4V 
Osteoblast adhesion and viability to surfaces functionalized with two molecules was 
assessed through fluorescence microscopy (Figure 5.5). Adhesion was determined by counting 
the number of live osteoblast cells present on the Ti-6Al-4V surfaces (Table 5.3, Figure 5.6). At 
the initial timepoint, the number of live cells on each sample was comparable to the control. On 
Day 4 however, substrates modified with vancomycin and spermine NONOate showed statistically 
less live osteoblast cells on the surface compared to controls. This was also observed on the same 
day for substrates where spermine NONOate and KRSR(C) were co-immobilized. On Day 7 









Figure 5.5: Representative Live/DeadTM fluorescent images of osteoblasts attached to control 
unmodified and bioactive molecule dual functionalized Ti-6Al-4V on Days 1, 4, and 7. A= 
unmodified Ti-6al-4V, B= acrylate & carboxylic terminated SAMs, C= acrylate & thiol 
terminated SAMs, D= carboxylic & thiol terminated SAMs, E= KRSR(C) & spermine 
NONOate dual functionalized, F= KRSR(C) & vancomycin dual functionalized, G= 
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Viability of cells present on functionalized surfaces was also examined (Table 5.4, Figure 
5.7). On Day 1, there was no statistical difference in viability between functionalized Ti-6Al-4V 
and controls. Differences were observed between SAM linkers and spermine NONOate and 
Substrate 
Normalized Number of Live Osteoblasts + SE 
Day 1 Day 4 Day 7 
Unmodified Ti-6Al-4V 100 ± 17 100 ± 9 100 ± 10 
Acrylate & thiol terminated SAMs 108 ±12 78 ± 5 53 ±11 
Acrylate & carboxylic terminated SAMs 85 ± 12 77 ± 5 75 ± 9 
Carboxylic & thiol terminated SAMs 70 ± 14 85 ±3 69 ± 13 
KRSR(C) & vancomycin dual functionalized 82 ± 9 64 ± 8 76 ± 12 
KRSR(C) & spermine NONOate dual functionalized 61 ± 13 52 ± 4 84 ± 7 
Spermine NONOate & KRSR(C) dual functionalized 57 ± 8 46 ± 6 55 ± 8 
Table 5.3: Osteoblast adhesion to functionalized Ti-6Al-4V on Days 1, 4, and 7.  





























Thiol & Acrylate 
Thiol & Carboxylic 
Acrylate & Carboxylic 
Vancomcyin & KRSR(C) 
Vancomycin & Spermine NONOate 
Spermine NONOate & KRSR(C) 
Figure 5.6: Osteoblast adhesion to unmodified and dual functionalized Ti-6Al-4V on Days 
1, 4, and 7. Vancomycin co-immobilized with spermine NONOate decreased osteoblast 
adhesion on Day 4 when compared to controls. Spermine NONOate co-immobilized with 
KRSR(C) decreased osteoblast adhesion compared to controls on Day 4.   # = statistically 








KRSR(C); viability was lower on the functionalized substrates. On Day 4 no differences were 
observed between samples and controls. On Day 7, the viability of osteoblasts grown on substrates 












Normalized Osteoblast Viability + SE 
Day 1 Day 4 Day 7 
Unmodified Ti-6Al-4V 100 ± 5 100 ± 7 100 ± 4 
Acrylate & thiol terminated SAMs 110 ±2 103 ± 5 90 ± 6 
Acrylate & carboxylic terminated SAMs 110 ± 3 91 ± 4 76 ± 6 
Carboxylic & thiol terminated SAMs 110 ± 4 99 ± 5 79 ± 11 
KRSR(C) & vancomycin dual functionalized 113 ± 4 96 ± 7 92 ± 5 
KRSR(C) & spermine NONOate dual functionalized 78 ± 6 79 ± 4 88 ± 5 
Spermine NONOate & KRSR(C) dual functionalized 85 ± 4 72 ± 4 60 ± 4 
























Thiol & Acrylate 
Thiol & Carboxylic 
Acrylate & Carboxylic 
Vancomcyin & KRSR(C) 
Vancomycin & Spermine NONOate 
Spermine NONOate & KRSR(C) 
Table 5.4: Osteoblast viability on unmodified and dual functionalized Ti-6Al-4V on Days 1, 
4, and 7.   
Figure 5.7: Osteoblast viability on unmodified and dual functionalized Ti-6Al-4V on Days 
1, 4, and 7. On Day 7, vancomycin co-immobilized with spermine NONOate reduced 










5.4.3 Triple Functionalized Ti-6Al-4V 
 Osteoblast adhesion and viability on surfaces functionalized with all three bioactive 
molecules was characterized (Figure 5.8). The number of live osteoblasts on Day 1 for each 
sample was statistically the same as the control (Table 5.5, Figure 5.9). Changes in the number 
of live osteoblast cells were observed on Day 4. On Day 4, substrates modified with thiol, acrylate, 
and carboxylic acid terminated SAMs, which were used as chemical linkers, showed statistically 
less live osteoblast cells on the surface when compared to controls. This was also observed for 
substrates where spermine NONOate and KRSR(C) were co-immobilized. On Day 7 however, no 
difference was noted between samples and controls.  









Figure 5.8: Representative Live/DeadTM fluorescent images of osteoblasts attached to control 
unmodified and bioactive molecule triple functionalized Ti-6Al-4V on Days 1, 4, and 7. A= 
unmodified Ti-6al-4V, B= thiol, acrylate, and carboxylic terminated SAMs, C= vancomycin, 
KRSR(C), and spermine NONOate triple functionalized Ti-6Al-4V.  























The viability of cells present on functionalized surfaces was also examined. On Day 1, 
there was no statistical difference in viability between functionalized Ti-6Al-4V and controls 
Substrate 
Normalized Number of Live 
Osteoblasts + SE 
Day 1 Day 4 Day 7 
Unmodified Ti-6Al-4V 100 ± 17 100 ± 9 100 ± 10 
Thiol, acrylate, & carboxylic SAM 60 ± 5 57 ± 8 67 ± 7 
Vancomycin, KRSR(C), & spermine NONOate triple functionalized 68 ± 15 66 ±11 100 ± 12 
Table 5.5: Osteoblast adhesion to triple functionalized Ti-6Al-4V on Days 1, 4, and 7.  




























Figure 5.9: Osteoblast adhesion to unmodified and triple functionalized Ti-6Al-4V on Days 
1, 4, and 7. On Day 4, thiol, acrylate, and carboxylic acid terminated SAMs reduced osteoblast 
adhesion compared to controls.  # = statistically different, * = statistically different than 
controls. 
Unmodified  
Thiol, Acrylate & Carboxylic 




(Table 5.6, Figure 5.10). This was noted on Day 4 as well. On Day 7, the viability of osteoblasts 
cultured on thiol, acrylate, and carboxylic SAMs was statistically lower than controls, but triple 




Normalized Osteoblast Viability + SE 
Day 1 Day 4 Day 7 
Unmodified Ti-6Al-4V 100 ± 5 100 ± 5 100 ± 4 
Thiol, acrylate, & carboxylic SAM 110 ± 4 72 ± 6 71 ± 6 
Vancomycin, KRSR(C), & spermine NONOate triple functionalized 73 ± 9 87 ± 10 86 ± 6 
Table 5.6: Osteoblast viability on triple functionalized Ti-6Al-4V on Days 1, 4, and 7.  
Figure 5.10: Osteoblast viability on unmodified and triple functionalized Ti-6Al-4V on Days 
1, 4, and 7. Thiol, acrylate, and carboxylic acid terminated SAMs reduced osteoblast viability 
on Day 7.   # = statistically different, * = statistically different than controls. 
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5.5 Discussion 
 Successful integration between orthopedic implants and the host bone is crucial for implant 
longevity and stability. Integration occurs when osteoblasts, which are cells responsible for the 
formation of new bone, are able to adhere to the surface and proliferate. However, osteoblast 
adhesion and proliferation on Ti-6Al-4V is limited. Here, Ti-6Al-4V was functionalized with 
several bioactive molecules aimed at preventing bacterial colonization and encouraging osteoblast 
adhesion. A cell adhesion peptide, KRSR(C) was chemically immobilized to the Ti-6Al-4V 
surface solely and in combination with vancomycin and spermine NONOate. Vancomycin and 
spermine NONOate were included to address bacterial colonization.    
 The adhesion to and viability of osteoblasts on functionalized Ti-6Al-4V as well as Ti-6Al-
4V modified with the SAM linkers used to immobilize the molecules was examined. The 
molecules and their SAM linkers should not be cytotoxic to osteoblasts since osteoblast 
recruitment to and proliferation on Ti-6Al-4V is essential for implant integration. The presence of 
the cell adhesion peptide KRSR alone and in combination with the other molecules should 
encourage osteoblast adhesion and viability as this peptide specifically targets osteoblasts.12, 16-19 
 Cellular response on single functionalized substrates was characterized using fluorescence 
microscopy. Osteoblasts were able to adhere to Ti-6Al-4V regardless of bioactive molecule 
functionalization or SAM modification (Figure 5.3). Furthermore, these alterations to the Ti-6Al-
4V surface did not exhibit any cytotoxic effects on cells (Figure 5.4). Covalent attachment of the 
cell adhesion peptide, KRSR(C) at the interface did not support osteoblast adhesion or viability 
beyond what was observed for unmodified Ti-6Al-4V. This result was unexpected, given 
precedence in the literature for the selectivity and increased adhesion of osteoblasts to KRSR.12, 
17-18, 20-21 16, 19, 22-23 This discrepancy may be attributed to a few different causes. The surface density 
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of the cell adhesion peptide has been shown to affect its ability to encourage osteoblast adhesion.23 
It is possible that while the KRSR(C) was present at the interface, the surface coverage was not 
substantial enough to cause an observable effect. Another is the orientation of KRSR(C) at the 
interface. If KRSR(C) was not oriented on the surface in a way in which it could be recognized by 
the osteoblast cell its functionality could be reduced. Studies have demonstrated the specificity of 
this sequence for desirable adhesion, therefore masking of the sequence could inhibit its adhesion 
properties.19, 23-24 In previous work, the addition of the sacrificial cysteine did not affect KRSR 
activity.18, 20 
 Co-immobilization of multiple bioactive molecules to the surface may alter cellular 
response. When this was examined, co-immobilized vancomycin and KRSR(C) did not negatively 
or positively affect osteoblast adhesion or viability (Figure 5.6, Figure 5.7). These results were 
consistent with those observed in single functionalized substrates (Figure 5.3, Figure 5.4). 
Substrates with spermine NONOate co-immobilized with either KRSR(C) or vancomycin 
negatively affected osteoblast adhesion and viability on specific days (Figure 5.6, Figure 5.7). 
Single functionalized vancomycin and KRSR(C) did not show similar effects. Osteoblast tolerance 
and compatibility of/with KRSR and vancomycin are well documented within literature.12, 16-17, 19-
20, 22, 25-26 The undesirable cell response may be attributed to the presence of spermine NONOate 
in the dual functionalization. While single functionalized spermine NONOate did not affect 
adhesion or viability (Figure 5.3, Figure 5.4), its presence in combination with vancomycin and 
KRSR(C) was not tolerated by the cells. 
 Spermine NONOate is a nitric oxide releasing molecule and nitric oxide generates reactive 
species.27-38 While this was tolerated with single functionalized substrates, negative effects were 
observed with dual functionalized substrates (Figure 5.6, Figure 5.7). This may be due to the local 
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concentration and release rate of the nitric oxide. Results from the nitrate/nitrite colorimetry assay 
performed previously indicated a larger amount of nitric oxide released from co-immobilized 
spermine NONOate (Figure 3.20, Figure 3.17) compared to single immobilized spermine 
NONOate (Figure 3.12). This difference in concentration could explain the differences observed 
in cellular response. Additionally, evidence in the literature suggests that lower concentrations of 
nitric oxide (picomolar) are not cytotoxic to osteoblasts but higher concentrations can negatively 
affect cells.39-42 The rate at which the nitric oxide is released greatly affects its local 
concentration.43 As the nitric oxide concentration has a profound effect on cellular activity, the 
release kinetics form the NO donor must be considered when understanding the observed cytotoxic 
effects.43-47 Spermine NONOate has a half-life of approximately 40 minutes, therefore there would 
be a large initial influx of nitric oxide.48 This high, localized concentration may explain the 
decreased adhesion and viability of osteoblasts when spermine NONOate was co-immobilized.  
  The cytotoxic effects observed on dual functionalized Ti-6Al-4V possessing spermine 
NONOate were not observed on triple functionalized surfaces (Figure 5.9, Figure 5.10). Again, 
this can be connected to the amount of nitric oxide released from these surfaces. Nitric oxide 
release from single functionalized Ti-6Al-4V (Figure 3.12) was comparable to release determined 
for the triple functionalized Ti-6Al-4V (Figure 3.21). This concentration was tolerated by the 
osteoblasts with both the single (Figure 5.3, Figure 5.4) and triple (Figure 5.9, Figure 5.10) 
functionalized Ti-6Al-4V.  
 While Ti-6Al-4V functionalized with the three different bioactive molecules did not affect 
osteoblast adhesion or viability, the SAMs used to chemical immobilize these molecules to the 
surface did (Figure 5.9, Figure 5.10). In the single (Figure 5.3, Figure 5.4) and dual (Figure 5.6, 
Figure 5.7) SAM modified substrates, these results were not observed. Therefore, it is the unique 
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surface chemistry and distribution of the triple SAM which is the cause of this effect. Interactions 
between osteoblasts and materials depend on several aspects including topography, chemistry, or 
surface energy.8 49-50 The surface charging has also been shown to play a role in osteoblast 
adhesion.12 The changes to any number of these characteristics due to the presence of the triple 
SAM may be responsible for the decrease in osteoblast adhesion and viability observed.     
5.6 Conclusions 
 Immobilization of the cell adhesion peptide, KRSR(C) alone and in combination with 
vancomycin and/or spermine NONOate did not improve osteoblast adhesion or viability on Ti-6-
Al-4V. The combination of spermine NONOate with either vancomycin or KRSR(C) negatively 
affected adhesion and viability. This was due to high, local concentrates of nitric oxide. Inclusion 
of all three bioactive molecules on the surface showed no effect on osteoblast cells. The SAM 
linkers used to immobilize these molecules altered the surface chemistry, inhibiting osteoblast 
attachment and viability.  
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Chapter 6: Summary 
6.1 Conclusions 
 Orthopedic implant surgery occurrences are expected to rise in the coming decades due to 
the aging population and prevalence of degenerative diseases.1-2 These implants are comprised of 
several materials including polymers, ceramics, and metals.3 A metal frequently used in orthopedic 
implant applications is the titanium alloy, titanium aluminum vanadium (Ti-6Al-4V). This alloy 
is chosen due to its corrosion resistance and mechanical properties.4-7 Unfortunately, Ti-6Al-4V is 
not osteoinductive or osteoconductive, therefore new bone deposition by osteoblasts onto Ti-6Al-
4V is limited.8 Additionally, Ti-6Al-4V is susceptible to bacterial colonization by several species 
including Gram positive Staphylococcus bacteria, such as Staphylococcus aureus and 
Staphylococcus epidermidis and Gram negative species including Pseudomonas aeruginosa.9-14 
This lack of new bone deposition and bacterial proliferation contribute to implant failure, which 
necessitates implant removal.9, 14-15 
 Osseointegration and bacterial adhesion are addressed via several strategies. Methods 
focus on modifying the surface of Ti-6Al-4V with coatings to encourage osteoblast attachment 
and prevent bacterial adhesion.12, 16-19 These coatings tend not to be multifunctional and there are 
concerns associated with stability and release of toxic agents through degradation.20 In this work, 
an alternative strategy using self-assembled monolayers (SAMs) was employed to functionalize 
the surface of Ti-6Al-4V. SAMs were chosen due to their non-toxic nature and stability.16, 21-25 
The tail group of the SAM allows for chemical reactions at the interface, which can be used to 
covalently immobilize bioactive molecules.   
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In order to generate a multifunctional surface, SAMs possessing different tail groups were 
formed on Ti-6Al-4V in single, dual, and triple SAM modified surfaces. Modification of reaction 
conditions including spray cycles and substrate pretreatment resulted in the formation of stable 
and ordered SAMs. Of the phosphonic acid SAMs formed on Ti-6Al-4V, molecules terminated 
with a thiol, acrylate, or carboxylic acid were chosen as linkers for the attachment of bioactive 
molecules (Figure 6.1). These specific tail groups formed SAMs in a consistent, facile manner on 
the Ti-6Al-4V surface with ordered alkyl chains whether or alone or in combination with one 
another. Furthermore, these tail groups allowed for orthogonal chemical reactions to immobilize 







The bioactive molecules selected for immobilization addressed both osteoblast adhesion 
and bacterial colonization. Spermine NONOate, a nitric oxide releasing molecule, and 
vancomycin, an antibiotic, were chosen to prevent bacterial colonization. KRSR(C), a cell 
adhesion peptide was selected to encourage osteoblast adhesion to Ti-6Al-4V. Vancomycin was 
immobilized to Ti-6Al-4V through the use of a maleimide crosslinker. Spermine NONOate was 




Figure 6.1: Functionalization of Ti-6Al-4V using SAMs as linkers for the immobilization of 
bioactive molecules. 
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peptide KRSR(C) was chemically attached through a thiol-ene Michael addition with an acrylate 
terminated SAM. Ti-6Al-4V substrates were functionalized with one, two, or all three of the 
bioactive molecules. This was undertaken so that their activity in each could be assessed and 
compared. 
The single, dual, and triple immobilization of these molecules was confirmed through 
diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy. The covalent attachment of 
these molecules resulted in hydrophilic surfaces with contact angle values less than 90°. Nitric 
oxide release from functionalized Ti-6Al-4V was assessed through the Griess assay, with single 
and triple functionalized surfaces releasing comparable amounts of nitric oxide, 77.0 ± 1.8 and 
74.7 ± 1.6 nanomoles respectively. Dual functionalized substrates with co-immobilized spermine 
NONOate exhibited higher nitric oxide release of 107.6 ± 1.5 nanomoles for spermine NONOate 
with KRSR(C) and 117.6 ±1.4 nanomoles for spermine NONOate with vancomycin.  
The activity of the antimicrobial molecules immobilized alone and in conjunction with the 
other bioactive molecules was determined via challenges with Staphylococcus epidermidis (S. 
epidermidis), a Gram positive species and Escherichia coli (E. coli), a Gram negative species 
through fluorescence staining and imaging of the bacteria. Vancomycin immobilized alone was 
able to reduce the viability of S. epidermidis by 64 ± 27% (SD). Spermine NONOate was able to 
reduce viability of E. coli by 27 ± 20% but not that of S. epidermidis. The selectivity observed was 
attributed to Gram positive species’ ability to generate their own nitric oxide, leading to tolerance 
of nitric oxide’s effects.26 Spermine NONOate was able to prevent the adhesion of both species to 
single functionalized surfaces which has previously been observed in the literature on other 
substrates.27-29 
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Antimicrobial effectiveness was only maintained for one of the dual functionalizations, 
when KRSR(C) was co-immobilized with vancomycin. This dual functionalized surface showed 
a reduction in S. epidermidis viability of 36 ± 28% (SD). This was approximately half the reduction 
in viability observed for vancomycin immobilized alone. The loss in effectiveness may be due to 
interactions between vancomycin and KRSR(C) or lower surface loading. Surfaces possessing all 
three bioactive molecules were not able to limit viability of either bacterial species. Local 
concentrations were either not sufficient or interactions between molecules negatively impacted 
their effectiveness.   
 Finally, osteoblast adhesion and viability on functionalized Ti-6Al-4V was characterized 
through fluorescence staining and microscopy. Covalent attachment of these bioactive molecules 
should not elicit cytotoxic effects within osteoblast cells. Furthermore, attachment of the KRSR(C) 
cell adhesion peptide to Ti-6Al-4V was expected to encourage osteoblast adhesion to Ti-6Al-4V 
and improve cell viability. While individual immobilization of bioactive molecules did not 
negatively affect adhesion or viability, KRSR(C) functionalized substrates showed no statistically 
significant increase in live osteoblast adhesion or viability. Surface loading and distribution of the 
cell adhesion peptide dictate its effectiveness at recruiting osteoblast adhesion.30 These factors may 
contribute to the lack of a positive, observed effect.  
Co-immobilization of spermine NONOate with either vancomycin or KRSR(C) negatively 
impacted osteoblast viability. Dual functionalized substrates exhibited higher concentrations of 
nitric oxide release than single or triple functionalized. The larger, local concentrations are thought 
to be the source of observed cytotoxicity. The lack of observed cytotoxicity on triple functionalized 
substrates supports this, as these substrates showed nitric oxide release consistent with single 
functionalized Ti-6Al-4V.  
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In this work, SAMs were used to covalently link the bioactive molecules vancomycin, 
spermine NONOate, and KRSR(C) to Ti-6Al-4V through specific organic reactions with the SAM 
tails and target functional groups within the bioactive molecules. These molecules were 
immobilized on their own and in combination. While desirable antimicrobial properties were noted 
for single functionalized substrates these effects were lost in triple functionalized substrates. 
Surface loading and coverage were likely not sufficient. Furthermore, co-immobilization of 
spermine NONOate with the other bioactive molecules showed cytotoxic effects to osteoblasts, 
due to large surface concentration. This work highlights the importance of concentration, 
molecular interactions, and release rates of molecules on cellular response.  
6.2 Future Work 
 Bacteria and osteoblast behavior on functionalized Ti-6Al-4V was distinctly influenced by 
the unique surface properties of each functionalization. While the surfaces were characterized 
using DRIFT and contact angle analysis, other complimentary techniques could be used to provide 
a more complete understanding of the surface chemistry.  
 The distribution of the functionalized molecules on the surface affects their activity. The 
distribution of bioactive molecules could be assessed using matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry imaging. With this technique, mapping of 
the immobilized molecules would be possible with a spatial resolution of approximately 100 
microns.31-32 Differences in distribution and surface coverage between single, dual, and triple 
functionalized substrates could be assessed. This information would help explain if surface 
coverage was the cause of decreased bioactivity within triple functionalized substrates. 
Additionally, the accuracy of mass spectrometry would allow for the specific determination of the 
covalent bonds formed in each immobilization. If undesirable reactions between bioactive 
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molecules occurred, this would be elucidated with mass spectrometry analysis. Side reactions with 
portions of the molecules responsible for their mechanism of action would impact their efficacy.  
 Furthermore, bioactive molecule selection could be adjusted to improve osteoblast 
adhesion while preventing bacterial colonization. For instance, spermine NONOate could be 
replaced with an antibiotic that targets Gram negative species. In this work the inclusion of 
spermine NONOate demonstrated limited antimicrobial efficacy combined with osteoblast 
cytotoxicity. While KRSR(C) was chosen in this application due to its enhanced osteoblast 
binding, its immobilization showed no effect on osteoblast adhesion and viability for any of the 
functionalizations examined. If this observation was a consequence of surface coverage or 
molecular interactions is unclear. A peptide with the RGD sequence with a cysteine modification 
could be easily substituted in this platform for the KRSR(C). This alteration may improve 
osteoblast adhesion and viability.33-35 
6.3 Project Impact 
Surfaces of metallic orthopedic implants strongly influence their chemical and biological 
properties as they serve as the interface between the bulk metal and host environment. Alteration 
of these surfaces is necessary to facilitate successful host-implant integration. In this work, SAMs 
were utilized as a platform to chemically immobilize bioactive molecules to the Ti-6Al-4V surface 
aimed at addressing osteoblast adhesion and bacterial colonization. 
This flexible platform allows for the immobilization of a variety of molecules including 
antibiotics, peptides, and nitric oxide releasing compounds. Although in this work immobilized 
molecules did not retain their bioactivity, alternative immobilization strategies can be employed. 
The functional groups within these molecules used in the formation of covalent bonds are prevalent 
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in other classes of bioactive molecules. This permits control of the interfacial properties of Ti-6Al-
4V with bioactive molecules specific to the metal’s application. Furthermore, as SAMs form on 
other metal oxide surfaces, this transferable platform can be used to alter their interfacial properties 
as well.  
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